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Zusammenfassung 
PTEN (phosphatase and tensin homolog deleted on chromosome 10) ist eine dualspezifische 
Protein-Tyrosin-Phosphatase (PTP). Als Tumorsuppressor spielt PTEN im Bezug auf 
zelluläre Homöostase eine wichtige Rolle. Die PTEN-Aktivität wird im physiologischen 
Zusammenhang von H2O2 inhibiert, das durch einen Redox-Signalweg und oxidativen Stress 
produziert wird. Die oxidative Inhibition durch H2O2 führt zur Disulfidbildung zwischen dem 
katalytischen Cystein C124 und dem räumlich benachbarten Cystein C71. Die Auswirkung 
der Disulfidbildung auf die Proteinstruktur ist jedoch bisher unbekannt. Um die Effekte der 
PTEN-Inhibition zu untersuchen, dienen Bisperoxidovanadium (bpV) Komplexe als wichtige 
Modellverbindungen. Diese bpV Komplexe weisen bei neuronalen und myokardialen 
Verletzungen einen regenerativen Effekt auf und besitzen damit Potential für deren 
Behandlung. Allerdings blieb deren Wirkungsweise auf PTEN unklar. Daher wurden in der 
vorliegenden Arbeit molekulare Effekte von H2O2 und bpV-phen auf PTEN mithilfe von 
Aktivitiätsmessungen, Massenspektrometrie und Röntgenkrsitallographie untersucht.  
Sowohl H2O2 als auch bpV-phen führen durch oxidative Inhibition am aktiven Zentrum von 
PTEN zu einer Disulfidbindung zwischen C124 und C71, was aber nur geringe strukturelle 
Änderungen zur Folge hat. Im Vergleich zu bekannten PTP-Strukturen im oxidierten Zustand 
ist dies zwar analog zur lymphoiden Tyrosinphosphatase, jedoch unterscheidet es sich von 
CDC25B und PTP1B, die signifikante Konformationsänderungen des aktiven Zentrums 
zeigen. Ausserdem zeigt PTEN auch unter stringenter H2O2-Behandlung eine hohe 
Reaktivierbarkeit, wogegen CDC25B und PTP1B auch irreversible Oxidation erfahren. Damit 
besitzt PTEN möglicherweise einen effizienteren Schutzmechanismus gegen irreversible 
Modifikationen als andere PTPs. Desweiteren wurde mit 
51
V-NMR Spektroskopie die 
Reaktion von PTEN mit bpV-phen näher untersucht. Die oxidative Inhibition führt zur 
Bildung eines Orthovanadatmoleküls, das eine schwache Affinität zum aktiven Zentrum des 
oxidierten PTEN aufweist. Im Gegensatz zu einigen anderen Phosphatasen zeigt 
Orthovanadat keine inhibitorische Wirkung auf die Enzymaktivität von PTEN, was bestätigt, 
dass die durch bpV-phen vermittelte PTEN-Inhibition auf die Disulfidbildung zurückzuführen 
ist. Die hier nachgewiesene reversible Inhibition durch bpV-phen könnte sich positiv auf 
therapeutische Anwendungen auswirken, da irreversible Inhibition dieses zentralen 
Tumorsuppressors systemische Störungen verursachen könnte. In dieser Hinsicht können die 
neuen Erkenntnisse über die Wirkungsweise von bpV-phen zur weiteren Entwicklung dieser 
Inhibitorklasse beitragen. 
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1 Introduction  
1.1 Protein tyrosine phosphatases 
The reversible phosphorylation of proteins is of central importance to the regulation of 
numerous physiological processes in living organisms
1,2
. As one of the post-translational 
modifications, phosphorylation involves covalent functional modifications of proteins, which 
results in alteration of their biological activity, stability, subcellular localization and protein-
protein interaction properties among others
1
. In particular, phosphorylation of a tyrosine 
residue plays a crucial role in growth control, as it is deeply implicated in transmembrane 
signaling
3,4
. Indeed, cellular tyrosine phosphorylation increases during oncogenic 
transformation (total tyrosine phosphorylation of proteins from 0.01 % to 2 %.)
5,6
. Tightly 
regulated phosphorylations are essential in maintaining cellular homeostasis and aberrant 
protein phosphorylation is associated with the development of many human diseases such as 
cancer, diabetes, rheumatoid arthritis, hypertension and neurodegeneration
2,4,6,7
. 
Protein phosphorylation is governed by two classes of enzymes. Protein kinases convey 
phosphorylation at serine/threonine and tyrosine residues of their protein substrates. Protein 
phosphatases reverse this action. Particularly, protein tyrosine phosphatases (PTPs), a 
subgroup of protein phosphatases, downregulate the tyrosine phosphorylation in signaling 
pathways. PTPs harbor a characteristic phosphate-binding loop (P-loop) in their active site 
involving a structural motif with the consensus sequence: HCXXGXXR
8,9
. The conserved 
cysteine residue is responsible for the catalytic activity
8,9
. In addition, the active site of PTPs 
exhibits an acidic microenvironment
8,9
, which supports efficient recognition of negatively 
charged phosphotyrosine in their protein substrates. This acidic property promotes the 
presence of a deprotonated version of the catalytic cysteine at neutral pH
10
. The resulting 
protein thiolate is more nucleophilic than its protonated version, but susceptible to 
oxidation
10
. During phosphatase reaction, the catalytic cysteine in the active site P-loop 
nucleophilicly attacks the phosphorous atom of the phosphotyrosine (Figure 1)
11
. Upon 
obtaining a proton from a catalytic aspartic acid in the WPD (Trp-Pro-Asp)-loop, the protein 
substrate with the dephosphorylated tyrosine residue is released from the active site. The 
remaining cysteinyl-phosphate intermediate is stabilized by the neighboring arginine residue 
in the P-loop and subsequently hydrolyzed by a water molecule in the release of a free 
phosphate.  
INTRODUCTION  2 
 
 
 
 
Figure 1 | Catalytic mechanism of dephosphorylation of phosphotyrosine by PTP. Catalytic 
cysteine in P-loop nucleophilicly attacks the phosphate group of the phosphotyrosine and releases the 
dephosphorylated protein substrate. A water molecule activated by an aspartate in WPD-loop 
subsequently hydrolyzes the phosphocysteine, liberating an orthophosphate. The figure is based on 
Zhao et. al. (2014)
11
. 
The PTP superfamily including 107 human PTPs can be divided into four classes based on the 
amino acid sequence of their catalytic domains
2,12,13
. Class I cysteine-based PTPs involve the 
majority of this superfamily with 38 classical PTPs and 61 dual-specificity protein tyrosine 
phosphatases (DUSPs)
2,12,13
. Compared to classical PTPs with specific phosphotyrosine 
recognition, DUSPs are able to catalyze dephosphorylation of both tyrosine and 
serine/threonine substrates. The class II cysteine-based PTPs in the human genome comprises 
a single member, which is low-molecular weight PTP
2,12,13
. Its catalytic domain is structurally 
related to bacterial arenate reductases
12,13
. The class III cysteine-based PTPs contain three 
members, CDC25A, CDC25B, and CDC25C
12,13
. These cell cycle regulators are dual-specific 
for phosphothreonine and -tyrosine residues on their substrates cyclin-dependent kinases. 
Compared to cysteine-based PTPs, the class IV involves aspartate as a key catalytic 
residue
12,13
. Four eya genes belong to this group and have been shown to have tyrosine and 
serine phosphatase activity
12,14-16
.  
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1.2 PTEN  
1.2.1 Phosphatase PTEN 
As a member of class I cysteine-based PTPs, PTEN (phosphatase and tensin homolog deleted 
on chromosome 10) is a dual-specificity protein tyrosine phosphatase and one of the most 
important tumor suppressors
17-19
. PTEN governs a wide spectrum of physiological processes 
including proliferation, cell size determination, differentiation, cell fate specification and 
energy metabolism
20,21
. Frequently found loss-of-function mutations of pten gene in human 
cancers implicate its importance in the regulation of cellular survival signaling. Beside its 
crucial role as a gatekeeper in tumorigenesis, PTEN constitutes a critical factor in 
regenerative processes
22-24
 (Chapter 1.2.5). Both implications are mainly related to its 
inhibitory effect on PI3-K/Akt signaling pathway
25
 (Figure 2). 
 
 
Figure 2 | PTEN antagonizes PI3-K/Akt signaling pathway. The activated PI3-K/Akt pathway is 
involved in cell proliferation, growth and regenerative processes via pro-survival signaling. PTEN 
inhibits this signal transduction by catalyzing dephosphorylation of PIP3 to PIP2.  
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The signal transduction of PI3-K/Akt pathway is initiated by binding of insulin or growth 
factors to receptor tyrosine kinase (RTK) on the cell surface, which promotes phosphorylation 
of insulin receptor substrate 1 (IRS-1) and subsequently phosphoinositide 3-kinase 
(PI3-K)
26,27
. The activated PI3-K catalyzes phosphorylation of phosphatidylinositol (4,5)-
bisphosphate (PIP2) to (3,4,5)-trisphosphate (PIP3) at the plasma membrane
26,27
. PIP3 
production induces activation of downstream proteins including PDPK1
28
, Akt
29,30
 and 
mTORC1
31
. The following pro-survival signaling leads to enhanced glucose metabolism, cell 
growth and proliferation (Figure 2). As an antagonist in this pathway, PTEN reverses the 
action of PI3-K by converting PIP3 to PIP2 and prevents PIP3 accumulation
25,32,33
. In 
consequence, PTEN inhibits PI3-K/Akt signaling and modulates cell cycle progression and 
cell survival
33
. Thereby, the lipid phosphatase activity of PTEN is a critical factor for 
thorough regulation of this signaling and the cellular homeostasis.  
Although the lipid phosphatase activity is the main enzymatic function of PTEN, it also has 
the capability of dephosphorylating protein substrates. As a member of DUSP (Chapter 1.1)
34
, 
PTEN exhibits substrate specificity towards a phosphoserine/threonine and -tyrosine. For 
instance, PTEN inhibits focal adhesion kinase (FAK) by dephosphorylating phosphotyrosine 
(pY397), which is phosphorylated in response to integrin-mediated cell adhesion
35,36
. As a 
result, PTEN hinders cell migration, invasion, spreading, and focal adhesions
35,37,38
. Protein 
phosphatase activity of PTEN has also been demonstrated by its action on IRS-1
39
. 
Dephosphorylating two phosphotyrosine residues (pY612, pY989), PTEN inhibits the insulin 
signaling mediated by IRS-1 in PI3-K/Akt pathway. Finally, PTEN manifests an 
autodephosphorylation feature. As a highly regulated enzyme, cellular activity of PTEN is 
controlled by its intramolecular phosphorylation. Autodephosphorylation at pT366 on 
PTEN’  regulatory C-tail has been suggested to promote the membrane targeting for its 
antagonistic function in PI3-K/Akt pathway
40
.  
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1.2.2 PTEN structure 
PTEN is a non-redundant and evolutionary conserved tumor suppressor containing 403 amino 
acids
25,41
. PTEN consists of four functional domains involving central phosphatase and C2 
domains flanked by two N- and C-terminal regulatory polypeptide regions (Figure 3a). 
Detailed insight into protein folding of the central globular domains was provided by the 
crystal structure of Lee et al. (1999) (PDB
42
 1D5R)
43
 (Figure 3b). However, structural 
information of the full-length PTEN is still missing, which would allow us to understand the 
functional regulation of this tumor suppressor. 
Phosphatase domain of PTEN consists of 170 amino acids (residues 16-185) (Figure 3b). As a 
member of DUSPs, PTEN contains the wide and deep active site compared to classical PTPs 
with a small and deep pocket for a substrate specificity
44
. Notably, PTEN exhibits an even 
larger phosphatase active site than the structurally similar DUSP human vaccinia H1-related 
phosphatase (VHR)
43,44
.  Given the lipid phosphatase activity of PTEN, the enlarged width of 
the active site might be a crucial feature to accommodate PIP3 substrate that is bulkier than 
phosphorylated tyrosine, serine or threonine residues
43
. Moreover, the P-loop motif of PTEN 
includes two lysines (residues 123-HCKAGKGR-130) that are conserved in the tensin-type 
lipid phosphatases
43,45
. These basic amino acids may stabilize PIP3 substrate binding by 
interacting with the phosphate groups at position D1 and D5 of the inositol ring
43,45
. 
C2 domain of PTEN, including 165 amino acids (residues 186-350), is mainly composed of 
an     p        β-sandwich structure (Figure 3b). This domain exhibits structural homology to 
the classical C2 domain that mediates membrane association in a Ca
2+
-dependent manner
43
. 
However, PTEN C2 domain lacks two out of three conserved Ca
2+
-binding loops (CBR1, 
CBR2, CBR3) and is unlikely to bind Ca
2+
. Nonetheless, five lysine residues with net +5 
charge in the present CBR3-loop (residues 260-269) might serve to mimic Ca
2+
-binding and 
promote interaction with phospholipids in the plasma membrane
43
. PTEN C2 domain has an 
additional structural element with solvent-exposed b             . Cα2 (residues 326-335) 
closely located to the active site harbors three lysines and one arginine. This structural 
element may contribute to membrane recruitment together with the CBR3-loop
43
. Another 
structural feature in PTEN C2 domain is the D-loop (residues 286-309) involving 24 amino 
acids. This region was not included for the protein crystallization, due to its flexible nature
43
. 
In addition, very little is known about the functional role of this loop. So far, it has been 
shown that the D-loop is affected by caspase-3-dependent proteolytic cleavage and 
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ubiquitination at D301 and K289, respectively
46,47
. 
 
 
Figure 3 | Domain architecture and structure of PTEN. (a) PTEN consists of four functional 
domains. The active site in the phosphatase domain contains a catalytic cysteine (C124), which is 
essential for its lipid phosphatase activity at the plasma membrane. (b) Only phosphatase and C2 
domains are structurally elucidated, while structural information of the regulatory N- and C-tails is still 
missing.  
The N-tail comprises 15 amino acids including the proposed PIP2-binding motif (residues 6-
KEIVSRNKRR-15) (Figure 3b)
48
. The densely located basic amino acids are suggested to 
interact with the negatively charged head group of PI-(4,5)-P2, which is the dephosphorylation 
product of PI-(3,4,5)-P3 by the lipid phosphatase activity of PTEN
48
. Notably, previous in 
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vitro and in vivo studies show that this motif is essential for the catalytic activity and plasma 
membrane localization
45,48-55
.  
The C-tail consists of 52 amino acids (residues 352-403) (Figure 3b). This structurally 
flexible domain is responsible for the conformational change via post-translational 
modification and the following subcellular localization (Chapter 1.2.3). Upon 
phosphorylation, PTEN undergoes a conformational change to the “       and inactive”  tate 
and resides in the cytosolic compartment
56,57
. PDZ-binding motif (residues 401-403) located 
at the end of the C-tail contributes to the formation of a signaling complex at the plasma 
membrane
58,59
.  
A translational variant of PTEN was recently discovered by two independent groups 
involving an alternative translation initiation site CUG upstream to the canonical start codon 
AUG
60,61
. This isoform, called PTEN-L, constitutes a longer form of PTEN with 173 
additional amino acids at the N-terminus. This extended region is predicted to be intrinsically 
disordered
60-63
. Notably, PTEN-L is able to be secreted and also to enter adjacent cells
60,61
. It 
has been suggested that this feature be attributed to the presence of a poly-arginine stretch R
6
 
(residues 47-52), which is similar to the poly-basic sequences found in cell-permeable 
peptides
60
.  
1.2.3 Post-translational modification of PTEN 
PTEN activity is regulated by multiple post-translational modifications including 
phosphorylation, ubiquitination, acetylation, and oxidation (Figure 4). Among others, 
phosphorylation of PTEN is the most heavily studied modification. It serves as a critical 
factor to modulate cellular tumor-suppressing activity of PTEN by determining subcellular 
localization. PTEN is mainly phosphorylated at serine/threonine clusters of the C-tail (S362, 
T366, S370, S380, T382, T383, S385)
64,65
 by CK2
57,66,67
, GSK-3β67,68, and PICT-169. Upon 
phosphorylation, the negatively charged C-tail domain undergoes intramolecular interaction 
with the positively charged central globular domains, interfering with the electrostatic 
interaction between the core domains and the plasma membrane
55,70,71
. The resulting closed 
conformation leads to the cytosolic localization of PTEN in its inactive, but more stable state 
(Figure 5)
56,72
. On the contrary, previous mutation studies demonstrated that the open and 
active state of PTEN is induced by alanine substitution at these phosphorylation sites
70,71
. This 
dephosphorylation mimicry results in the increased membrane recruitment and nuclear 
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localization
73
. Other phosphorylation modifications on PTEN C2 domain have also been 
reported. Phosphorylation at S229, T232, T319, and T321 catalyzed by ROCK promotes 
membrane localization of PTEN in chemoattractant-treated leukocytes
74
. In addition, 
phosphorylation at Y336 conveyed by RAK protects PTEN from ubiquitin-mediated 
proteolysis
75
.  
 
Figure 4 | Post-translational modifications of PTEN. Ubiquitination regulates subcellular 
localization and protein levels of PTEN, while phosphorylation and acetylation affect its enzymatic 
activity. In addition, reactive oxygen species induces catalytic impairment of PTEN via disulfide bond 
formation. The figure is reconstructed based on Shi et al. (2012) and Worby et al. (2014)
64,65
.  
Ubiquitination regulates subcellular localization and protein levels of PTEN (Figure 5). 
Monoubiquitination mediates the nuclear import of PTEN and enables its tumor suppressor 
function in phosphatase-independent manner (Chapter 1.2.4)
47
. However, polyubiquitination 
directs PTEN to proteasomal degradation
76
. This is consistent with low protein levels of 
PTEN observed in cancer cells, which is in coincidence with aberrant overexpression of 
ubiquitin ligase (e.g. NEDD4-1)
77,78
. So far, three E3 ligases (e.g. NEDD4-1
77
, WWP2
76
, and 
XIAP
79
) have been identified to promote this modification. Analogous to ubiquitination on 
other proteins, this modification occurs on solvent-exposed lysines of PTEN such as K13 and 
K289 (Figure 4).  
Acetylation of PTEN is associated with its activity regulation and protein-protein interaction. 
Lysine acetyltransferase PCAF promotes acetylation of PTEN at K125 and K128 in response 
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to growth factor stimulation
80
. As both residues are located within the active site P-loop, 
enzymatic activity of PTEN is reduced consequently
80
. PTEN is also acetylated on its C-
terminal PDZ binding motif (K402). This has been suggested to have an influence on physical 
interaction between PTEN and PDZ-domain-containing proteins
64,65,81
.  
Phosphatase activity of PTEN is regulated by oxidation (Chapter 1.3.4). It has been reported 
that H2O2-treatment or endogenously produced reactive oxygen species inactivate PTEN
82,83
. 
In both cases, disulfide formation between cysteines C124 and C71 was observed
82,83
. In 
addition to phosphatase inhibition, oxidative stress promotes nuclear localization of PTEN via 
phosphorylation at the C-tail (pS380)
84
. Nuclear PTEN contributes to increase of p53 levels in 
the phosphatase-independent manner, which leads to p53-mediated G1 cell growth arrest, cell 
death, and a reduction in cellular ROS production
65,84
.  
 
Figure 5 | Subcellular localization of PTEN. Phosphorylation triggers the conformational closure 
and leads to the cytosolic localization in the inactive state. Upon activation, PTEN is translocated to 
the plasma membrane. Subcellular localization and cellular protein level of PTEN are also controlled 
by ubiquitination. Monoubiquitination of PTEN promotes its nuclear import, while polyubiquitination 
induces proteasomal degradation.  
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1.2.4 Tumor suppressing effects of nuclear PTEN 
As previously described, PTEN constitutes a key negative regulator in the PI3-K/Akt 
signaling and attenuates pro-survival signal (Chapter 1.2.1). This feature is attributed to its 
lipid phosphatase activity at the plasma membrane. However, growing evidence supports the 
functional importance of PTEN, also, in the nucleus. Contrary to its cytoplasmic activity, 
nuclear PTEN exerts tumor suppression function in a phosphatase-independent manner by 
controlling genomic stability and cell cycle progression
21,85,86
. PTEN maintains chromosomal 
integrity by physical association with centromere protein C1 (CENPC1)
85
. Under genotoxic 
stress, PTEN contributes to DNA double-strand repair by inducing the expression of 
RAD51
85
. Nuclear PTEN also promotes formation of a complex between an E3 ubiquitin 
ligase APC/C and CDH1. The resulting protein complex recruits its specific substrates (e.g. 
PLK1, Aurora A, CDC20, SKP2) for ubiquitin-mediated proteolysis, which are overexpressed 
in the tumor progression
87
. In addition, cooperative effects of two major tumor suppressors 
PTEN and p53 have been demonstrated in earlier studies. Direct interaction of PTEN with 
p53 regulates the protein levels of p53 and also leads to overexpression of PTEN itself via an 
autoregulating mechanism
88,89
. PTEN also enhances the acetylation of p53 and thereby 
activates this tumor suppressor by inducing tetramerization
90
.  
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1.2.5 PTEN in regenerative processes 
Axons in the mammalian adult central nervous system (CNS) are not able to regenerate 
spontaneously after nerve injury
22
. This property is ascribed to the extracellular inhibitory 
environment and the reduced intrinsic growth ability
22,24
. For this reason, enzymatic removal 
of axon regrowth inhibitors (e.g. chondroitin sulphate proteoglycans, myelin-associated 
inhibitors) occurring in the extracellular matrix after nerve injury has been demonstrated to 
promote axonal regeneration
91,92
. However, this strategy shows regeneration effect only to a 
small extent
91,92
. Another approach includes modulation of the intrinsic growth control. This 
is based on two findings, which are increased axon outgrowth by amplification of PI3-K/Akt 
pathway
93,94
 and extensive expression of the antagonist PTEN in peripheral neurons, 
including those that have been injured
95
. Indeed, genetic deletion of PTEN has been reported 
to promote neuronal survival and robust axon regeneration after nerve injury by activating the 
downstream protein mTOR
22
. Regenerative effects of PTEN inhibition are also highlighted in 
terms of cardioprotection. This is due to the fact that, analogous to nerve injury, activation of 
PI3-K/Akt signaling pathway significantly reduces ischemia/reperfusion injury
*
, which 
consequently leads to myocardial infarction (heart attack)
96,97
. Consistently, PTEN inhibition 
promotes myocardial
†
 survival and limits infarct size
97,98
. These implications in cellular 
regeneration make PTEN a pharmacological target for the treatment of nerve injury, stroke 
and myocardial infarction. However, due to potential tumorigenesis from the long-term 
knock-down, pharmacological inhibition of PTEN would be confined to acute treatment. 
Nevertheless, research on the pharmacological effect of PTEN inhibition is still in its infancy 
and requires further investigation.    
                                                 
*
 Ischemia refers to the state, in which the blood supply to tissues and organs is restricted. Reperfusion refers to 
the restoration of blood supply after a period of ischemia.  
†
 Relating to the muscular tissue of the heart. 
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1.3 Reactive oxygen species 
1.3.1 Occurrence and effect of reactive oxygen species 
Reactive oxygen species (ROS) are a collective term for chemically reactive molecules 
containing oxygen. Hydrogen peroxide (H2O2), hydroxyl radical (OH
•
), superoxide (O2
•-
), 
nitric oxygen (NO
•
) and singlet oxygen (
1
O2) belong to these species (Figure 6). ROS are 
produced in a wide range of physiological processes
99
. ROS are formed as a natural byproduct 
of metabolic processes, while ROS levels can also increase by exposure to extrinsic stress 
factors (e.g. UV, γ-radiation, chemicals). ROS formation is furthermore involved in certain 
physiological circumstances (e.g. hypoxia, oncogene activation) and the following oncogenic 
transformation
100
. The resulting ROS have diverse effects depending on their cellular level
100
. 
Low levels of ROS promote cell survival and proliferation particularly via growth factor-
induced signaling events (Chapter 1.3.2). In this controlled metabolic state, normal cells 
utilize antioxidants (e.g. thioredoxin, reduced glutathiones) to regulate intracellular ROS 
content within nontoxic range
101
. However, once ROS levels become exceedingly high, they 
can exert detrimental oxidative stress ranging from tumorigenesis to apoptosis
100,102
. Notably, 
cancer cells thoroughly control and maintain the household of ROS at moderate level, so that 
they escape from the cell death but further induce ROS-related mutations
100
. Moreover, ROS 
also activate various transcription factors (e.g. NF-κB, AP-1, HIF-1α, STAT3)     
downregulate expression of tumor suppressor proteins (e.g. p53, Rb, PTEN)
103
. In this regard, 
thorough regulation of ROS levels is very important for cellular homeostasis.  
 
 
Figure 6 | Reactive oxygen species (ROS). ROS are generated by various sources ranging from 
metabolic to extrinsic factors. Depending on the level of ROS, different potential cellular outcomes 
occur ranging from cell survival through tumorigenesis up to cell death. The figure is reconstructed 
based on Cairns et al. (2011)
100
. 
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1.3.2 Growth factor-induced hydrogen peroxide generation 
H2O2 is the most abundant ROS (about 10
-7 M in the steady state)
104,105
. Among the different 
ROS, H2O2 is relatively stable with cellular half-life of about 1 ms
104
. H2O2 is diffusible 
through membranes with its small molecular size and non-polarity
104,105
. Furthermore, H2O2 
exhibits selective reactivity, especially to PTPs
104,105
. Its cellular concentration can be 
controlled by the antioxidant defense system
105
. Collectively, these properties make H2O2 
suitable to act as a second messenger in different redox signaling pathways, unless its 
concentration is exceedingly high to exert an oxidative stress
106,107
. In particular, H2O2 plays a 
crucial role in the PI3-K/Akt signaling. Once external signals stimulate receptor tyrosine 
kinase with growth factors (e.g. EGF, PDGF, VEGF, insulin), NADPH oxidase 1 (NOX1) is 
activated in the downstream signaling event and produces H2O2 (Figure 7)
105
. The elevated 
level of H2O2 potentiates the inactivation of PTPs including PTEN, since the local 
inactivation of these antagonists is required to increase the accumulation of PIP3 to a 
sufficient level for the downstream events
108,109
. As a result, subsequent activation of Akt 
kinase leads to cell survival and proliferation. Given that PTEN is a key antagonist of this 
pathway, oxidative inhibition of PTEN by H2O2 in response to cell stimulation might be an 
important determinant of PIP3 generation in timing and localization for the effective 
regulation of a signal transduction
109
. In this respect, PTEN requires efficient redox regulation 
involving a highly reversible character of oxidative inactivation and selective switching 
between oxidized and reduced states.  
 
Figure 7 | H2O2 generation in response to a growth factor in PI3-K/Akt pathway. Cellular 
stimulation via various growth factors reinforce the PI3-K/Akt signaling via H2O2 production, which 
in turn inhibits its negative regulator PTEN. GF: growth factor, RTK: receptor tyrosine kinase, PI3-K: 
Phosphoinositide 3-kinase, PTP: protein tyrosine phosphatase, NOX: NADPH oxidase. The figure is 
reconstructed based on Kwon et. al. (2004)
109
. 
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1.3.3 Molecular consequences of PTPs upon hydrogen peroxide 
Cysteines play a crucial role in numerous biological processes. They are involved in 
stabilization of protein structures (e.g. disulfide formation), regulation of protein functions 
(e.g. post-translational modifications), coordination with metals (e.g. Fe, Zn, Cu), and 
enzymatic reactions (e.g. active site cysteines)
110,111
. This stems from unique features of 
thiols, for instance from their high reactivity, polarizability, high affinity for metals, redox-
mediated modification, and responsiveness to local environments
112
. Such versatile properties 
make cysteine residues special in protein chemistry, although they are one of the least 
abundant amino acids in proteins (1 – 2 %)111. In particular, the catalytic cysteine in the active 
site of PTPs is sensitive to oxidative inhibition by ROS. This is due to the fact that the active 
site manifests an acidic environment with an unusually low pKa value (pKa = 4.7 – 5.4), 
whereas the thiol group of most cysteines exhibits pKa at about 8.5
113
. As a result, the 
catalytic cysteine residue in PTPs is present in the deprotonated form as a protein thiolate, 
which is stabilized by polar or positively charged amino acids in the active site 
P-loop
8,9,105,114
. The charged nature of the protein thiolate makes them more nucleophile but 
susceptible to oxidation
10,115-117
. Upon exposure to H2O2, the protein thiolate is initially 
oxidized to sulfenic acid, which is located at a crossroad of reversible and irreversible 
oxidative modifications (Figure 8a). This highly reactive sulfur species can be further 
oxidized to sulfinic or sulfonic acid, resulting in irreversible catalytic impairment. 
Alternatively, in the presence of another proximal cysteine (Figure 8b) or an activated main-
chain amide (Figure 8c), sulfenic acid undergoes an intramolecular condensation reaction to 
form disulfide or sulfenyl-amide bond. These modifications constitute a protective mechanism 
from further irreversible inactivation of the protein and enable the restoration of the active 
form under reductive conditions
10
.  
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Figure 8 | Molecular consequences of protein thiolates upon H2O2 oxidation. a) The catalytic 
cysteine in PTP is present as thiolate that is particularly susceptible to oxidation. Upon exposure to 
H2O2, cysteine thiolate at the active site of PTP is converted to sulfenic acid, which subsequently 
undergoes disulfide or sulfenyl-amide formation in the presence of cysteine or activated amide in the 
neighborhood. Alternatively, additional equivalent of H2O2 can facilitate irreversible oxidative 
modification of sulfenic acid to sulfinic or sulfonic acid. b) Intramolecular disulfide formation. c) 
Intramolecular sulfenyl-amide formation. 
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1.3.4 Structural changes of PTPs upon oxidation 
PTPs take advantage of the reversible nature of disulfides and sulfenyl-amides to switch 
between active and inactive forms, while these chemical modifications simultaneously have a 
protective effect against irreversible abrogation of their catalytic activity. Depending on the 
underlying mechanisms, the reversible modifications can be categorized into three different 
classes
118
, although they have the initial oxidation of the catalytic cysteine to sulfenic acid in 
common. First, reversible sulfenyl-amide formation is promoted by a nucleophilic attack from 
the main chain amide of the next residue to the sulfenic acid. As observed in the crystal 
structures of PTP1B, this intramolecular five-membered ring extensively distorts the P-loop 
conformation (Figure 9, PDB 2HNP vs. 1OEM)
119-123
. Second, disulfide formation occurs 
between two cysteine residues separated by several amino acids in the primary sequence. A 
representative example is the low molecular weight protein tyrosine phosphatase (i, i+5 for 
LMW-PTP)
124,125
. The last mechanism also involves disulfide formation. However, the 
intramolecular condensation reaction is induced by the spatial proximity of two cysteine 
residues, even though both are located far apart from each other in the primary 
sequence
82,126-128
.  
So far, there are two human PTPs of which the structural impact of the disulfide formation is 
elucidated with crystal structures. These are CDC25B
126
 and LYP
118
. Interestingly, CDC25B 
undergoes a significant conformational change of the active site P-loop upon disulfide 
formation (PDB 1YMK vs. 1YS0), whereas LYP maintains the backbone structure (PDB 
2P6X vs. 3H2X) (Figure 9). Dual-specificity phosphatase PTEN also belongs to this last 
class. Upon oxidative stress, disulfide bond formation occurs between its catalytic cysteine 
C124 with the spatially aligned cysteine C71
82,83
. However, the structural consequences of 
disulfide formation remain elusive. Moreover, PTP1B (PDB 1OEO) and CDC25B (PDB 
1YMD) experience the irreversible modification including sulfonic acid formation under 
extensive oxidation condition (Figure 9)
122,123,126
.  
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Figure 9 | Summary of oxidative modifications of the known human PTP crystal structures. 
Depending on the oxidizing conditions, catalytic cysteine of the reduced state (gray) undergoes 
reversible (blue; disulfide or sulfenyl-amide formation) or irreversible modification (red; sulfonic 
acid). Thereby, the conformation of the active site P-loop can be distorted to a large extent. PTP: 
protein tyrosine phosphatase, DUSP: dual-specific phosphatase, N/A: not available.  
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1.4 Bisperoxidovanadium-based PTEN inhibitors 
As discussed above (Chapter 1.2.5), regenerative effects of PTEN inhibition provide new 
possibilities for acute treatment of stroke and nerve injury. Concerning PTEN inhibitors, there 
are both an organic compound (SF1670) and organovanadium complexes available. However, 
vanadium complexes are mainly used to study the effects of PTEN inhibition, due to their 
higher potency with sub-micromolar IC50 ranges. These vanadium-based PTEN inhibitors are 
categorized into two classes depending on the oxidation state. Vanadium (IV)-based VO-
OHpic contains oxovanadium that is coordinated by a water molecule and two 3-
hydroxypicolinic acid in a bidentate manner
129,130
. The other compound class involves 
vanadium (V)-based bisperoxidovanadium (bpV) complexes
130-133
. In these organometallic 
molecules, a central oxovanadium is complexed with two peroxido ligands as well as an 
organic bidentate ligand in a pentagonal bipyramidal geometry
134,135
. The widely used PTEN 
inhibitors in this class include an aromatic ligand such as phenanthroline (phen), picolinic 
acid (pic), 5-hydroxypicolinic acid (HOpic) (Figure 10). In addition, pharmacological 
inhibition of PTEN has been demonstrated in CNS/cardiomyocyte-injury and stroke using 
bpV-complexes
136-141
. Consistent with physiological effects resulting from the genetic 
deletion, PTEN inhibition by these compounds enhanced PI3-K/Akt signaling and revealed 
neuronal and cardiac protection in earlier in vitro and in vivo studies
136-141
. However, the 
mode of action of bpV-complexes on PTEN is still under debate
132,133
. Its elucidation could 
support further optimization of these compound class to achieve improved efficacy.  
 
Figure 10 | Bisperoxidovanadium-based PTEN inhibitors.  Central oxovanadium is coordinated by 
two peroxides and an organic ligand involving phenanthroline (phen), picolinic acid (pic), or 
5-hydroxypicolinic acid (HOpic).  
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2 Aim of the thesis 
As a central tumor suppressor, tight regulation of PTEN phosphatase activity is crucial for 
cellular homeostasis. In the physiological context, PTEN activity is inhibited by H2O2 
produced in the redox signaling and oxidative stress
82,83,109
. Thereby, PTEN renders disulfide 
formation between the catalytic cysteine C124 and the proximal cysteine C71
82
. However, 
structure-based implications of PTEN inhibition remain elusive, which would provide better 
understanding of its oxidative regulation. On the other side, pharmacological inhibition of 
PTEN phosphatase activity by bisperoxidovanadium (bpV) complexes has been shown to 
have cellular regenerative effects involving potential application for treatments after nerve 
and cardiac injury
136-141
. So far, the mode of action of these compounds is still unclear. Its 
elucidation would contribute to further development of this compound class. Therefore, 
inhibition of PTEN phosphatase activity shall be investigated in this study using biochemical 
and structural biology methods. H2O2 and bpV-phen are selected as representative model 
compounds for physiologically relevant and synthetic PTEN inhibitors, respectively.  
Different PTEN constructs shall be produced using recombinant protein expression. Due to 
the post-translational modification-dependent conformational change, PTEN shall be 
overexpressed in E.coli and insect cells following molecular cloning of the protein constructs. 
Subsequently, structural consequences of H2O2-mediated disulfide formation shall be studied 
using X-ray crystallography to compare the effects with other PTP structures. Given that two 
other members of the PTP superfamily, PTP1B
122
 and CDC25B
126
, experience irreversible 
modifications (e.g. sulfonic acid formation) under extensive treatment of H2O2, it shall be 
tested, if the catalytic cysteine of PTEN also shows irreversible oxidation at physiologically 
relevant H2O2 concentrations. Furthermore, the mode of action of bpV-phen shall be studied. 
Knowing that PTP1B is oxidatively inhibited by peroxidovanadate
153
, an oxidative 
mechanism of bpV-phen-mediated PTEN inhibition is considered. Potential chemical 
modifications of PTEN shall be determined using mass spectrometry and X-ray 
crystallography. 
51
V-NMR spectroscopy will be used to determine the vanadium species 
involved. In addition, protein-ligand-interactions between PTEN and other activity 
modulators (e.g. PIP2, nhPIP3) will be studied. Biochemical and structural biology methods 
will be utilized to characterize their binding modes on PTEN. 
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3   Results and discussion 
3.1 Protein expression and purification  
3.1.1 Protein expression and purification of the various constructs 
To characterize biochemical effects of activity modulators on PTEN, human PTEN 
(UniProt
142
 P60484) was recombinantly produced using heterologous protein expression 
systems. Thereby, protein expression of eight different constructs in the presence and absence 
of regulatory domains was performed to study protein-ligand interaction (Figure 11). Protein 
constructs containing N-terminal regulatory domain were divided into the full-truncation 
(∆ residues 1-16) and the presence of PIP2 b     g       (∆          1-6). The absence of 
C-terminal regulatory domain involved the entire C-tail region with 52 amino acids 
(∆ residues 352-403, Figure 3b and Figure 11b). In addition, a protein construct (PTEN 7-353 
Δ286-309) was produced based on the available crystal structure of PTEN (PDB 1D5R)43. 
This construct served to study structural effects of activity modulators on PTEN. Protein 
expression was carried out using insect cells, due to its capability of introducing post-
translational modifications. However, expression of the full-length PTEN was additionally 
performed in the prokaryotic host organism Escherichia coli to represent its open state
51
. This 
is due to the fact that intrinsic activity modulation of PTEN depends on the phosphorylation-
mediated conformational change (Chapter 1.2.3) and E. coli lacks background 
phosphorylation by intrinsic kinases
143
.  
Initially, production of full-length PTEN was performed with E. coli using BL21 derivative 
Rosetta host strain, since this cell line is supplemented with an additional plasmid pRARE 
encoding tRNAs for rare codons. After transformation with the sequence-verified human 
wild-type pten, Rosetta cells produced the protein construct at 20 °C to facilitate proper 
protein folding. Full-length PTEN was overexpressed in a soluble form and isolated from cell 
lysate. The purified protein exhibits lipid phosphatase activity. However, this protein 
construct tends to form undefined multiple protein complexes during overexpression in 
E. coli, which does not demonstrate the physiologically relevant PTEN species (PTEN, 
47 kDa). Formation of the protein complexes was detected by size exclusion chromatography 
(Figure 12). The majority of the protein was eluted at the void volume, indicating a protein 
size larger than the largest protein standard (Thyroglobulin, 669 kDa) used for comparison 
(Figure 12, upper panel). In order to obtain a monomeric species, the isolated protein was 
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treated with various detergents (Triton, NP-40, CHAPS) and incubated under high ionic 
strength environment (2 M NaCl). Besides, diverse protein tags (His6, GST, MBP) were 
employed for improvement. Overall, His6-THB-PTEN construct
III
 encoded in pET28a vector 
delivered the best result with a small fraction of monomeric species (Figure 12), although 
treatments with detergents or salt were unsuccessful for improvement. However, the 
following His6-tag cleavage resulted in unspecific degradation of this protein construct 
(Figure 12, lower right). Altering the protease cleavage site, His6-TEV-PTEN construct
IV
 was 
subsequently overexpressed. Nearly all protein was obtained in the form of multiple protein 
complexes, together with a significantly lower expression level.  
 
 
Figure 11 | Summary of PTEN constructs for the biochemical assays and the structural biology 
investigation. Depending on the presence of N- and C-terminal regulatory domains, various PTEN 
constructs were overexpressed in insect cells due to post-translational modifications e.g. 
phosphorylation. Only full-length construct was additionally produced in E. coli, representing its open 
active conformation. PTEN constructs (a) harboring and (b) lacking C-tail are varied with the 
presence of N-terminal PIP2 binding motif (residues 6-15). PTEN 7-353 ∆286-309 was used for the 
crystallographic analysis with activity modulators. PBM: PIP2 binding motif. 
                                                 
III
 THB: Thrombin protease cleavage site (LVPR|GS). 
IV
 TEV: tobacco etch virus protease cleavage site (ENLYFQ|G/S). 
RESULTS AND DISCUSSION  22 
 
 
 
 
Figure 12 | Protein purification of His6-THB-PTEN 1-403 from E. coli.
V
 Size exclusion 
chromatography (SEC, HiLoad Superdex S200 16/60) and the corresponding SDS-PAGE reveals the 
multiple protein complex formation of the full-length PTEN overexpressed in the prokaryotic host 
organism. A significant amount of the protein is eluted at the void volume (45 ml), indicating a protein 
size larger than 669 kDa. In addition, proteolytic cleavage of His6-tag using thrombin protease leads to 
unspecific degradation of the protein. (THB: thrombin protease cleavage site; *: His6-THB-PTEN 
1-403) 
Furthermore, full-length PTEN was overexpressed in High Five insect cells using 
baculovirus. The recombinantly produced PTEN construct contained an additional N-terminal 
His6-tag and TEV-protease cleavage site for efficient protein purification. Due to the 
occurrence of numerous phosphorylation patterns during protein expression (Figure 23), the 
different PTEN species were not separated for the biochemical studies. PTEN was first 
purified with Ni
2+
-beads via IMAC (Figure 13a, lane E), followed by proteolytic cleavage of 
His6-tag with TEV-protease (Figure 13a, lane TEV). Thereby, the redundant region including 
the protein affinity tag (His6-TEV) was removed proteolytically. Only a glycine was left as an 
                                                 
V
 Protein purification of His6-THB-PTEN 1-403 from E. coli was performed by Sandra Bäcker for he  M     ’  
Thesis (Fakultät für Chemie und Chemische Biologie, TU Dortmund)
144
. 
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artifact originating from the TEV-protease cleavage site (ENLYFQ|G). The successful 
cleavage was demonstrated by the protein band shift in SDS-PAGE towards the lower 
molecular weight after treatment with TEV-protease. Full-length PTEN was furthermore 
purified with size exclusion chromatography as a final purification step (Figure 13b). 
Compared to the chromatograms of protein standards, the retention volume of the full-length 
PTEN indicates its monomeric nature. Overall, the purified PTEN shows high purity, as 
determined by SDS-PAGE analysis. The yield of full-length PTEN averages out at about 
25 mg from 1 liter culture volume in the final purity. 
 
Figure 13 | Protein expression and purification of His6-TEV-PTEN 1-403 from insect cells. (a) 
SDS-PAGE analysis of protein expression, affinity chromatography and His6-tag cleavage. (b) SEC 
chromatogram (HiLoad Superdex S200 16/60) and SDS-PAGE analysis of the full-length construct in 
final purity. Its retention volume indicates the monomeric species compared with protein standards. 
For information about expression and purification of other PTEN constructs, see chapter 7.3 (TEV: 
tobacco etch virus protease). This figure is from the reference No. 171, © 2015 The Authors. 
Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
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Four additional recombinant PTEN constructs were produced and purified (Figure 14). 
Analogous to the full-length PTEN from insect cells, these protein constructs containing His6-
tags were overexpressed in High Five insect cells and purified via IMAC, proteolytic cleavage 
of His6-tag, and size exclusion chromatography. The corresponding chromatograms and SDS-
PAGE analyses are found in Figure 46 – Figure 50.  
 
Figure 14 | SDS-PAGE analysis of PTEN constructs. The isolated five PTEN constructs 
overexpressed in insect cells are represented with final purity. The proteins were initially purified with 
affinity chromatography via His6-tag, which was subsequently removed by treatment with TEV-
protease. Size exclusion chromatography served as final purification.   
Recombinant PTEN 1-353 could not be isolated by heterologous protein expression. Western 
blot analysis confirms the overexpression of this protein construct in insect cells (Figure 15). 
However, His6-TEV-PTEN 1-353 appears to be insoluble. Given the possibility of strong 
interaction with the cell membrane and the following sedimentation, several detergents such 
as Triton X-100, NP-40, CHAPS, and sodium cholate were added during lysis. Nevertheless, 
the solubility of His6-TEV-PTEN 1-353 was not improved, implicating precipitation during 
protein expression. 
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Figure 15 | PTEN 1-353 is overexpressed in insoluble form.
VI
 Analogous to other constructs, 
protein production of PTEN 1-353 was induced in insect cells using baculovirus-mediated expression 
system. Due to its insolubility, western-blot analysis was employed to validate the protein expression. 
The overexpression is confirmed in insect cell cultures infected with four independently produced 
virus stocks. However, protein bands specific for PTEN are missing in the soluble fraction indicating 
protein production in insoluble form. (*: His6-TEV-PTEN 1-353, Mr = 44.6 kDa; TEV: tobacco etch 
virus protease recognition site) 
3.1.2 Truncated version of PTEN (tPTEN) for protein crystallization 
To study structural impact of activity modulators on PTEN, X-ray crystallography was 
employed. This method requires a well-ordered protein crystal, which is formed by regular 
packing of the protein of interest through intermolecular non-covalent interactions. Thereby, 
the target protein should be designed preferably as a rigid body to facilitate the crystallization 
process, since flexible regions may disturb proper crystal packing and consequently results in 
failure of crystallization or low data quality. In addition, a successful crystallographic effort 
frequently includes optimization of the recombinant protein expression and purification. This 
is due to the fact that formation of a protein crystal is promoted by high purity and 
concentration of the protein of interest. 
                                                 
VI
 Western-blot analysis of PTEN 1-353 was performed by Sandra Bäcker for     M     ’  T      (             
Chemie und Chemische Biologie, TU Dortmund)
144
. 
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Figure 16 | Crystallization construct of tPTEN and its purification strategy. The crystallization 
construct PTEN 7-353 Δ286-309 adopted by the aforementioned crystal structure comprises PIP2 
binding motif, phosphatase and C2-      . T      x b      p   g    Δ286-309 and the C-tail domain 
are not included. Following the serial purification steps, PTEN undergoes protein crystallization. 
(IMAC: immobilized metal ion affinity chromatography, TEV: tobacco etch virus protease, IEX: ion 
exchange chromatography, SEC: size exclusion chromatography)  
For the crystallographic effort, the available crystal structure of PTEN was adopted. Lee et al. 
(1999) solved the structure with a truncated version including PTEN 7-353 Δ286-309 
(tPTEN, PDB 1D5R), after they identified a rigid body using limited proteolysis with 
subtilisin
43,47
. This protein construct comprises PIP2 binding motif, phosphatase and C2-
domain and exhibits active site cysteine in the reduced state
43
 (Figure 16). However, this 
protein construct lacks flexible regions such as the entire C-tail region with 50 amino acids 
(residues 354-403) and D-loop with 24 amino acids (residues 286-309), which were deleted 
for proper crystal formation. In this study, tPTEN was produced containing an additional N-
terminal His6-tag and TEV-protease cleavage site (His6-TEV-tPTEN) for efficient protein 
purification. Analogous to the preceding crystal structure and the full-length PTEN, His6-
TEV-tPTEN was produced in High Five insect cells via baculovirus. Following cell lysis, 
tPTEN was purified over five steps, including IMAC, proteolytic cleavage of His6-tag, buffer 
exchange, ion exchange chromatography and size exclusion chromatography. After the serial 
purifications, tPTEN was subjected to protein crystallization.   
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Figure 17 | Protein purification of PTEN 7-353 Δ286-309. (a) SDS-PAGE analysis of protein 
expression, affinity chromatography and His6-tag cleavage. (b) IEX chromatogram (HiTrap SP HP) 
and SDS-PAGE analysis. Two tPTEN species are separated by overall charge differences. (NaCl 
concentration; A: 264 mM, B: 305 mM) (c) SEC chromatogram (HiLoad Superdex S200 16/60) and 
SDS-PAGE analysis of the crystallization construct in final purity (species A, Figure 17b). Its 
retention volume indicates the monomeric species compared with protein standards. (TEV: tobacco 
etch virus protease) 
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His6-TEV-tPTEN was initially isolated using affinity chromatography with Ni
2+
-beads, 
followed by treatment with TEV-protease (Figure 17a). The evident protein band shift in 
SDS-PAGE analysis indicates successful removal of the redundant region (His6-tag and TEV-
protease cleavage site; Figure 17a, lane E and TEV). The subsequent protein buffer exchange 
allowed to separate variably charged tPTEN species with ion exchange chromatography, 
which are engendered by the post-translational modification (Figure 17b). Since the 
isoelectric point of the crystallization construct (pI = 8.7) is above the pH-value of the running 
buffer (pH = 7.0), cation exchange chromatography was employed with increasing salt 
concentration, from 100 mM to 400 mM over 12 column volumes (CV). As demonstrated in 
the chromatogram, two tPTEN species could be isolated using this method (NaCl 
concentrations: 264 mM for species A, 305 mM for species B). These two species were 
treated separately in the subsequent purification and crystallization steps. As a final step, 
tPTEN was purified by size exclusion chromatography. Given the fact that this method allows 
us to change the buffer environment along with purification, the buffer used in this step is the 
final protein storage buffer prior to crystallization set-up. The buffer composition was 
modified by employing a lower salt concentration (150 mM NaCl instead of 400 mM NaCl in 
the previous report
43
), as the reduced ionic strength decreases solubility and thereby promotes 
the crystallization process. As seen in the chromatogram, tPTEN manifests its monomeric 
nature compared to protein standards (Figure 17c). In addition, high protein purity was 
validated by SDS-PAGE analysis. 18 mg and 8 mg of the species A and B (Figure 17b) were 
yielded in the final purity from 1l insect cell culture, respectively. Protein expression and 
purification of various PTEN constructs are summarized in Table 1. 
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Table 1 | Summary of protein expression and purification. Eight different PTEN constructs in the 
presence and absence of regulatory domains were recombinantly expressed to study protein-ligand 
interaction. Six PTEN constructs have been successfully isolated. (IMAC: immobilized metal ion 
affinity chromatography, TEV: tobacco etch virus protease, IEX: ion exchange chromatography, SEC: 
size exclusion chromatography) 
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3.2 Effects of PIP2/PIP3-derivatives on phosphatase activity 
The enzymatic activities of five successfully isolated PTEN constructs (Figure 14) were 
furthermore determined using malachite green assay
145
. This standard phosphatase assay takes 
advantage of the colorimetric change upon the orthophosphate released by phosphatases. The 
resulting phosphate molecule forms a malachite green phosphomolybdate complex under 
acidic condition. This green-colored inorganic complex exhibits an absorption range at 620-
650 nm and thereby the amount of released phosphate can be quantified. Particularly, this 
assay allows           PTEN’            b       PIP3. In this study, PI(3,4,5)P3-diC8, a 
derivative of PIP3 with truncated lipid acid side chains (C8 instead of C18-20), was employed 
to ensure solubility of the substrate and homogeneous assay conditions (Figure 18c). 
Phosphatase activity was measured at 1, 5, and 10 min after addition of PIP3 (75 µM) to 
PTEN (50 nM) at 25 °C. Since the enzymatic activities show logarithmic curves, the relative 
PTEN activity was determined using the initial conversion rate. PTEN activities of the five 
constructs were plotted in normalized values, setting the phosphatase activity of the full-
length PTEN 1-403 to 100 % (Figure 18a). Notably, there is a limitation of this assay. In this 
experimental setup, enzymatic reaction of PTEN occurs in solution, and not at the plasma 
membrane. In this regard, PTEN activity illustrated herein may not reflect the entire 
physiological events upon PTEN activation, involving subcellular localization and protein-
protein interaction at the plasma membrane. Nevertheless, this assay is sufficient to compare 
the construct-dependent relative phosphatase activities of PTEN. 
Consistent with an earlier in vitro study
48
, the N-terminal domain appears to be essential for 
the PTEN activity (Figure 18a, gray). Compared with the full-length PTEN 1-403 
(100 ± 3 %), the absence of the N-terminal domain leads to almost complete loss of enzymatic 
activity (PTEN 16-403: 12 ± 8 %), implicating its involvement in enzymatic reaction. 
Notably, a significant reduction of phosphatase activity is observed in PTEN 6-403 (25 
± 1 %), even though this construct still includes the entire PIP2 binding motif (residues 6-
KEIVSRNKRR-15). This observation implies a potential hydrophobic interaction of N-
terminal five amino acids (residues 1-MTAII-5) with fatty acid side chains of 
phosphatidylinositol. The contribution of N-                   PTEN’    zy             y    
also shown in the C-terminal truncated versions e.g. PTEN 6-353 (163 ± 1 %) and PTEN 16-
353 (1 ± 1 %). In the latter construct, the absence of the entire N-terminal domain diminishes 
phosphatase activity of PTEN.  
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Figure 18 | Phosphatase activity of PTEN depends on the protein constructs and can be 
modulated by small molecules. (a) Using malachite green assay, phosphatase activity of various 
PTEN constructs was determined depending on the presence of N- and C-terminal regulatory domains. 
(gray, no addition of additives; for more information about protein constructs, see Figure 11). Due to 
its autocatalytic property, the construct-dependent activating effect was investigated performing the 
same assay with the addition of PIP2 (red; 50 nM PTEN, 75 µM PI(3,4,5)P3-diC8 as substrate, 50 µM 
PI(4,5)P2-diC8, T = 25 °C, t = 30 min; triplicates, errors represent ± SD, * P < 0.05, ** P < 0.01, *** 
P < 0.001, ns: not significant) (b) Effects of activity modulators on the phosphatase activity of PTEN 
were demonstrated. Full-length PTEN (50 nM) was pre-incubated for 10 min with either PIP2 (50 µM, 
red), nhPIP3 (50 µM, purple), H2O2 (400 µM, blue), bpV-phen (1 µM, orange), bpV-pic (1 µM, 
yellow), or bpV-HOpic (1 µM, green), followed by addition of PIP3 (75 µM, T = 25 °C, t = 30 min; 
triplicates, errors represent ± SD, * P < 0.05, ** P < 0.01, ns: not significant). (c) Chemical structures 
of PIP-derivatives. 
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The C-terminal domain (residues 352-403) has an inhibitory effect on the phosphatase activity 
of PTEN (Figure 18a, gray). Under our assay conditions, it is validated that PTEN 6-353 
shows significantly higher activity than PTEN 6-403 and the full length construct, which is in 
agreement with previous reports
55,71
. 
As previously mentioned (Chapter 1.2.1), PTEN catalyzes hydrolysis reaction of PIP3 and 
releases PIP2. However, an activating effect of the reaction product PIP2 on PTEN has been 
reported in an earlier in vitro study, indicating an autocatalytic mechanism
48
. This property of 
PIP2 is also validated in this study (Figure 18a, red). The presence of additional PIP2 (50 µM) 
increases the enzymatic reaction rate in PTEN constructs including N-terminal domains 
(PTEN 1-403, PTEN 6-403, PTEN 6-353). Only a slight increase of the reaction rate in PTEN 
6-353 is ascribed to a very high hydrolysis rate under this condition that was optimized to 
ensure the activity differences of PTEN constructs. Under this assay condition, almost 
complete conversion of PIP3 by PTEN 6-353 was observed in the absence of additional PIP2, 
even at the first measurement point (1 min). 
Next, phosphatase activity of full-length PTEN (50 nM) was determined in the presence of 
different activity modulators (Figure 18b). Incubation with PIP2 or nhPIP3
VII
 (50 µM for each) 
increases enzymatic activity of PTEN (100 ± 7.5 %) to 119.3 ± 6.4 % and 127.7 ± 6.4 %, 
respectively, implicating a potential allosteric binding site for PIP2 or nhPIP3, and no 
selectivity for PIP2 or PIP3. Activity modulation of PTEN was subsequently measured with its 
inhibitors. Under our assay conditions, H2O2 (400 µM), bpV-phen, bpV-pic and bpV-HOpic 
(1 µM for each bpV-complex) shows efficient inhibition (H2O2: 21.4 ± 3.5 %, bpV-phen: 10.3 
± 2.5 %, bpV-pic: 6.0 ± 2.0 %, bpV-HOpic: 9.3 ± 1.5 %).  
Having characterized the activity modulating effects of the regulatory domains of PTEN and 
the available modulators, fluorescence polarization (FP) assay was employed to identify the 
binding domain of PIP2 (Figure 19). Fluorescein-labled PIP2 (20 nM) was incubated with six 
different PTEN constructs in serial dilution and the fluorescence polarization was 
measured
146
. Notably, FP assay result shows no effective binding of PTEN constructs 
containing C-tail with PIP2, while PTEN constructs lacking C-tail shows higher affinity for 
this activity modulator. Concerning that phosphatase activity of PTEN constructs containing 
C-tail is increased in the presence of PIP2, this result may implicate the competition of 
                                                 
VII
 nhPIP3 is a non-hydrolyzable version of PIP3 involving a thiophosphate at D3-position (Figure 18c).  
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intramolecular C-     w                b  w    PTEN’                   PIP2 (Figure 18a, 
Figure 18b and Figure 19a). In addition, PIP2 affinity of PTEN 16-353, which lacks PIP2 
binding motif, appears comparable to PTEN 6-353 (Figure 19b), indicating PIP2 binding 
motif-independent interaction between PIP2 and the core domains. Giving the possibility of 
PIP2 interaction with either the active site or an allosteric binding site, phosphatase and C2 
domains (Figure 3) were separately expressed using E. coli and insect cells
VIII147
. However, it 
was not possible to obtain the single domains in soluble and monomeric forms. Therefore, 
investigation of PTEN interaction with PIP2 and nhPIP3 was discontinued. 
 
Figure 19 | C-tail of PTEN may compete with interaction between PTEN’s core domain and 
PIP2.
IX
 Fluorescence polarization (FP) assay served to determine the interaction of various PTEN 
constructs with fluorescein-labeled PIP2 (20 nM, measured at 494 nm). (a) PTEN constructs including 
C-tail show very low affinity for PIP2 (KD > 500 µM, single point measurements). (b) PTEN 
constructs lacking C-tail show higher affinity for PIP2 compared to those with C-tail. PTEN 16-353 
devoid of the putative PIP2-binding motif shows comparable PIP2 affinity to PTEN 6-353 and PTEN 
7-353 (Δ286-309) (triplicates, errors represent ± SD). 
  
                                                 
VIII
 Recombinant protein expression of phosphatase and C2 domains was performed by Carolin Müller for her 
M     ’  T      (             C          C         B    g  , T          )147. 
IX
 FP-assay of PTEN in the presence of PIP2 w   p         by A    K pp           M     ’  T      (         
für Chemie und Chemische Biologie, TU Dortmund)
146
. 
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3.3 Oxidative modification of PTEN by hydrogen peroxide and bpV-phen 
3.3.1 Determination of half-maximal inhibitory concentration  
Initially, biochemical effects of H2O2 and bpV-complexes on full-length PTEN were validated 
by determining the half-maximal inhibitory concentrations (IC50) of both compounds. 
Analogous to the previous phosphatase activity measurement (Chapter 3.2), malachite green 
assay was performed using the truncated version of PIP3, PI(3,4,5)P3-diC8
145
. 
 
Figure 20 | H2O2 and bpV-inhibitors inhibit phosphatase activity of PTEN. Half-maximal 
inhibitory concentrations (IC50) of H2O2 (blue), bpV-phen (orange), bpV-pic (green) and bpV-HOpic 
(yellow) were determined by phosphatase activity measurements using malachite green assay. (50 nM 
full-length PTEN, 75 µM PI(3,4,5)P3-diC8 as substrate, T = 25 °C, t = 30 min; triplicates, errors 
represent ± SD.) 
App y  g 50  M PTEN     75 μM   b      , PTEN  x  b          xp      p   p       
activity. In the presence of H2O2, bpV-phen, bpV-pic, and bpV-HOpic with serial dilution, 
IC50 were subsequently determined to be 60 ± 23 μM, 0.18 ± 0.02 μM, 0.050 ± 0.004 μM,     
0.058 ± 0.006 μM, respectively. The values are in agreement with the previously reported 
range
82,131
. Remarkably, IC50 of H2O2 is significantly higher than its intracellular 
concentration in mammals, which varies from 0.001 to 0.7 μM for the redox signaling in the 
basal state
148 X
. Given oxidation of PTEN observed in the growth factor-mediated redox 
signaling
109
 (Chapter 1.3.2), this physiological event is implicated to occur in response to 
local high concentration of H2O2.  
                                                 
X
 IC50 (H2O2) is higher by about 85 times compared to its maximal intracellular concentration. 
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3.3.2 Reactivation assay 
Oxidative inhibition of PTEN by H2O2 via disulfide formation and its reactivation under 
reductive conditions have already been shown in previous studies
82,83
. Prior to structural 
characterization, the reversible character of PTEN inhibition by H2O2 was confirmed using 
malachite green assay. PTEN was pre-incubated with H2O2 (3.5 mM), followed by dilution 
with buffer either containing or lacking reducing agent (mock). The residual phosphatase 
activity was subsequently determined. Effective inhibition was demonstrated in the absence of 
the reducing agent (residual activity = 8 ± 4 %), whereas PTEN reveals complete reactivation 
upon dilution with dithiothreitol (DTT, 4 mM; residual activity = 99 ± 3 %). In addition, the 
presence of physiologically relevant reducing agents (e.g. glutathione (GSH, 4 mM), 
thioredoxin system (5 μM         x   1, 0.1 μM         x                 200 μM 
NADPH)) also resulted in significant restoration of phosphatase activity (73 ± 4 % and 75 ± 
2 %, respectively)
XI
. These observations are in agreement with previous reports and validate 
the reversible character of PTEN inhibition by H2O2
82
.  
Concerning bpV-based PTEN inhibitors, bpV-phen was chosen for further studies due to its 
highest stability in aqueous solution
152
. Inhibitory effect of bpV-phen was validated in the 
aforementioned chapter (Chapter 3.3.1). However, it is so far unknown, how these 
compounds exert inhibition upon PTEN. According to Huyer et al. (1997), treatment with 
peroxidovanadate, a chemically related compound harboring peroxide ligands, promotes 
hyperoxidation of the catalytic cysteine in PTP1B to sulfonic acid
153
. Hence, the question 
shall be answered, whether bpV-phen exerts non-covalent or oxidative inhibition on PTEN. 
Given the latter case, it was worthwhile to discern two possible modifications: Disulfide bond 
(reversible) vs. hyperoxidation (irreversible). For that reason, the reactivation test of 
phosphatase activity was performed, analogous to the preceding assay with H2O2. The 
effective inhibition (residual activity = 4 ± 4 %) was determined by treatment of bpV-phen 
(400 μM)       b  q              w         y  educing agents (mock). In analogy to H2O2-
treated PTEN, DTT, GSH and the Trx system restored the phosphatase activity to 95 ± 7 %, 
69 ± 5 % or 15 ± 5 %, respectively. This result indicates the oxidative inhibition and supports 
disulfide formation of PTEN upon bpV-phen treatment.  
                                                 
XI
 Concentrations of glutathione and thioredoxin 1 applied in this assay were chosen according to the 
endogenous concentrations of both molecules (GSH: 0.5 – 10 mM, TRX1: 1 – 10 µM)149,150,151. 
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Figure 21 | PTEN inhibition by H2O2 and bpV-phen is reversed under reductive conditions. 
Following the incubation with 3.5 mM H2O2 (blue) or 400 µM bpV-phen (orange), treatment of 5 µM 
full-length PTEN with 4 mM DTT, 4 mM GSH or thioredoxin system (Trx) reactivates its phosphatase 
activity. (Trx is composed of 5 μM         x  , 0.1 μM         x                 200 μM NA PH.; 
triplicates, errors represent ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001) 
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3.3.3 Mass-spectrometric analysis 
Next, chemical modification of PTEN upon oxidative inhibition was studied. Upon treatment 
with H2O2, PTEN undergoes disulfide formation involving the active site cysteines C124 and 
C71
82
. However, it remains elusive, if bpV-phen treatment induces the same disulfide bond. 
For this purpose, HPLC-coupled high resolution MS and MS/MS analysis were applied to 
investigate covalent protein modification of PTEN upon oxidative inhibition in cooperation 
with Dr. Tanja Bange (MPI Dortmund). Sample preparation was performed by the author of 
this thesis. Measurements and data analysis were carried out by Dr. Tanja Bange and 
Franziska Müller. Full-length PTEN samples were first treated with H2O2 or bpV-phen. 
Subsequent incubation with iodoacetamide allowed to prevent the free cysteine thiols from 
further modifications as well as thiol-disulfide shuffling. The following tryptic digestion was 
performed in the absence of reducing agents to maintain the disulfide bond. The resulting 
peptide fragments were separated and analyzed using HPLC-MS. Treatment with H2O2 or 
bpV-phen provided a new tryptic fragment with a monoisotopic mass of 930.918 Th (MH
4+
) 
(Figure 22a and b, upper panel)
XII
. In both cases, MS/MS sequencing of this peak revealed a 
peptide fragment harboring a disulfide bond crosslinked between C71 and C124 (Figure 52). 
Notably, subsequent treatment of the oxidized sample with 10 mM DTT diminished the 
corresponding isotopic pattern (Figure 22b, lower panel), supporting the occurence of 
disulfide bond upon H2O2 or bpV-phen treatment. Concerning the irreversible hyperoxidation 
of PTP1B by peroxidovanadate treatment instead of reversible oxidative sulfenyl-amide 
formation
122,123,153,154,173
 (Figure 8 and Figure 9), the disulfide bond formation of PTEN by 
bpV-phen underpins the proposed protective mechanism from irreversible inactivation
10,116
. 
Prior to structural analysis of PTEN upon oxidative modification, the applicability of the 
crystallization construct (tPTEN) was confirmed for the following X-ray crystallography 
study. Treatment of tPTEN with H2O2 and bpV-phen resulted in tryptic fragments involving 
the same disulfide formation (Figure 53 and Figure 54). 
                                                 
XII
 For more spectral data, please see Figure 51 – Figure 54. 
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Figure 22 | H2O2 and bpV-phen-induced oxidative inactivations result in disulfide formation
XIII
. 
(a) The resulting peptide fragment of PTEN after H2O2 or bpV-phen treatment and the subsequent 
incubation with iodoacetamide and trypsin. The disulfide bond is formed between C71 and C124 (Th: 
Thomson = Da / e). (b) Compared to the untreated control (black), high-resolution MS validates the 
disulfide formation after H2O2 (1 mM, blue) or bpV-phen (1 mM, orange) treatment (upper panel; 
T = 25 °C, 100 µM PTEN, t = 10 min), detecting the corresponding monoisotopic pattern of the tryptic 
fragment. Consistent with the reversible property of disulfide bond, subsequent incubation with DTT 
(10 mM, 10 min) diminishes the signal (lower panel). This figure is reconstructed based on Lee et al. 
(2015)
171
. 
  
                                                 
XIII
 Measurements of HPLC-MS and MS/MS and the following data analysis were carried out by Dr. Tanja 
Bange and Franziska Müller (MPI Dortmund, Germany). 
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3.4 Crystal structure of reduced PTEN 
3.4.1 Protein crystallization of the full-length PTEN and reduced tPTEN 
Structural effects of activity modulators on PTEN were furthermore investigated. For this 
purpose, full-length PTEN was initially subjected to protein crystallization. So far, structural 
information of the full-length PTEN remains elusive, which would additionally allow us to 
understand its functional regulation. Given that phosphorylation-mediated “      ” 
conformation of PTEN is facilitated by electrostatic interaction between globular domains and 
the phosphorylated C-tail
55,70,71
 (Chapter 1.2.3), full-length PTEN in the autoinhibited state 
might be crystallized as a rigid body. For the successful crystallization, the host organism for 
protein production should be able to phosphorylate PTEN. The recombinantly expressed full-
length PTEN should also be isolated with a single phosphorylation pattern in high purity.  
Full-length PTEN was overexpressed in High Five insect cells and initially purified with Ni
2+
-
beads via IMAC. After His6-tag cleavage and buffer exchange, different phosphorylation 
species were separated by ion exchange chromatography. Since the isoelectric point of the 
crystallization construct (pI = 5.95) is below pH-value of the running buffer (pH = 8.0), anion 
exchange chromatography was employed with increasing salt concentration from 50 mM to 
500 mM (Figure 23a). Concerning the multiple phosphorylation sites (Figure 4), a flat salt 
gradient over 125 CV was employed. Nonetheless, merged pattern of peaks was observed, 
indicating numerous post-translationally           p     . P                       w  “q     
p    ” w                 p          p      y     g size exclusion chromatography (species A 
and B, Figure 23b). Large-scale screening was performed for protein crystallization of both 
species using pre-mixed crystallization buffers (Qiagen
®
 NeXtal JCSG Core Suites) (Table 2). 
Protein drops contraining three different PTEN concentrations (20, 15, 10 mg/ml) and 
reservoir solution (ratio 1:1) were set up implementing the sitting drop vapor diffusion 
crystallization method
206
. Notably, crystalline formation was observed only from one 
condition (Qiagen
®
 NeXtal JCSG Core I, No. 5
XIV
, T = 20 °C; species A) including 
1,6-hexanediol (Figure 23c). However, its reproduction for the further optimization was 
unsuccessful in the grid screening format, in which pH and 1,6-Hexanediol concentration of 
the reservoir solution were varied.  
                                                 
XIV
 Composition: 100 mM Tris (pH 8.5), 200 mM MgCl2, 3.4 M 1,6-Hexanediol 
RESULTS AND DISCUSSION  40 
 
 
 
 
 
Figure 23 | Protein crystallization of the full-length PTEN. (a) IEX chromatogram (MonoQ 
5/50 GL). Two PTEN species were isolated. (NaCl concentration; A: 95 mM, B: 122 mM) (b) SDS-
PAGE analysis of the full-length construct in final purity. (c) Time course of crystallization. 
Crystalline formation was observed in one condition only (Qiagen
®
 NeXtal JCSG Core I Suite, No. 5, 
T = 20 °C; species A).  
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Table 2 | Crystallization conditions used for the full-length PTEN. The isolated species A and B 
were subjected to initial protein crystallization using JCSG Core screening suites (Qiagen
®
 NeXtal). 
Protein drops containing three different PTEN concentrations (c = 20, 15 and 10 mg/ml) and reservoir 
solution (ratio 1:1) were set up employing the sitting drop vapor diffusion crystallization method
206
. 
Protein crystallization was performed at 20 and 4 °C. 
Species A   Species B  
20 °C 4 °C  20 °C 4 °C 
Core I  Core I   Core I Core I 
- Core II  Core II Core II 
Core III Core III  Core III Core III 
- Core IV  - Core IV 
 
Next, protein crystallization of the truncated construct tPTEN (PTEN 7-353 Δ286-309) was 
established based on the previous crystal structure of PTEN. As previously shown in the 
chapter 3.1.2, protein production of tPTEN in high purity allowed us to perform both large-
scale and grid crystallization screenings. For the latter method, parameters (e.g. pH, 
concentration of precipitant and additive, temperature) were varied to find the optimum 
around the known crystallization condition
XV
 (PDB 1D5R)
43
. Although the large-scale 
screening did not deliver a suitable protein crystal
XVI
, box-like protein crystals of tPTEN 
appeared in the grid screen after two days, but only from species A (Figure 17b), and grew 
over five days at 20 °C (Figure 24). tPTEN crystals tend to grow in fewer numbers but larger 
under lower concentrations of the precipitant (L-tartrate) and the additive (glycerol). The best 
diffracting crystals were obtained under slightly acidic condition with lower tartrate 
concentration
XVII
. After optimization of the crystallization condition, protein composition of 
tPTEN crystals was additionally confirmed by SDS-PAGE analysis. Proteins in the crystals 
showed highest purity, as crystallization is a sort of purification process (Figure 24). Prior to 
                                                 
XV
 100 mM Tris-HCl, 1.3M Na/K L(+)-tartrate, 5 % ‒ 10 % (v/v) glycerol, 10 mM DTT (pH 8.0), T = 20 °C,  
c(tPTEN) = 20 mg/ml
43
 
XVI
 Protein crystallization of tPTEN was set up using Qiagen® NeXtal suites (JCSG Core Suites I, II, III, IV, 
Classics Suites I, II, Cryo Suite, MPD Suite, PEGs Suites I, II, Protein Complex Suite). Implementing the sitting 
drop vapor diffusion crystallization method
206
, tPTEN (20, 10 and 5 mg/ml) was incubated with reservoir 
solution (ratio 1:1) at 4 °C.  
XVII
 100 mM MES (pH 6.5), 1.25M Na/K L(+)-tartrate, 7.5 % (v/v) glycerol, T = 20 °C,  c(tPTEN) = 20 mg/ml 
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data collection at synchrotron, tPTEN crystals were soaked in reservoir solution supplemented 
with higher glycerol concentration
XVIII
 and flash-frozen.  
 
Figure 24 | SDS-PAGE analysis of PTEN 7-353 Δ286-309 and its protein crystals. Protein purity 
of each purification step is represented with SDS-PAGE analysis. Protein crystals (right) were 
confirmed using SDS-PAGE (Mr = 38.4 kDa). This figure is from the reference No. 171, © 2015 The 
Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
3.4.2 Structure determination 
Protein crystals of PTEN allowed us to analyze its 3D-structure using X-ray crystallography. 
At first, monochromatic diffraction data of a tPTEN crystal (Chapter 3.4.1) were collected 
under cryogenic condition at a synchrotron radiation source (Swiss Light Source, Villigen, 
Switzerland) implementing the rotating-crystal method
155,156
. The wavelength of 1.000 Å was 
utilized for data collection. 1440 frames of X-ray diffraction patterns were recorded at every 
0.25º, as the tPTEN crystal was gradually rotated by 360º. The diffraction dataset was 
furthermore processed using X-ray detector software XDS
157
 by analyzing the diffraction 
pattern, which originates from the position and intensity of reflections on the detector. 
XSCALE
157
 was used to reduce the data to the lowest resolution of 2.2 Å (Table 3)
XIX
. The 
scaled dataset involves overall 99.9 % of data completeness.  
                                                 
XVIII
 100 mM MES (pH 6.5), 1.25M Na/K L(+)-tartrate, 25 % (v/v) glycerol 
XIX
 Criteria for selection of the lowest resolution were data completeness (> 95 %), signal-noise ratio (I/I) > 1) 
and correlation coefficient (CC1/2 > 70 %)
158
.  
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Table 3 | Dataset statistics of reduced tPTEN crystal. I/states signal to noise ratio of unique 
reflections. Rmeas is a redundancy-independent R-factor
159
. CC1/2 is indicative of the correlation 
percentage between reflection intensities from random half-datasets
158
. Correlation significant at the 
0.1 % level is highlighted by an asterisk. 
Resolution 
[Å] 
Number of reflections Completeness 
[%] 
  I/I) 
Rmeas 
[%] 
CC1/2 
[%] Observed Unique Possible 
20.0 1595 152 168 90.5  49.07 5.2 99.9* 
15.0 2465 191 191 100.0  56.02 3.8 99.9* 
10.0 10456 787 787 100.0  61.54 3.4 99.9* 
8.0 11729 1022 1023 99.9  51.87 3.8 99.9* 
6.0 37679 2852 2853 100.0  42.13 5.1 99.9* 
4.0 149789 11368 11368 100.0  41.87 5.5 99.9* 
3.1 249220 18387 18391 100.0  22.27 11.5 99.8* 
3.0 47158 3510 3511 100.0  9.53 32.0 98.9* 
2.9 55999 4062 4062 100.0  8.64 36.2 99.0* 
2.8 64274 4620 4621 100.0  6.49 51.2 98.0* 
2.6 161522 11530 11534 100.0  4.21 80.8 95.5* 
2.5 96191 7198 7203 99.9  2.65 129.9 88.8* 
2.4 107706 8435 8436 100.0  2.05 163.2 83.2* 
2.3 134037 9953 9961 99.9  1.63 203.3 81.3* 
2.2 163197 11832 11843 99.9  1.17 273.9 72.7* 
Total 1293017 95899 95952 99.9  13.96 15.6 99.9* 
Data processing generates a reflection data containing information about the experimental 
data, which serves to calculate an electron density map with structure factor amplitudes. By 
default, this software automatically determines and suggests the highest probable 
crystallographic parameters such as space group and the unit cell constants based on the 
diffraction patterns during the data processing. However, the intrinsic twinning character of 
the tPTEN crystal (two twin fractions, ratio: 0.49 and 0.51) hindered to find the correct 
parameters with the software XDS, which consequently resulted in high R-factor in the later 
refinement step (Eq. 5)
XX
. Since a twinned crystal is a composition of single crystals that are 
arranged with different orientations in a crystal, mathematical operators should be applied to 
solve the structure after determination of correct crystallographic parameters (Table 4). This 
issue was resolved by processing the diffraction data with implementation of a lower 
                                                 
XX
 R-factor is a measure of agreement between the structure model and the experimental data (Eq. 5). High 
R-factor indicates that the structural solution is in accordance with the experimental data with low probability.   
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symmetry
XXI
 and applying detwinning functions (operators: k, h, -l and h, k, l) in the model 
refinement process. Following data processing, electron density map was generated to 
determine the structure solution. This requires structure factors of the crystallized protein 
including amplitude and phase information for calculation. However, the experimental data 
provides only amplitude but lacks phase information. Among various approaches to solve the 
“p     p  b   ”,             p         w    pp                 y. This method is based on 
utilizing the phase term of the available structure that exhibits high sequence homology. 
Molecular replacement was performed with the reflection data against the known PTEN 
structure (PDB 1D5R)
43XXII
. In a unit cell, the structure solution contains eight asymmetric 
units, which are the smallest units that can be used to reproduce a complete unit cell by 
applying symmetry operations. The asymmetric unit of tPTEN consists of four protomers 
(Chain A – D, Figure 25). The structure model was subsequently built in the electron density 
and refined in the iterative way
XXIII
, until the discrepancy (R-factor) between crystallographic 
structure model and experimental X-ray diffraction data reached a minimum (Rwork = 0.19 and 
Rfree = 0.22). Crystallographic parameters and refinement statistics of tPTEN crystal (reduced, 
PDB 5BZZ) are summarized in Table 4.  
In the final structure model, electron density is resolved from 14 to 351 in all four protomers 
of tPTEN (PDB 5BZZ). The missing electron density (∆         : 7-13 and 352-353) 
implicates flexible nature of N- and C-termini in the structure. In addition, four protomers of 
tPTEN in the asymmetric unit were compared using the final structure model. Discrepancies 
were calculated based on root-mean-square deviation (RMSD). As a rule of thumb, RMSD 
under 2 Å manifests a similar three-dimensional structure. The maximal RMSD value is 
represented with 1.46 Å (314 Cα atoms), indicating very similar structures.  
                                                 
XXI
 XDS suggested space groups P4 and its subunits (SG 89 – 96), which comprises two PTEN protomers per 
asymmetric unit. The correct space group is determined to be C2221 (SG 20) involving four PTEN molecules in 
the asymmetric unit. 
XXII
 Molecular replacement was performed using PhaserMR (CCP4 suite
200,201
). 
XXIII
 Coot
195
 and Refmac
196
 were utilized for manual correction and automatic refinement of the structure model, 
respectively.   
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Figure 25 | Arrangement of four PTEN molecules in the asymmetric unit shows intermolecular 
contacts in the protein crystal. Each protomer in the asymmetric unit is represented with different 
colors. RMSD values (314 Cα atoms) under 2 Å reflect high similarity to each other (Chain A: gray; 
chain B: yellow; chain C: green; D: purple; RMSD: root-mean-square deviation). This figure is from 
the reference No. 171, © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.  
  
RESULTS AND DISCUSSION  46 
 
 
 
Table 4 | Crystallographic data collection and refinement statistics of reduced tPTEN crystal. 
Structure coordinates have been deposited in the RCSB Protein Data Bank
42
 with the accession code 
5BZZ. Values in the parenthesis involve the highest resolution shell. RFree was calculated from 5 % of 
the reflections omitted from refinement process. 
 
tPTEN 
PDB code 5BZZ 
  
Data Collection 
 
Space group C2221 
Unit-cell parameters 
 
  a, b, c (Å) 207.17, 207.39, 87.78 
, ,  (°) 90, 90, 90 
Wavelength (Å) 1.000010 
Resolution limits (Å) 46.36 - 2.20 (2.30 - 2.20) 
No. of unique reflections 95899 (11832) 
Completeness (%) 99.9 (99.9) 
Multiplicity 13.48 (13.79) 
I/I) 13.96 (1.17) 
CC1/2 99.9 (72.7) 
Robs 15.0 (263.7) 
  
Refinement 
 
Resolution limits (Å) 46.36 - 2.20 (2.30 - 2.20) 
RWork / RFree 0.1920 / 0.2207 
R.m.s.d. 
 
  Bond length (Å) 0.0094 
  Bond angles (°) 1.567 
  B-factors (Å
2
) 61.4 
No. atoms 
 
  Protein 10338 
  Ligand 40 
  Water 890 
Ramachandran plot (%) 
 
  Favored regions 92.9 
  Allowed regions 6.2 
  Disallowed regions 0.9 
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3.4.3 PTEN structure in the reduced form 
tPTEN structure (PDB 5BZZ) consists of phosphatase and C2 domains (Figure 26). The 
phosphatase domain is composed of five central beta strands, which are surrounded by five 
alpha helices. The active site in the phosphatase domain is facing to the putative membrane 
binding region. The active site pocket contains conserved structural motifs of PTPs (e.g. WPD 
loop and P-loop). In particular, D92 in WPD loop, C124 and R130 in P-loop are essential 
components for hydrolysis reaction of a phosphorylated substrate (Figure 1, Figure 26a and 
Figure 26b)
11
. Importantly, reduced form of the catalytic cysteine C124 is confirmed by 
2 Fo – Fc electron density map (Figure 26c). In addition, a molecule of tartrate is bound to the 
active site in the crystal structure, which originates from the crystallization solution (Figure 
26b). The following C2 domain involving     p        β-sandwich structure has been reported 
to be crucial for membrane binding
43. T                    CBR3    p     Cα2   g   , 
which are enriched with lysine residues. Notably, side chains of two lysines in CBR3 loop are 
not resolved implicating their flexible nature. The tandem phosphatase and C2 domains are 
stabilized by an extensive interface (~1400 Å
2
)
43
. Seven aromatic and hydrophobic residues 
are involved in hydrophobic interactions. Nine residues contribute to hydrogen bond networks 
via side chains and backbone groups (Figure 26a). 
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Figure 26 | Crystal structure of reduced tPTEN. (a) Crystal structure of tPTEN comprises 
phosphatase and C2 domains. Phosphatase domain harbors the active site decorated with WPD-loop as 
well as the catalytic cysteine in P-loop. C2-domain contains Cα2 and CBR3 loops, which are enriched 
with lysines and crucial for membrane binding. The interface of both domains is stabilized by 
extensive hydrophobic interactions and hydrogen bond networks. (b) Tartrate bound to the active site 
is represented with 2 Fo – Fc                y        p (    ,              1σ). S              C71, 
D92, C124, and R130 are shown with stick representations. (c) Active site P-loop with 2 Fo – Fc 
electron density map. (mesh: contoured at 1 σ) The figures 26b and 26c are from the reference No. 
171, © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
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3.4.4 Structural comparison of PDB 5BZZ with PDB 1D5R 
Prior to studying the structural alteration upon H2O2 or bpV-phen treatment, reduced tPTEN 
crystal structure (PDB 5BZZ) was compared to the previous reported one (PDB 1D5R). 
Notably, only one tPTEN molecule is available in PDB 1D5R, although two protomers should 
be present in the asymmetric unit according to the crystallographic parameter applied in this 
study
43
. Structural discrepancies were calculated in RMSD by comparing each protomer in 
the novel structure (Chain A – D) to this available tPTEN molecule PDB 1D5R (Figure 27a). 
The maximal RMSD value is represented with 1.29 Å (314 Cα atoms), indicating overall 
comparable crystal structures to each other. Importantly, the active site P-loops of both 
structures are closely superimposed (Figure 27b). 
 
Figure 27 | PTEN (reduced) exhibits high similarity to the preceding structure. (a) Structural 
overlay of reduced tPTEN (gray, PDB 5BZZ, chain A) and PDB 1D5R (cyan, chain A). RMSD (307 
Cα atoms) under 2 Å reflects high overall similarity.  (b) The active site P-loop of the reduced tPTEN 
(gray, chain A) is closely superimposed on PDB 1D5R (cyan, chain A). This figure is from the 
reference No. 171, © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
Despite the analogy of the crystallization conditions and the structures, the crystal structure 
(PDB 5BZZ) was solved with different crystallographic parameters, implicating distinct 
molecule packing in the protein crystal (Figure 28 and Figure 29). PDB 5BZZ and PDB 1D5R 
harbor four and two protomers in the asymmetric unit, respectively. Each asymmetric unit is 
arranged in a unit cell with a base-centered orthorhombic and body-centered tetragonal 
character involving two-fold and four-fold rotations, as reflected in distinguished space 
groups (PDB 5BZZ: C2221; PDB 1D5R: I4) (Figure 28). In addition, the unit cell of PDB 
5BZZ is determined to be five times larger than PDB 1D5R (unit cell constants | reduced 
tPTEN: 206 X 206 X 89 Å; PDB 1D5R: 113 X 113 X 59 Å). Compared to PDB 1D5R (Figure 
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29a), PDB 5BZZ is packed with big solvent channels (Figure 29b). Taking advantage of this 
feature, soaking experiment with small molecules might be beneficial for the further structural 
investigations. 
 
Figure 28 | Geometric comparison of lattice types of PTEN 7-353 Δ286-309 crystal structures. 
The lattice packing of PDB 5BZZ is different from the preceding PTEN structure (PDB 1D5R) in spite 
of the analogous crystallization condition. The asymmetric units represented by blue spheres are 
positioned with a base-centered orthorhombic character in PDB 5BZZ, compared to the body-centered 
tetragonal lattice type of PDB 1D5R. 
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Figure 29 | Crystal packing of reduced tPTEN in unit cells compared with PDB 1D5R. (a) Front 
and side views of the lattice packing of PDB 1D5R. Two molecules (chain A – B) are assigned to an 
asymmetric unit with space group I4. (chain A: gray; chain B: yellow) (b) Front and side views of the 
lattice packing of reduced PTEN construct. Four Protomers (chain A – D) are present in an 
asymmetric unit with space group C2221. (chain A: gray; chain B: yellow; chain C: green; D: purple) 
A green outlined lattice displays a unit cell. The size of the unit cells is adjusted to the scale shown 
with bars. This figure is from the reference No. 171, © 2015 The Authors. Published by Wiley-VCH 
Verlag GmbH & Co. KGaA. 
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3.4.5 Protein crystallization of tPTEN complexed with PIP2/PIP3-derivatives 
Having established protein crystallization of tPTEN (Chapter 3.4.1), ligand-soaking 
experiments were employed to study the interaction between PTEN and PIP2 and PIP3-
derivatives. Since the physiologically relevant natural products harbor long flexible fatty acid 
side chains (C16) and may interfere with crystallization, those truncated versions with octanoic 
acids (C8) were used. The soaking experiments were performed by transferring the protein 
crystals to a reservoir solution involving high concentration of the ligand (Table 5). The 
incubation time was adjusted to the crystal stability during soaking experiments. To ensure 
sufficient diffusion through the protein crystals, ligand concentration and incubation time 
were chosen as high and long as possible. 20 mM PIP2 and nhPIP3 were incubated with 
tPTEN crystals for 3.5 h and 7 h, respectively. PTEN substrate PIP3 was also utilized with and 
without the preceding oxidation of the active site using H2O2 (1 mM, 1 h). In case of PIP3, 
relatively low concentration (1 mM) and a short incubation time (< 60 min) were chosen due 
to the potential enzymatic digestion. The corresponding crystal structures were solved 
applying the same crystallographic parameters previously used for reduced tPTEN (Table 4). 
However, none of the ligand-soaking attempts yielded additional electron density indicating 
the presence of a ligand. 
Table 5 | Ligand-soaking strategies for PIP2/PIP3-derivatives into tPTEN protein crystals.  
Ligands Strategy Ligand concentration Comments 
PI-(4,5)-P2-diC8 
(alias PIP2) 
Soaking 
20 mM, 3.5 h 
No back-soaking 
Crystals dissolve 
after 3.5 h. 
PI-(3,4,5)-P3-diC8 
(alias PIP3) 
Soaking 1 mM, 40 min  
H2O2, followed by 
PI-(3,4,5)-P3-diC8 
(alias PIP3) 
Soaking 
1 mM, 60 min, 
then 1 mM, 60 min 
back-soaking 
Crystals dissolve 
after the given time. 
3S-PI-(3,4,5)-P3-diC8 
(alias nhPIP3) 
Soaking 
20 mM, 7 h 
No back-soaking 
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3.5 Crystal structure of H2O2-treated PTEN 
Ligand-soaking experiments were furthermore employed to elucidate structural alteration 
upon H2O2 treatment. Protein crystals of tPTEN were incubated with 1 mM H2O2 for 1 h and 
flash-frozen. Data collection and processing were performed in analogy to the initial structure 
determination of tPTEN (PDB 5BZZ). However, 1280 out of 1440 frames were used for data 
processing, as signal-noise ratio (I/) has decreased with the last 160 frames. Dataset of 
H2O2-treated tPTEN crystal was reduced to the lowest resolution of 2.4 Å, which yielded data 
completeness of 100 % (Table 6 and Table 7). The final structure model exhibits Rwork and 
Rfree of 0.18 and 0.21, respectively (PDB 5BUG, Table 7). The overall structure shows high 
similarity to the reduced state of tPTEN (  x     RMS    1.57       314 Cα      , Figure 
30a). However, minor structural alterations are observed within the active site. Compared to 
the clearly separated electron density between the catalytic cysteine C124 and the proximal 
C71 in the protein crystal without oxidative treatment (Figure 30b), the evidently connected 
electron density confirms disulfide formation in the H2O2-treated crystal (Figure 30c and 
Figure 31a). Disulfide bonds are observed consistently in all four protomers of the 
asymmetric unit (Figure 31b). This is in agreement with the high-resolution MS result 
(Chapter 3.3.3). H2O2-triggered disulfide formation is promoted by rotation of the side chain 
in catalytic cysteine C124 towards the back-door cysteine C71. Notably, there is no 
  g             g     Cα-dis      b  w    C71     C124 (       : 5.2     .        : 5.0  ). 
T                        xp         g                 b    (4.4   – 6.8  )115. Most 
importantly, the entire active site including P-loop experiences only small conformational 
changes (RMSD = 0.37       10 Cα      , Figure 31c). In addition, analogous to the reduced 
state, H2O2-treated crystal structure of tPTEN harbors a molecule of tartrate bound to the 
active site (Figure 31d). The bound tartrate moves slightly deeper into the active site, due to 
the space rendered by disulfide formation. Concerning the bound tartrate in the reduced and 
oxidized tPTEN structures, it was furthermore investigated, if tartrate has an influence on the 
oxidative inhibition and reactivation of PTEN. Full-length PTEN was pre-incubated with 
H2O2 (5 mM), followed by dilution with buffer either containing or lacking DTT (4 mM). In 
order to reflect the crystal soaking condition, high tartrate concentration (c = 1.5 M) was 
maintained during oxidation and reduction steps. Phosphatase activity of PTEN was 
monitored using malachite green assay
145
, providing comparable enzymatic activities to the 
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control samples lacking tartrate (Figure 55)
XXIV
. This indicates that tartrate does not have an 
effect on PTEN oxidation and reactivation, which may be due to the low affinity of tartrate 
for PTEN (IC50 (tartrate) = 337 ± 9.5 mM; Figure 56). 
Table 6 | Dataset statistics of H2O2-phen-treated tPTEN crystal. I/states signal to noise ratio of 
unique reflections. Rmeas is a redundancy-independent R-factor
159
. CC1/2 is indicative of the correlation 
percentage between reflection intensities from random half-datasets
158
. Correlation significant at the 
0.1 % level is highlighted by an asterisk. 
Resolution 
[Å] 
Number of reflections Completeness 
[%] 
  I/I) 
Rmeas 
[%] 
CC1/2 
[%] Observed Unique Possible 
20.0 1258 153 167 91.6  58.28 3.8 100.0* 
15.0 2110 192 192 100.0  59.7 3.5 99.9* 
10.0 9154 777 777 100.0  75.95 3.0 100.0* 
8.0 10471 1017 1018 99.9  64.77 2.9 100.0* 
6.0 33239 2824 2824 100.0  50.76 4.1 99.9* 
4.0 133147 11293 11294 100.0  49.98 4.3 100.0* 
3.1 220671 18232 18233 100.0  24.19 9.7 99.9* 
3.0 41674 3477 3477 100.0  9.16 28.6 98.8* 
2.9 49418 4043 4043 100.0  7.86 33.0 98.8* 
2.8 56363 4570 4570 100.0  5.86 45.0 97.7* 
2.7 66226 5327 5327 100.0  4.18 64.3 96.2* 
2.6 76859 6126 6128 100.0  3.18 85.8 91.8* 
2.5 85407 7119 7120 100.0  2.18 122.5 86.3* 
2.4 95199 8347 8348 100.0  1.59 166.0 77.6* 
Total 881196 73497 73518 100.0  19.82 10.4 99.9* 
 
  
                                                 
XXIV
 Inhibition with H2O2: residual activities = 6.7 ± 2.1 % (lacking tartrate) vs. 7.1 ± 1.6 % (containing tartrate)  
       Reactivation with DTT: residual activities = 96.5 ± 3.8 % (lacking tartrate) vs. 92.8 ± 2.5 % (containing 
tartrate) 
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Table 7 | Crystallographic data collection and refinement statistics of H2O2-treated tPTEN 
crystal. Structure coordinates have been deposited in the RCSB Protein Data Bank
42
 with the 
accession code 5BUG. Values in the parenthesis involve the highest resolution shell. RFree was 
calculated from 5 % of the reflections omitted from refinement process. 
 
tPTEN + H2O2 
PDB code 5BUG 
  
Data Collection  
Space group C2221 
Unit-cell parameters  
  a, b, c (Å) 206.87, 206.83, 87.43 
, ,  (°) 90, 90, 90 
Wavelength (Å) 1.000010 
Resolution limits (Å) 48.76 - 2.40 (2.50 - 2.40) 
No. of unique reflections 73497 (8347) 
Completeness (%) 100 (100) 
Multiplicity 11.99 (11.41) 
I/(I) 19.82 (1.59) 
CC1/2 99.9 (77.6) 
Robs 10.0 (158.5) 
  
Refinement  
Resolution limits (Å) 48.76 - 2.4 (2.5 - 2.4) 
RWork / RFree 0.1751 / 0.2106 
R.m.s.d.  
  Bond length (Å) 0.0100 
  Bond angles (°) 1.6794 
  B-factors (Å
2
) 70.2 
No. atoms  
  Protein 10338 
  Ligand 40 
  Water 751 
Ramachandran plot (%)  
  Favored regions 93.5 
  Allowed regions 5.7 
  Disallowed regions 0.8 
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Figure 30 | Disulfide formation upon H2O2-treatment has a minor structural impact on PTEN. 
(a) Overlay representation demonstrates that four protomers per asymmetric unit are structurally 
comparable. (Chain A: gray; chain B: yellow; chain C: green; D: purple). Implicated by low RMSD 
values, H2O2-treatment does not induce significant conformational change in the overall structure of 
PTEN. (b, c) Active site P-loop and the adjacent cysteine of reduced (b: gray, chain A) and H2O2-
treated PTEN (c: blue, chain A). Side chains of C71 and C124 are shown explicably with 2 Fo – Fc 
               y        p (    ,              1σ). This figure is from the reference No. 171, © 2015 
The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
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Figure 31 | Structural alteration of the active site P-loop upon exposure to H2O2. (a) The active 
site of H2O2-treated PTEN (blue, chain A) with 2 Fo – Fc electron density map (mesh: contoured at 
1 σ). (b) Close alignment of four protomers per asymmetric unit demonstrates high similarity at the 
active sites of H2O2-treated PTEN (Chain A: gray; chain B: orange; chain C: green; D: purple). (c) 
Structural overlay of the active sites in reduced (gray, chain A) and H2O2-treated PTEN (blue, 
chain A). Disulfide formation has a minor structural impact on the active site of PTEN. (d) 
Superimposition of the active sites in reduced (gray, chain A) and H2O2-treated PTEN (blue, chain A). 
The position of the bound tartrate changes upon disulfide formation. Tartrates and side chains of C71 
and C124 are shown with stick representations. This figure is from the reference No. 171, © 2015 The 
Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
Conformational changes at the active site of PTEN were compared with other available PTP 
structures exhibiting reversible oxidative modification. Minor structural change of PTEN 
P-loop is analogous to human lymphoid tyrosine phosphatase, which also involves disulfide 
formation
118,160
 (LYP, RMSD = 0.39 Å, Figure 32a and 32b). Interestingly, LYP reveals a 
substantial change of WPD-loop at its active site upon disulfide formation, whereas the entire 
active site in PTEN remains unaffected during this process. In contrast, CDC25B (disulfide, 
RMSD = 2.48  , Figure 32c)126 and PTP1B (sulf  y -     , RMS    2.38  , Figure 32d)122 
show a significant structural alteration in the active site P-loop upon reversible oxidative 
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modification. Notably, irreversible modification (e.g. sulfinic or sulfonic acid) was also 
observed at the catalytic cysteine of these PTPs upon long incubation time with H2O2 (t > 
20 min)
122,126
. Concerning the potential hyperoxidation with intensive H2O2 treatment, 
tolerance of the reversible modification was tested in PTEN under stringent oxidative 
conditions. Full-length PTEN was first treated with H2O2 in the time- and concentration-
dependent manner (Figure 33), followed by dilution with buffer lacking (mock) or containing 
DTT (10 mM, 20 min). Remarkably, phosphatase activity of PTEN was restored upon DTT 
treatment up to 20 mM H2O2 and 80 min incubation time. Such robust reactivation implies a 
very efficient protective mechanism of PTEN from irreversible catalytic impairment under 
oxidative stress.  
 
Figure 32 | Structural comparison of active site P-loops upon reversible oxidative modification. 
(a) Superimposition of reduced and oxidized PTEN structures shows conservation of backbone 
conformation of the P-loop. (b) Analogous to PTEN, disulfide formation of lymphoid tyrosine 
phosphatase does not alter its P-loop conformation (PDB: 2P6X, 3H2X)
118,160
. (c) Significant 
structural change of CDC25B upon disulfide formation (PDB: 1YMK, 1YS0)
126
. (d) H2O2 treatment 
promotes sulfenyl-amide formation of PTP1B resulting in structural distortion in the P-loop (PDB: 
2HNP, 1OEM)
120,122
. This figure is from the reference No. 171, © 2015 The Authors. Published by 
Wiley-VCH Verlag GmbH & Co. KGaA. 
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Figure 33 | Kinetic measurements of PTEN oxidation by H2O2 and its reactivation under 
reductive condition. (a – c) PTEN inhibition by H2O2 was studied in the concentration- and time-
dependent manner. PTEN (100 µM) was treated with H2O2 (a: 2 mM, b: 5 mM, c: 20 mM) during the 
given time ranges, followed by incubation (20 min) with buffer lacking or containing DTT (10 mM). 
Errors represent ± SD. (triplicate of triplicates; ns: P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001) 
This figure is reconstructed based on Lee et al. (2015)
171
. 
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3.6 Structural impact of PTEN inhibition by bpV-phen 
3.6.1 Reaction product of bpV-phen 
The preceding results implicate an oxidative mode of action of bpV-phen, which results in 
inhibition of PTEN phosphatase activity via disulfide bond formation (Chapters 3.3.2 and 
3.3.3). However, it remains elusive, which vanadium species is formed as a reaction product. 
In addition, it is not clear whether the oxidized form of PTEN differs between H2O2 and 
bpV-phen treatments. 
 
Figure 34 | Orthovanadate is a reaction product of bpV-phen treatment upon PTEN and exhibits 
low affinity for the pre-oxidized PTEN
XXV
. (a) 
51
V-NMR titration measurements demonstrate the 
conversion of bpV-phen (50 – 200 μM)                         p           PTEN (100 μM). (b) The 
binding property was determined using 
51
V-NMR measurments. Na3VO4 (50 – 200 μM) was titrated in 
the p             b         100 μM p  -oxidized full-length PTEN. This figure is from the reference 
No. 171, © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
  
                                                 
XXV
 
51
V-NMR spectroscopic analysis was carried out by Jonas Hanske and Dr. Christoph Rademacher at Max 
Planck Institute of Colloids and Interfaces, Berlin, Germany. 
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To elucidate the reaction product of bpV-phen upon PTEN inhibition, 
51
V-NMR 
spectroscopic analysis
XXVI
 was performed in cooperation with the group of Dr. Christoph 
Rademacher (Max Planck Institute of Colloids and Interfaces, Berlin, Germany). This method 
provides an excellent platform for the investigation of vanadate species with a very wide 
chemical shift range. For the efficient workflow, sample preparation was performed by the 
author of this thesis. NMR spectroscopic analysis was carried out by Dr. Christoph 
Rademacher and Jonas Hanske. In initial tests, bpV-phen proved to be stable under assay 
conditions (pH 8.0, 25 °C), y      g     g            xp         g  (δ   -744 ppm, Figure 
34a)
161
. Full-length PTEN (100 μM) w                 w             g bpV-phen 
concentrations ranging from 50 to 200 μM. Notably, bpV-phen peak rapidly disappeared at 
low bpV-phen concentration (50 μM,    p               : < 15    ), p       g              
                  w p    (δ = -553 ppm). This new signal was assigned to be dihydrogen 
orthovanadate (H2VO4
-
) by direct comparison with Na3VO4 titration (Figure 34a)
162
. In 
addition, a residual bpV-phen signal detected at its increased concentrations (100 and 
200 μM)              the quantitative oxidation of PTEN by bpV-phen under these 
conditions. 
Given that disulfide formation is promoted by bpV-phen and orthovanadate is a phosphate 
mimicry, binding affinity of the reaction product orthovanadate for oxidized PTEN was 
studied. Full-length PTEN pre-oxidized with H2O2 (100 µM) was titrated with sodium 
orthovanadate (50 – 200 µM) )XXVII (Figure 34b). Upon ligand binding, a chemical shift 
change is expected and the corresponding signal should exhibit line-broadening
163
. However, 
no significant chemical shift or line broadening was observed indicating low affinity of 
orthovanadate for pre-oxidized PTEN (KD > 1 mM). Given that orthovanadate inhibits some 
human phosphatases at sub-micromolar concentrations (e.g. PTP1B (Ki = 0.38 µM)
153
, 
alkaline phosphatase (Ki = 0.6 µM)
164
), it was furthermore investigated, if the formed 
orthovanadate has an influence on PTEN activity. For that purpose, phosphatase activity of 
PTEN was monitored in the presence of orthovanadate using malachite green assay (Figure 
                                                 
XXVI
 
51
V-NMR spectroscopic analysis was carried out by Jonas Hanske and Dr. Christoph Rademacher at Max 
Planck Institute of Colloids and Interfaces, Berlin, Germany. 
XXVII
 Full-length PTEN was oxidized with H2O2 and purified using size exclusion chromatography to remove 
residual H2O2 in the protein buffer. Oxidation yielded two species detected in the chromatogram. Protein 
fractions corresponding to monomeric species (the second peak) were used for 
51
V-NMR experiments. For more 
details about chromatograms and inhibitory as well as reactivating properties, see Figure 57. 
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35). Compared with efficient inhibition by bpV-phen, only 20 % PTEN inhibition was 
observed at 1 mM orthovanadate. Given that 1 mM orthovanadate is equivalent to over 5000-
fold higher concentration than IC50 of bpV-phen, inhibition of PTEN phosphatase activity is 
mainly induced by bpV-phen-mediated disulfide formation. 
 
Figure 35 | Catalytic impairment of PTEN is not affected by orthovanadate. Phosphatase activity 
of PTEN was determined using malachite green assay. Full-length PTEN (50 nM) was incubated 
either with bpV-phen or Na3VO4 (T = 25 °C, t = 10 min; triplicates, errors represent ± SD; ns: not 
significant, * P < 0.5, ** P < 0.01, *** P < 0.001). This figure is from the reference No. 171, © 2015 
The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
3.6.2 Crystal structure of bpV-phen-treated PTEN 
Next, structural consequences of bpV-phen-mediated PTEN inhibition were studied using 
X-ray crystallography. Analogous to structural investigation upon H2O2-treated PTEN, 
soaking experiments were employed. A tPTEN crystal in the reduced state was treated with 
1 mM bpV-phen for 4 h and flash-frozen prior to data collection. Compared to the 
aforementioned H2O2-treated PTEN structure (λ   1.000  ), dataset was collected at a longer 
w      g   (λ   1.771  ). This allows to utilize specific elemental character such as 
anomalous scattering and consequently provides the precise localization of potential 
vanadium species. As represented in Figure 36, absorbance of incident X-ray photons 
increases with longer wavelength up to an absorption edge. This elemental property is 
intensified in elements involving higher atomic numbers, which results in more intensive 
anomalous scattering. In addition, elemental components of amino acids except for sulfur 
hardly contribute to the anomalous scattering even at a longer wavelength. Taking advantage 
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of this property, an additional electron density map can be generated, which provides a 
specific density map representing potential vanadium species and thiols.  
 
Figure 36 | Anomalous scattering property facilitates an electron density map yielded from 
vanadium and sulfur. X-ray absorbance of vanadium (purple) and sulfur (blue) increases with longer 
wavelength up to absorption edge (upper panel, vanadium absorption edge = 2.27 Å). These elements 
largely contribute to anomalous scattering, compared to other elemental components (e.g. C, H, N, O) 
present in the protein and buffer. This is represented with f  ” scattering coefficients (lower panel). f ’ 
and f  ”                 g    y    p                   g             , respectively. The theoretical plot 
is generated based on S Brennan and PL Cowan (1992)
165
.
XXVIII
  
  
                                                 
XXVIII
 The figure is modified based on the plot which is generated on the following homepage: 
http://skuld.bmsc.washington.edu/scatter/ (Jan. 2016) 
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Following data collection of the bpV-phen-treated tPTEN crystal, data processing was 
performed in analogy to the reduced tPTEN (PDB 5BZZ) to determine structure factor 
amplitude and to generate 2 Fo – Fc electron density map. Dataset of the bpV-phen-treated 
tPTEN crystal was reduced to the lowest resolution of 2.5 Å, which yielded data completeness 
of 100 % (1440 frames, Table 8 and Table 9). The final structure model was built with Rwork 
and Rfree of 0.18 and 0.20, respectively (PDB 5BZX, Table 9). Close alignment of four 
protomers in the asymmetric unit confirms high structural similarity among symmetry-
relevant structures (Figure 37). The overall structures are determined to be very similar to the 
reduced and H2O2-treated PTEN (maximal RMSD = 1.42   and 1.37       314 Cα      ). 
Consistent with the previous high resolution MS results upon bpV-phen treatment, disulfide 
formation at the active site is observed in all protomers involving connected electron densities 
between C71 and C124 (2 Fo – Fc omit map, Figure 38).  
Table 8 | Dataset statistics of bpV-phen-treated tPTEN crystal. I/states signal to noise ratio of 
unique reflections. Rmeas is a redundancy-independent R-factor
159
. CC1/2 is indicative of the correlation 
percentage between reflection intensities from random half-datasets
158
. Correlation significant at the 
0.1 % level is highlighted by an asterisk. 
Resolution 
[Å] 
Number of reflections Completeness 
[%] 
  I/I) 
Rmeas 
[%] 
CC1/2 
[%] Observed Unique Possible 
20.0 1552 152 167 91.0  52.51 3.7 100.0* 
15.0 2476 192 192 100.0  59.43 4.1 100.0* 
10.0 10715 778 778 100.0  65.55 3.6 100.0* 
8.0 13692 1024 1024 100.0  57.69 3.6 100.0* 
6.0 35011 2832 2833 100.0  39.73 5.4 99.9* 
4.0 149571 11341 11341 100.0  39.86 5.7 99.9* 
3.1 248426 18311 18312 100.0  18.51 13.5 99.8* 
3.0 42575 3496 3497 100.0  6.56 39.6 98.0* 
2.9 49248 4049 4049 100.0  5.71 44.2 97.8* 
2.8 58498 4590 4591 100.0  4.34 60.0 96.0* 
2.7 67403 5341 5341 100.0  3.04 85.4 92.1* 
2.6 77080 6142 6144 100.0  2.25 114.7 85.1* 
2.5 87652 7145 7147 100.0  1.53 161.9 73.1* 
Total 843899 65393 65416 100.0  17.43 12.3 99.9* 
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Table 9 | Crystallographic data collection and refinement statistics of bpV-phen-treated tPTEN 
crystal. Structure coordinates have been deposited in the RCSB Protein Data Bank
42
 with the 
accession code 5BZX. Values in the parenthesis involve the highest resolution shell. RFree was 
calculated from 5 % of the reflections omitted from refinement process. 
  tPTEN + bpV-phen 
PDB code 5BZX 
  
Data Collection  
Space group C2221 
Unit-cell parameters  
  a, b, c (Å) 207.06, 206.90, 87.67 
  , ,  (°) 90, 90, 90 
Wavelength (Å) 1.771190 
Resolution limits (Å) 46.29 - 2.50 (2.60 - 2.50) 
No. of unique reflections 65393 (7145) 
Completeness (%) 100 (100) 
Multiplicity 12.91 (12.27) 
I/(I) 17.43 (1.53) 
CC1/2 99.9 (73.1) 
Robs 11.8 (155.2) 
  
Refinement  
Resolution limits (Å) 46.29 - 2.50 (2.60 - 2.50) 
RWork / RFree 0.1752 / 0.2037 
R.m.s.d.  
  Bond length (Å) 0.0094 
  Bond angles (°) 1.5376 
  B-factors (Å
2
) 72.0 
No. atoms  
  Protein 10310 
  Ligand 40 
  Water 880 
Ramachandran plot (%)  
  Favored regions 92.8 
  Allowed regions 6.7 
  Disallowed regions 0.6 
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Figure 37 | There is no overall significant structural change of tPTEN upon bpV-phen treatment. 
Structural overlay represents close alignment of four protomers of bpV-phen-treated tPTEN structures 
in an asymmetric unit (PDB 5BZX, upper panel; chain A: gray; chain B: orange; chain C: green; D: 
purple). As reflected by RMSD values, the crystal structure incubated with bpV-phen shows high 
similarity to reduced and H2O2-treated crystal structures (lower panel). This figure is from the 
reference No. 171, © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
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Figure 38 | bpV-Phen exerts oxidative modification on tPTEN via disulfide formation. (a – d) The 
crosslinked 2 Fo – Fc omit map (mesh: contoured at 1 σ) validates the disulfide formations between 
C71 and C124 in all protomers of the bpV-phen-treated crystal structure. Orthovanadate, tartrate, and 
side chains of C71 and C124 are shown with stick representations. This figure is from the reference 
No. 171, © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
Next, an additional electron density map was generated based on the anomalous scattering 
signal applying the Bijvoet-difference Fourier method
166
. Oxidation of thiol group to disulfide 
by bpV-phen is, again, confirmed in all protomers with the anomalous density map (Figure 
39a and b). The evidently connected density of C71 and C124 in bpV-phen-treated PTEN is 
distinct from the reduced PTEN, indicating disulfide bond formation (Figure 39). 
Interestingly, different density map patterns are observed in the middle of the active site, 
which implicates varied occupancy of vanadium species. Taking ratio of density size 
(disulfide vs. vanadium species) and their anomalous scattering contribution into account 
(Figure 36), ligand populations were determined. Chain A harbors primarily orthovanadate, 
whereas both chain B and D contain one molecule of tartrate analogous to H2O2-treated 
PTEN. Chain C exhibits a partial occupancy of tartrate and orthovanadate (~70:30) (Figure 
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38). Different ligands bound to the active site are also validated by their differing density 
pattern in 2 Fo – Fc electron density map (Figure 40a, b and c). This X-ray crystallographic 
observation involving mixed ligand occupancy is consistent with low affinity of 
orthovanadate for the active site of pre-oxidized PTEN, as demonstrated by 
51
V-NMR 
spectroscopic analysis (Figure 34b). Notably, in spite of the distinctions in four protomers, 
close overlay of the P-loops and overall structures implicates low structural impact of the 
bound ligands on the active ste conformation (Figure 40d). 
 
Figure 39 | bpV-phen-treated PTEN crystal structure exhibits disulfide bond and harbors 
partial occupancy of orthovanadate at the active site. Active sites of bpV-phen-treated (orange; a: 
chain A, b: chain B) and reduced PTEN (gray; c: chain A). Orthovanadate, tartrate and side chains of 
C71 and C124 are shown with stick representations. Anomalous scattering property of vanadium and 
sulfur facilitates generation of an electron density map (resolution: 5.0 Å, mesh: contoured at 3.4 σ), 
which shows specific locations of both elements. The intensity of the electron density allows to 
determine varied orthovanadate occupancies at the active sites of bpV-phen-treated PTEN. This figure 
is from the reference No. 171, © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. 
KGaA. 
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Figure 40 | 2 Fo – Fc electron density confirms disulfide formation and different ligand 
occupancy at the active site of bpV-phen-treated PTEN. (a, b) 2 Fo – Fc electron density map of 
bpV-phen-treated PTEN (orange) is clearly resolved at the active site exhibiting varied ligand 
occupancy and connected density for disulfide bond. Active sites of chain A and B are shown 
representatively. (c) Compared to the disulfide structure, electron density is separated between C71 
and C124 at the active site of reduced PTEN (gray). 2 Fo – Fc electron density map is represented in 
                      1σ. (d) Superimposition of bpV-phen-treated PTEN active sites shows high 
structural similarity among four protomers present in the asymmetric unit (Chain A: gray; chain B: 
yellow; chain C: green; D: purple). This figure is from the reference No. 171, © 2015 The Authors. 
Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
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3.7 Discussion 
Herein, modulation of PTEN phosphatase activity was investigated using biochemical and 
structural biology methods. This study was divided into two sections involving investigation 
of activation by phosphatidylinositol derivatives and inhibition by the second messenger H2O2 
as well as a synthetic inhibitor bpV-phen.  
Upon activation, PTEN is localized to the plasma membrane and catalyzes dephosphorylation 
of PIP3 to PIP2
25,32,33
. Thereby, the N-terminal domain (residues 1-15, Figure 3) containing a 
PIP2-binding motif (PBM, residues 6-KEIVSRNKRR-15) not only plays a crucial role for 
membrane association, but also is essential for PTEN phosphatase activity
48,73
. In addition, 
the dephosphorylation product PIP2 promotes membrane binding of PTEN and increases the 
phosphatase activity via autocatalytic mechanism
48,73
. In this context, earlier studies have 
proposed that the flexible N-terminal sequence of PTEN serves as an allosteric binding site of 
PIP2 for the preceding membrane activation
174,175
. However, it remains elusive, how PTEN is 
activated by PIP2 and which protein site is responsible for protein-ligand interaction. In order 
to elucidate the underlying mechanism mediated by PIP2, various PTEN constructs were 
recombinantly produced in the presence and absence of N- and C-terminal regulatory 
sequences (Figure 11). Consistent with previous studies
48,55,71
, subsequent phosphatase 
activity measurements of the constructs showed that the N-terminus (residues 1-15) is 
essential for PTEN activity, whereas the C-terminal tail (residues 352-403) has an inhibitory 
effect (Figure 18). It is an important finding that the absence of the N-terminal hydrophobic 
amino acids (residues 1-MTAII-5) reduces the phosphatase activity significantly, although the 
entire PBM is present. This implicates potential hydrophobic interaction with the hydrocarbon 
chains of PIP2/PIP3. In addition, autocatalytic property of PIP2 demonstrated herein is in 
agreement with the previous in vitro study
48
 (Figure 18). Importantly, comparable activating 
effect of the substrate analog nhPIP3 implicates the presence of an allosteric binding site and 
no selectivity for PIP2/PIP3-mediated enzymatic activation.  
The FP-measurements show that PTEN constructs containing the C-tail have low affinity for 
PIP2. Given that phosphatase activity of the corresponding constructs is increased in the 
presence of PIP2, this may implicate the competition of PTEN C-tail with PTEN-PIP2 
interaction (Figure 19a). In addition, PIP2 affinity of PTEN 16-353 lacking PBM appears 
comparable to PTEN 6-353, indicating PBM-independent interaction between PIP2 and the 
PTEN core domains (Figure 19b). Concerning the significance of lysine-enriched CBR3 loop 
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(residues 260-269) on the phosphatase activity and its potential interaction with PTEN C-tail 
implicated by earlier reports
71,167
, phosphatase and C2 domain were separately expressed 
using E. coli and insect cells to identify the allosteric binding site of PIP2/nhPIP3
147
. However, 
it was not possible to obtain the isolated domains in soluble and monomeric forms. It might 
be ascribed to the extensive hydrophobic interface between phosphatase and C2 domain, 
which hinders stable overexpression as single species (Figure 26a). Thereby, investigation of 
PTEN interaction with PIP2 and nhPIP3 was discontinued. 
To investigate inhibition of PTEN phosphatase activity, X-ray crystallography can provide an 
excellent platform to study structural alteration upon inhibition. Based on the known crystal 
structure (PDB 1D5R), protein crystallization of PTEN core domains (tPTEN) was 
established for ligand-soaking experiments (Figure 24). Structure determination of the 
corresponding protein crystal (PDB 5BZZ) is comparable to PDB 1D5R and shows the 
sulfhydryl group of the active site cysteine in the reduced state. Notably, PDB 5BZZ exhibits 
distinct protein packing from the original crystal structure (PDB 1D5R), involving different 
crystallographic parameters (e.g. space group, unit cell constants and the number of protomers 
in the asymmetric unit; Figure 28 and Figure 29). In this respect, it is an interesting finding 
that different protein packing is observed for analogous crystallization conditions. In addition 
to tPTEN, full-length PTEN was subjected to crystallization, since structural elucidation of 
the full-length PTEN would provide additional information of its autoinhibitory mechanism. 
However, no suitable crystal was obtained in spite of the large scale crystallization screening 
(Chapter 3.4.1). This is possibly attributed to two major factors. First, a single homogenous 
protein species could not be isolated due to extensive post-translational modifications 
produced during protein expression (Figure 23). Assuming the presence of only one 
conformation for a defined phosphorylation pattern, protein production with phosphomimicry 
mutations or native chemical ligation of a phosphorylated peptide may allow to resolve this 
issue. Second, the flexible region of the C-tail (50 amino acids) and the D-loop (24 amino 
acids) may be too long so that it could disturb the protein crystallization. In this respect, 
various truncated PTEN constructs should be tested to find a suitable length for 
crystallization.  
Inhibition of PTEN phosphatase activity by H2O2 was investigated in detail. H2O2 is not only 
involved in cellular oxidative stress as a major component of ROS, but also plays a crucial 
role in the redox signaling as a second messenger
99,104
. In the signal transduction, growth 
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factor-mediated cell stimulation promotes production of H2O2, which inhibits phosphatase 
activity of PTEN and reinforces PI3-K/Akt signaling
105,109
. Thereby, selective on/off 
switching of PTEN phosphatase activity and protection from irreversible inactivation 
constitute highly desirable features for the efficient regulation of the signaling
10,115
. In this 
regard, PTEN exhibits an active site cysteine (C124) susceptible to oxidation
8,9,10
. PTEN 
undergoes reversible inactivation via disulfide formation between this cysteine C124 and the 
proximal C71, which prevents irreversible oxidation
10,82,83
 (Figure 8a). In this study, 
reversible oxidative inhibition and disulfide formation of PTEN were confirmed employing 
phosphatase activity assay and mass spectrometric analysis, respectively. Notably, IC50 of 
H2O2 determined herein (60 ± 23 μM) is significantly higher than the intracellular H2O2 
concentration in mammals (0.001 – 0.7 μM        b          )148. This suggests that PTEN 
oxidation occurs in response to local high concentration of H2O2 and supports its role as a 
second messenger in the redox signaling. Structural consequences of PTEN inhibition by 
H2O2 were studied using ligand-soaking experiments. The subsequent X-ray crystallographic 
analysis revealed only small structural alterations in oxidized PTEN involving disulfide 
formation (Figure 41). Remarkably, earlier studies have shown that PTEN oxidation abolishes 
the interaction between the core domain and the phosphorylated C-tail peptide
70
. Its nuclear 
localization occurs in the open conformation and is promoted under oxidative stress (Figure 
5)
84,168
. Moreover, nuclear PTEN is also known to contribute to reduction of ROS 
production
84
. Taken together, nuclear PTEN may preserve the conformation of the central 
domains for the phosphatase-independent tumor suppressing effect, which is facilitated by 
protein-protein interaction via C2 domain
21,85,86
. In addition, this implicates a role of PTEN in 
a feedback mechanism for the regulation of cellular ROS concentration.  
So far, reversible oxidation of the catalytic cysteine has been found in PTPs such as 
PTP1B
169
, LYP
118
, VHR
169
, SHP-1/2
108,170
, LMW-PTP
124
, CDC25B
128
 and PTEN
82
. Among 
them, phosphatase domains of PTP1B
122,123
, CDC25B
126
, LYP
118
 and now PTEN
171
 have been 
structurally characterized in reduced and oxidized forms (Figure 32). Upon oxidation, PTP1B 
and CDC25B experience profound conformational changes of the active site P-loop with the 
formation of sulfenyl-amide and disulfide, respectively. It has been proposed that these 
structural changes may disrupt the interaction with their substrates and facilitate selective 
reduction by antioxidants
10,122,126
. For instance, sulfenyl-amide formation maintains the active 
site cysteine in a solvent-exposed manner, which enables the reductive reactivation by 
thioredoxin and GSH
122,150
. However, the disulfide bond of CDC25B is buried at the bottom 
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of the active site, which results in selective reduction by thioredoxin, but not by GSH
126,128
. In 
this context, minimal structural changes of PTEN’  active site upon oxidation are consistent 
with reactivation by physiologically relevant small-molecular reducing agents (e.g. 
GSH)
82,150,171
. Nevertheless, it remains to be seen, if the structural alteration of oxidized 
PTEN has an influence on its substrate binding and its subcellular localization
70,84,168
. Another 
remarkable aspect of PTEN is implicated with its robust protection from irreversible oxidation 
by H2O2. Compared to PTP1B and CDC25B (Figure 9), PTEN restores the phosphatase 
activity under reductive conditions even after intensive H2O2 treatment (Figure 33). This 
finding supports the efficient protection from irreversible catalytic impairment by ROS.  
 
Figure 41 | Oxidative modification does not induce significant conformational change. H2O2 
(blue, chain A) or bpV-phen (orange, chain A) treatment of PTEN promotes disulfide formation by 
rotating the catalytic cysteine C124 to the back-door cysteine C71. Structural overlay with reduced 
PTEN (gray, chain A) demonstrates maintenance of backbone conformation upon oxidation. This 
figure is reconstructed based on Lee et al. (2015)
171
. 
In addition, PTEN inhibition was investigated using bpV-complexes. These are the most 
frequently used tool compounds to study in cellulo and in vivo inhibition of PTEN. In earlier 
studies, bpV-complexes have shown cellular regenerative effects in neuronal and cardiac 
injury
136-141
. However, the mode of action of bpV-complexes on PTEN has been unclear ‒ It 
was speculated that bpV-mediated PTEN inhibition occurs in the non-covalent or oxidative 
manner. The latter case may occur via disulfide formation (reversible) or hyperoxidation 
(irreversible)
132,133
. So far, oxidative inhibition of PTP1B phosphatase activity has been 
demonstrated with peroxidovanadate
153
. Notably, formation of sulfonic acid was only 
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observed at the active site cysteine, implicating high potency of peroxidovanadium species for 
irreversible modification
153
. Herein, reversible oxidative inhibition of PTEN by bpV-phen 
was verified applying phosphatase activity assays and mass spectrometric analysis. 
Analogous to H2O2, bpV-phen induces the same disulfide bond, also with only minor 
conformational changes in the active site (Figure 41). However, the underlying mechanisms 
of both compounds are suggested to be different. Compared to intermediate sulfenic acid 
formation by H2O2 (Figure 8), peroxidovanadium-mediated thiol oxidation has been proposed 
to involve radical one-electron transfer steps
172
.  
In addition, NMR titration experiment preformed herein identified the formation of 
orthovanadate as a reaction product of bpV-phen (Figure 34). This is an important finding, 
since orthovanadate resulting from in vivo bpV-phen treatment may exert a secondary effect 
as an inhibitor of additional human enzymes (e.g. PTP1B
153
, alkaline phosphatase
164
 and 
ATPase
177
). Earlier studies showed cytoprotective effects of orthovanadate in ischemia and 
reperfusion injury
178,179,180
. Further cell-based studies are required to understand, whether 
orthovanadate has a synergetic effect with bpV-phen on neuronal and cardiac protection 
together.  
In this study, X-ray crystallographic analysis of PTEN was used to obtain structural insights 
into H2O2- and bpV-phen-mediated inhibition of PTEN phosphatase activity. In addition, the 
mode of action of PTEN inhibition by bpV-phen elucidated herein will help to evaluate the 
therapeutic potential of bisperoxidovanadium complexes. Importantly, the reversible 
oxidative inhibition of PTEN by these complexes may represent a highly beneficial feature, 
since irreversible impairment of this central tumor suppressor can cause systemic disturbance. 
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4 Summary 
PTEN is a dual-specificity protein tyrosine phosphatase. PTEN has a significant impact on 
cell fate determination between survival and apoptosis depending on its phosphatase activity 
in the PI3-K/Akt signaling. Therefore, tight regulation of its phosphatase activity is very 
important for cellular homeostasis. In this context, both selective on/off switching    PTEN’  
phosphatase activity and protection from irreversible inactivation constitute highly desirable 
features. The second messenger H2O2, which is produced under both growth factor-mediated 
signal transduction and oxidative stress, transiently inactivates PTEN in an oxidative manner. 
Under oxidative conditions, PTEN undergoes disulfide bond formation between the catalytic 
cysteine C124 and the proximal cysteine C71. The structural impact of disulfide formation on 
PTEN’            was unclear. Given the potential structural change and presence of other 
active site cysteine modifications, structural characterization of oxidized PTEN would 
facilitate a better understanding of its regulation and proposed protective mechanism as a 
central tumor suppressor. 
 
Figure 42 | Reversible oxidative modification of PTEN’s active site by H2O2. The active site 
cysteine of PTEN (gray) is oxidatively inhibited upon exposure to H2O2 (blue). This inhibitory process 
results in disulfide bond formation without significant conformational change. Due to its reversible 
character, the catalytic activity of PTEN can be reversed under reductive condition.  
H2O2-triggered oxidative inhibition and the reductive reactivation of PTEN were investigated 
using the malachite green phosphatase activity assay. HPLC-coupled high resolution mass 
spectrometry confirmed disulfide formation between cysteines C71 and C124. Structural 
alteration induced by PTEN oxidation was investigated applying X-ray crystallography. 
Reduced tPTEN (PDB 5BZZ) was treated with H2O2 using soaking experiment. The resulting 
oxidized tPTEN (PDB 5BUG) verifies disulfide bond formation at the active site (Figure 42). 
In comparison with two other members of the PTP superfamily, PTP1B and CDC25B, PTEN 
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exhibits only a small structural change and a very robust reactivation after stringent H2O2 
treatment. This indicates a very efficient protection from irreversible modifications which 
may represent a crucial feature of this important tumor suppressor. 
In addition, the structural consequences of PTEN inhibition by bisperoxidovanadium (bpV) 
complexes were studied using bpV-phen (bisperoxido (1,10-phenanthroline) oxovanadate 
(V)) as model compound. Importantly, it was previously shown that after nerve and cardiac 
injury, treatment with bpV-complexes can trigger cellular regeneration. However, the precise 
mode of action is still under debate. In this study, the reversible oxidative inhibition of PTEN 
by bpV-phen via disulfide formation was shown applying phosphatase activity assays and 
mass spectrometric analysis (Figure 43). 
51
V-NMR spectroscopy allowed the identification of 
orthovanadate as the reaction product of bpV-phen-mediated PTEN inhibition. Furthermore, 
X-ray crystallographic analysis was applied to study structural impact of disulfide formation 
in bpV-phen-treated PTEN (PDB 5BZX). Analogous to H2O2-treatment, PTEN inhibition by 
bpV-phen results in minor structural alteration at the active site. An additional electron 
density map based on the scattering property of vanadium verified the presence of 
orthovanadate in the active site. Varying occupancy in each protomer indicates a low affinity 
for the active site of oxidized PTEN, which was also validated by 
51
V-NMR titration 
experiments. Overall, this study successfully elucidated the mode of action of bpV-phen and 
the structural impact of disulfide formation on PTEN. The reversible oxidative inhibition of 
PTEN by bpV-phen may represent a highly beneficial feature, since irreversible impairment 
of this central tumor suppressor may cause systemic disturbance. The mode of action of bpV-
phen elucidated in this study can contribute to the further development of bpV-complexes as 
PTEN inhibitors.  
 
Figure 43 | Mode of action of bpV-phen. bpV-Phen inhibits reduced PTEN (gray) in an oxidative 
manner by promoting disulfide formation (orange). Orthovanadate is a reaction product originating 
from bpV-phen. 
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5 Material and methods 
5.1 Materials and equipments 
5.1.1 List of chemicals and materials 
The following chemicals and materials were used for the experiments performed in this thesis. 
Table 10 | List of chemicals and materials generally used for experiments. 
 
Chemicals and materials Manufacturer 
 
 
Acetic acid J. T. Baker 
 
 
Conical tube (15 ml, 50 ml) Sarstedt 
 
 
Dithiothreitol (DTT) Serva Electrophoresis GmbH 
 
 
Eppendorf tubes (0.5 ml, 1.5 ml, 2 ml) Eppendorf 
 
 
Ethanol (abs.) Sigma-Aldrich 
 
 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
 
 
Glycerol GERBU Biotechnik GmbH 
 
 
Hydrochloric acid (HCl) J. T. Baker 
 
 
Isopropanol J. T. Baker 
 
 
Syringe needle 100 Sterican
®
 B. Braun Melsungen AG 
 
 
Culture test tubes (sterile, 13 ml, 100 x 16 mm) Sarstedt 
 
 
Nalgene
®
 Bottle Top Filter with  
    PES  Membrane 
Thermo Scientific 
 
 
Sodium chlorid (NaCl) AnalaR
®
 NORMAPUR
®
 VWR 
 
 
Sodium hydroxide J. T. Baker 
 
 
Pipette tips (10 µl, 200 µl, 1250 µl Nerbe Plus 
 
 
Syringes (1 ml, 2 ml, 5 ml, 10 ml, 20 ml) B. Braun Melsungen AG 
 
 
Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt 
 
 
Syringe filter Filtropur S (0.2 µm, 0.45 µm) Sarstedt 
 
 
Tris (tris(hydroxymethyl)aminomethane Roth 
 
 
Falcon
®
 cell culture plate (10 cm) Corning 
 
 
Falcon
® 
cell culture plate (6 well) Corning 
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Table 11 | List of chemicals and materials used for molecular cloning. 
 
Chemicals and materials Manufacturer 
  
GelRed Nucleic Acid Stain (10.000x in DMSO) Biotium 
  
Gene Ruler 1 kb Plus DNA Ladder (#SM1333) Thermo Scientific 
  
Gentamycin sulfate Serva Electrophoresis GmbH 
  
Kanamycin A disulfate GERBU Biotechnik GmbH 
  
LB agar plates  
   (LB-Media und 1.5 % (w/v) agar): 
MPI-Medienküche 
(engl. Culture media supply 
service) 
  
-  gentamycin plate 
  
   containing gentamycin (10 µg/ml) 
  
-  kanamycin plate 
  
   containing kanamycin (50 µg/ml) 
  
-  kanamycin + chloramphenicol plate 
  
   containing kanamycin (50 µg/ml),     
     chloramphenicol  (34 µg/ml) 
  
-  blue-white-screening plate  
  
   containing kanamycin (50 µg/ml),  
     gentamycin (7 µg/ml), tetracycline  
     (10 µg/ml), X-gal (100 µg/ml) 
  
      and IPTG (40 µg/ml) 
  
LB-Media MPI-Medienküche 
  
   For 1 l:   
     10 g tryptone, 5 g yeast extract, 10 g NaCl 
(engl. Culture media supply 
service) 
  
PCR-Tubes (8er Kette) Sarstedt 
  
Phusion Flash PCR Master Mix Thermo Scientific
®
 
  
Surgical Disposable Scalpel B. Braun Melsungen AG 
  
Ultra Pure
TM
 Agarose Invitrogen 
  
6x DNA Loading Dye (#R0611) Thermo Scientific 
  
10x Fast Digest
®
 Buffer Fermentas 
  
10x T4 DNA Ligase Buffer Fermentas 
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Table 12 | List of chemicals and materials used for protein expression, purification and analytics. 
 
Chemicals and materials Manufacturer 
  
Acrylamide 4K-Solution (30 %) Mix 37.5:1 PanReac AppliChem 
  
Amicon
®
 Ultra-Filter, 10 kDa (15 ml, 0,5 ml) Merck Millipore 
  
Amicon
®
 Ultra-Filter, 30 kDa (15 ml, 0,5 ml) Merck Millipore 
  
Ammonium persulfate (APS) ChemCruz
TM
 
  
β-Mercaptoethanol Serva Electrophoresis GmbH 
  
Bradford - reagent 5x Serva Electrophoresis GmbH 
  
Bromophenol blue - sodium salt Serva Electrophoresis GmbH 
  
DNA-Transfection reagent (X-tremeGENE HP) Roche Diagnostics GmbH 
  
Gibco
®
 heat inactivated Fetal Bovine Serum (FBS) Life Technologies
TM
 
  
Glycine Roth 
  
Imidazole Roth 
  
Sodium dodecylsulfate (SDS) GERBU Biotechnik GmbH 
  
Nickel-NTA-Superflow Qiagen
®
 
  
Page Ruler
TM
 Plus Prestained Protein Ladder 
(#26019) 
Thermo Scientific 
  
Phenylmethylsulfonylfluorid (PMSF) Serva Electrophoresis GmbH 
  
Protein-free insect cell media Spodopan 
PAN
TM
 Biotech GmbH 
  
   L-Glutamine, 0,35 g/l NaHCO3, sterile 
  
Tetramethylethylenediamine (TEMED) Roth 
  
Tris(2-carboxyethyl)phosphine (TCEP) Serva Electrophoresis GmbH 
  
Trypan Blue solution (0.4 %) Sigma-Aldrich 
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5.1.2 Equipments and apparatus 
The following equipments and apparatus were used for the experiments performed in this 
thesis. 
Table 13 | List of equipments and apparatus used for experiments. 
Equipments / Apparatus  Manufacturer 
 
Äkta-FPLC GE Healthcare Life Sciences 
 
Horizontal electrophoresis apparatus Bio-Rad 
 
AlphaImager
®
 Biozym 
 
Analog Dry Block Heaters VWR
®
 
 
Avanti
TM
 J-25 Centrifuge  
Beckman Coulter
TM
  
  Rotor JA-25.50 
 
  Rotor JLA-8.1000 
 
  Centrifuge tube 
 
Incubator BINDER 
 
Centrifuge 5415 R Eppendorf 
 
Centrifuge 5804 R Eppendorf 
 
Digital Sonifier
®
 Cell Disruptor mit 102-C Converter Branson Ultrasonics Corporation 
 
Drigalski-Spatula (glass) Roth 
 
Epson Perfection 2400 photo scanner Epson
®
 
 
Falcon
TM
 EXPRESS Pipet-aid BD Biosciences 
 
Sample comb (horizontal electrophoresis appratus) Bio-Rad 
 
GFL
®
-3005 Orbital shaker Gesellschaft für Labortechnik 
 
Glass plates (SDS-PAGE) Bio-Rad 
 
High Performance UV Transilluminator UVP 
 
HiLoad
TM
 16/60 Superdex
TM
 200 preparative grade GE Healthcare Life Sciences 
 
HiTrap SP HP, 5 ml GE Healthcare Life Sciences 
 
Hot plate magnetic stirrer IKA
®
 
 
Microflow Class II advanced biological safety cabinet Nalge Nunc International 
 
Microscope: Olympus CX41 RF Olympus 
 
Microplate reader Safire2
TM
 Tecan
®
 
 
Microwave (700 Watt) Severin 
 
Millipore Q-water system Q-POD
TM
 Merck Millipore 
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Equipments / Apparatus (Continued) Manufacturer 
 Mini Gyro-rocker S SM3 Orbital shaker Stuart
®
 
 MiniSpin
®
 Eppendorf 
 Multifuge 3 S-R Heraeus / Thermo Scientific 
 NanoDrop® 2000c Spectrophotometer PEQLAB Biotechnologie GmbH 
 Neubauer chamber (0,0025 mm2, depth: 0,1 mm) Marienfeld-Superior 
 PCR-Thermo-Cycler (Mastercycler EP Gradient) Eppendorf 
 pH-Meter inoLab
®
 with pH Electrode SenTix
®
 81 
Plus 
WTW 
 
Pipettes (2.5, 10, 20, 100, 200, 1000 µl) Eppendorf 
 Electrophoresis chamber (SDS-PAGE) Bio-rad 
 Q-Exactive-MS mit Nano-HPLC Thermo Scientific 
 Rotator SB3 Stuart® 
 
SartoPac basic SPb-LA230P Sartorius 
 
Shaking incubator Ecotron Infors HAT 
 
Shaking incubator Innova
®
 42 New Brunswick Scientific  
 
Shaking incubator Innova
®
 4430 New Brunswick Scientific  
 
SDS-gel hand casting apparatus Bio-Rad 
 
PowerPac
TM
 HC und Basic Bio-Rad 
 
Thermomixer comfort Eppendorf 
 
Vortex Genie 2 Vortexer Scientific Industries 
 
Centrifuge Universal 320R Hettich GmbH 
 
96-Well Deep Well Plate VWR 
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5.1.3 Buffer and solution 
The following buffers and solutions were used for the experiments performed in this thesis. 
They were prepared with deionized water.  
Table 14 | List of buffer used for protein purification. 
Used for protein purification 
 
Description Composition 
  
Lysis buffer 
50 mM Tris-HCl (pH 8.0), 500 mM NaCl,  
5 % Glycerol, 5 mM β-Mercaptoethanol 
  
Washing buffer (batch mode) 
50 mM Tris-HCl (pH 8.0), 500 mM NaCl,  
5 % Glycerol, 5 mM β-Mercaptoethanol, 
20 mM Imidazol 
  
Elution buffer (batch mode) 
50 mM Tris-HCl (pH 8.0), 500 mM NaCl,  
5 % Glycerol, 5 mM β-Mercaptoethanol, 
300 mM Imidazol 
  
IEX running buffer A 
(tPTEN purification) 
25 mM Tris-HCl (pH 7.0), 100 mM NaCl,  
2 mM DTT 
  
IEX running buffer B 
(tPTEN purification) 
25 mM Tris-HCl (pH 7.0), 500 mM NaCl,  
2 mM DTT 
  
IEX running buffer A 
(Full-length purification) 
25 mM Tris-HCl (pH 8.0), 50 mM NaCl,  
2 mM DTT 
  
IEX running buffer B 
(Full-length purification) 
25 mM Tris-HCl (pH 8.0), 500 mM NaCl,  
2 mM DTT 
  
SEC running buffer 
(Biochemical Assay) 
25 mM Tris-HCl (pH 8.0), 200 mM NaCl,  
2 mM TCEP 
  
SEC running buffer 
(Protein crystallization) 
20 mM Tris-HCl (pH 7.5), 150 mM NaCl,  
5 mM DTT 
Table 15 | Buffer used for agarose gel electrophoresis. 
Used for agarose gel electrophoresis 
 
Description Composition 
  
50 x TAE-buffer 
50 mM EDTA, 2 M Tris-HCl (pH 8.5),  
5.71 % Acetic acid 
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Table 16 | List of buffer used for SDS-PAGE. 
Used for SDS-PAGE 
 
Description Composition 
  
Tris buffer for separating gel 1.5 M Tris-HCl (pH 8.8), 0.4 % SDS 
  
Tris buffer for stacking gel 500 mM Tris-HCl (pH 6.8), 0.4 % SDS 
  
5 x SDS-PAGE sample buffer
  
0.6 ml 1 M Tris-HCl (pH 6.8), 5 ml 50 % 
Glycerol, 2 ml 10 % SDS (w/v), 0.5 ml β-
Mercaptoethanol, 1 ml 1 % Bromphenol blue, 
0.9 ml ddH2O 
  
SDS-PAGE running buffer 
25 mM Tris-HCl (pH 8.3), 200 mM Glycine,  
0,1 % SDS 
  
Coomassie-Staining solution 
10 % Acetic acid, 
0,006 % (w/v) Coomassie Brilliant Blue G250 
Table 17 | List of solution used for protein crystallization. 
Used for protein crystallization 
 
Description Composition 
  
Protein crystallization solution 
100 mM MES (pH 6.5), 1250 mM K/Na-(L)-
tartrate, 7.5 % Glycerol 
  
Cryo solution 
100 mM MES (pH 6.5), 1250 mM K/Na-(L)-
tartrate, 25 % Glycerol 
  
Crystal-soaking solution 
             (H2O2) 
100 mM MES (pH 6.5), 1250 mM K/Na-(L)-
tartrate, 7.5 % Glycerol, 1 mM H2O2  
  
Crystal-soaking solution 
         (bpV-phen) 
100 mM MES (pH 6.5), 1250 mM K/Na-(L)-
tartrate, 7.5 % Glycerol, 1 mM bpV-phen  
  
Crystal-soaking solution 
              (PIP3) 
100 mM MES (pH 6.5), 1250 mM K/Na-(L)-
tartrate, 7.5 % Glycerol, 1 mM PI-(3,4,5)-P3 diC8 
  
Crystal-soaking solution 
              (PIP2) 
100 mM MES (pH 6.5), 1250 mM K/Na-(L)-
tartrate, 7.5 % Glycerol, 20 mM PI-(4,5)-P2 diC8 
  
Crystal-soaking solution 
            (nhPIP3) 
100 mM MES (pH 6.5), 1250 mM K/Na-(L)-
tartrate, 7.5 % Glycerol,   
20 mM 3S-PI-(3,4,5)-P3 diC8 
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5.1.4 Enyzmes 
The following enzymes were used for the experiments performed in this thesis.  
Table 18 | List of enzymes used for experiments. 
 
Enzyme Manufacturer 
  
Fast Digest
®
 NdeI (#FD0583) Fermentas 
  
Fast Digest
®
 SalI (#FD0644)  Fermentas 
  
Phusion Flash II DNA Polymerase Thermo Scientific 
  
TEV-Protease (1,8 mg/ml) Dortmund Protein Facility (MPI Dortmund) 
  
T4 DNA Ligase (1000 units/µl) 
(#EL0011)  
Thermo Scientific 
 
5.1.5 Reagent kits 
The following reagent kits were used for the experiments performed in this thesis. They were 
  p  y                 w                   ’              .   
Table 19 | List of reagent kits used for experiments. 
 
Reagent kits Manufacturer 
  
Cycle Pure Kit Omega Bio-Tek 
  
Gel Extraction Kit  Omega Bio-Tek 
  
Malachite Green Assay Kit  Echelon
®
 BioSciences 
  
QIA prep
®
 Spin Miniprep Kit QIAGEN
®
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5.1.6 Microorganisms and cells 
Table 20 | List of microorganisms and cells used for experiments. 
Taxonomy Strain/line Genotype Source 
E. coli OmniMax
TM
 F´ {proAB lacIq lacZΔM15 
Tn10(T  R ) Δ(ccdAB)} mcrA 
Δ(mrr hsdRMS-mcrBC) Φ 
80(lacZ)ΔM15 Δ(lacZYA-
argF)U169 endA1 recA1 supE44 
thi-1 gyrA96 relA1 tonA panD 
MPI, 
Dortmund 
 
(Originally 
from 
Invitrogen
TM
) 
E. coli DH10Bac
TM
 F- ,    A, ∆(   -hsd RMS-mcr 
BC), φ80   Z∆M15, ∆   X74, 
deoR, recA1,endA1, araD139, 
∆(   ,    )7697, g   , g  Kλ-rpsL, 
nupG/ bMON14272/ pMON7124  
MPI, 
Dortmund 
 
(Originally 
from 
Invitrogen
TM
) 
E. coli Rosetta
TM
  F- ompT hsdSB(rB- mB-) gal dcm 
pRARE (CamR) 
 
MPI, 
Dortmund 
 
(Originally 
from 
Merck 
Millipore
TM
) 
 
Spodoptera 
frugiperda 
(fall armyworm) 
IPLB-Sf-21-AE 
(Sf-9) 
- DPF, 
Dortmund 
 
(Originally 
from 
Invitrogen
TM
) 
Trichoplusia ni 
(Cabbage looper) 
BTI-TN-5B1-4 
(High Five cells) 
- DPF, 
Dortmund 
 
(Originally 
from 
Invitrogen
TM
) 
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5.2 Quantative analytical methods 
5.2.1 Photometric determination of DNA concentration 
Concentrations of the purified DNA including plasmids and linear PCR-products are 
determined photometrically using NanoDrop
®
 2000c spectrophotometer. The absorption 
values are measured at 260 nm, of which DNA shows the absorption maximum. This 
equipment calculates the DNA concentration proportionally, applying the absorption value of 
1 for 50 ng/µl double-stranded DNA as a standard measurement value.  
5.2.2 Photometric determination of protein concentration 
NanoDrop® 2000c spectrophotometer is applied to determine the protein concentration. 
Analogous to the measurement of DNA concentration (Chapter 5.2.1), the principle is based 
on Beer-Lambert law that states the proportional relationship of absorbance to the sample 
concentration in diluted solution (Eq. 1). The absorption values are monitored at 280 nm. For 
the concentration measurement of protein including significant amount of impurity, 
absorbance of 1 is set to the protein concentration of 1 mg/ml. After final purification, the 
extinction coefficient and molecular weight of the protein construct are given for the precise 
determination. Both values have been calculated using the ProtParam tool (ExPASy) in 
advance (Table 21)
181
.  
        (
  
 
)                 (Eq. 1) 
A: Absorbance, I0: I                y          g  , I: T                   y, ε:        x                     
[M
-1
 cm
-1
], c: concentration of the sample [mol l
-1
], d: Length of the light path through the sample [cm]. 
Extinction coefficients and molecular weights of PTEN constructs used for the protein 
concentration measurements are summarized as follows (Table 21). 
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Table 21 | Extinction coefficients and molecular weights of PTEN constructs. The values are 
calculated using the ProtParam tool
181
. 
PTEN constructs 
Extinction coefficient  
[M
-1
 cm
-1
] 
Molecular weight  
[kDa] 
PTEN (1-403) 45270 47.22 
PTEN (6-403) 45270 46.69 
PTEN (16-403) 45270 45.42 
PTEN (6-353) 42290 41.13 
PTEN (16-353) 42290 39.86 
PTEN (7-353) Δ286-309 42290 38.39 
5.3 Molecular biological methods 
5.3.1 Polymerase chain reaction (PCR) 
Polymerase chain reaction
182,183
 is employed to amplify a specific DNA sequence in a plasmid 
for recombinant protein expression. This method requires forward and reverse primers
XXIX
, 
template DNA, dNTPs, Mg
2+
-containing reaction buffer, and thermophilic DNA polymerase 
(Table 22). The reaction mixture is prepared by pipetting the components together. In this 
study, a commercially available premixed reagent, 2 x Phusion
® 
master mix is used, which 
contains dNTPs, reaction buffer with Mg
2+
 and DNA polymerase. 
Table 22 | Component scheme for polymerase chain reaction. 
Component 
Volume [µl] Volume [µl] 
Final Concentration 
preparative analytical 
Primer (forward) 5 1 1 µM 
Primer (reverse) 5 1 1 µM 
Template DNA 1 0.2 
~ 100 ng (preparative) 
~ 20 ng (analytical) 
2 x Phusion
®
 Master Mix 25 5 1x 
ddH2O 14 2.8 - 
Total 50 10 - 
Polymerase chain reaction is carried out using a thermocycler with the reaction mixture 
mentioned above. Thermocycling conditions have been programed in advance with the 
                                                 
XXIX
 Forward and reverse primers are also called sense and antisense primers, respectively. 
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following temperature/time profile (Table 23). Elongation time varies depending on the 
p  y            z                  . I   p                               ’              , 
elongation time of 60s per 1kb is applied in this study. Moreover, the number of PCR cycles 
is set not to exceed 25 cycles to avoid the potential introduction of mutation, as though the 
utilized polymerase had a proof-reading function. 
Table 23 | Thermocycling profiles for polymerase chain reaction. 
Steps Temperature [°C] Time [s] No. of cycles 
Initial denaturation 94 120 1 
Denaturation 94 30 
25 Annealing 53 30 
Elongation 72 60 per 1 kb 
Final extension 72 600 1 
Cooling down / Hold 4 ∞ - 
Afterwards, the crude product is purified with a purification kit ("Cycle Pure Kit, Omega Bio-
tek") following the manufacturer's instruction. The concentration of the purified PCR-product 
is determined using NanoDrop
®
 (Chapter 5.2.1) and stored at -20 °C until further use. 
5.3.2 Overlap extension PCR 
As a methodological variant, overlap extension PCR
184
 is especially useful to extend a PCR 
product by combining two fragments. Alternatively, this method can be applied to bring a 
target-oriented mutation into the sequence during the molecular cloning. Overlap extension 
PCR is achieved over two steps. First, two primer-directed PCR should be carried out. 
Thereby, the resulting two PCR products should include an overlapping sequence. Second, 
PCR-products from the first step serve as a primer and simultaneously as a DNA-template for 
the second polymerization. The following components (Table 24) are mixed together in a 
reaction tube and subjected to a subsequent thermocycling program.  
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Table 24 | Component scheme for overlap extension PCR. 
Component Volume [µl] Final Concentration 
Primer (forward) 5 1 µM 
Primer (reverse) 5 1 µM 
Template DNA 1 0.5 ~ 50 ng 
Template DNA 2 0.5 ~ 50 ng 
2 x Phusion
®
 Master Mix 25 1 x 
ddH2O 14 - 
Total 50 - 
Overlap extension PCR is performed using thermocycler with the same temperature/time 
profile as the standard PCR (Table 23). The crude reaction product is purified by using 
agarose gel electrophoresis (Chapter 5.3.3). Concentration of the purified PCR-product is 
determined using NanoDrop
®
 (Chapter 5.2.1) and stored at -20 °C until further use. 
5.3.3 Agarose gel electrophoresis 
Agarose gel electrophoresis
185,186
 is employed to analyze and purify the DNA fragments after 
PCR, colony PCR and restriction digest. In this study, 1 % (w/v) agarose gel is made with 
TAE-buffer (1x) as a standard gel density. 3 g of agar is boiled in 300 ml of TAE-buffer (1x) 
by microwave. 30 µl of the fluorescence stain called Gel Red
®
 Nucleic Acid Stain (10,000 x) 
is added to the agarose suspension, which is subsequently poured onto a tray. The gel is 
hardened in the presence of a comb that involves suitable pocket sizes.  
The samples for the agarose gel electrophoresis are prepared by mixing DNA-solution with 
6 x DNA loading buffer. The mixture and a DNA marker are given to each pocket in the gel 
that has been transferred to the TAE-buffer (1x) in the running chamber beforehand. 
Purification is run under 80 V (constant voltage) for 40 min. The DNA bands are visualized 
with UV light and cut using a scalpel. The DNA fragment is extracted from the agarose gel 
with "Gel Extraction Kit" (Chapter 5.1.5) following the manufacturer's instruction. 
5.3.4 Restriction digest  
For the recombinant protein expression, plasmids should be modified by insertion of the gene 
of interest. Plasmids are cleaved by specific restriction enzymes in the multiple cloning 
sites
187-189
, followed by ligation of plasmid DNA and the gene of interest using a ligase.  
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According to the Table 25, plasmid DNA or PCR product is resuspended with reaction buffer, 
ddH2O and restriction enzymes for the restriction digest. The reaction mixture is subsequently 
incubated for 1h at 37 °C. The crude product is furthermore purified using agarose gel 
electrophoresis (Chapter 5.3.3) in order to remove restriction enzymes and excised redundant 
DNA fragments. Concentration of the purified PCR-product is determined using NanoDrop
®
 
(Chapter 5.2.1) and stored at -20 °C until further use. 
Table 25 | Component scheme for restriction digest. 
Component 
Volume [µl] Volume [µl] Final 
Concentration Plasmid DNA PCR product 
Plasmid DNA 10 0 50 - 100 ng/µl 
PCR product - 15 ca. 60 ng/µl 
10 x Fast Digest
®
 Buffer 2 3 1 x 
Restriction enzyme (5'-end) 1 1.5  
Restriction enzyme (3'-end) 1 1.5  
ddH2O 6 9  
Total 20 30  
5.3.5 Ligation 
Through ligation
190-192
, two nucleic acid fragments are joined covalently to create a 
recombinant DNA molecule, in that phosphodiester bond formation is catalyzed by a ligase 
between 3'-hydroxyl of one DNA terminus and 5'-phosphate end of another. A linearized 
vector is incubated with a PCR product (from Chapter 5.3.4) in the presence of T4-ligase 
under the appropriate buffered condition (Table 26). After ligation at 25 °C for 1h, the 
reaction product is immediately subjected to the transformation (Chapter 5.3.6). 
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Table 26 | Component scheme for ligation of PCR product and linearized vector. 
 Component Volume [µl] Final Concentration 
Linearized vector DNA 2 3- 5 ng/µl 
PCR product  
(After restriction digest) 
7 ca. 20 ng/µl 
10 x T4-ligase Buffer 2 1 x 
T4-ligase 1  
ddH2O 8  
Total 20  
5.3.6 Transformation of the chemically competent cellsXXX 
Cellular transformation is a genetic alteration of the host organism by direct uptake or 
incorporation of the exogenous genetic materials. In laboratory practice, transformation serves 
to deliver genetically modified colonies harboring a homogenous genetic material. Depending 
on the host E. coli strains, transformed cells can be utilized to amplify plasmids or to produce 
recombinant proteins. In this study, commercially available E. coli-strain OmniMAX and 
BL21(DE3)-derivatives are used for the plasmid amplification and protein production, 
respectively. For the cellular transformation, E. coli cells should be made artificially 
competent prior to the DNA-uptake process. The corresponding E. coli cells have been 
prepared chemically competent using calcium chloride in advance
193
.  
50 – 100 µl of competent E. coli cells are thawed on ice. 10 µl of ligation product or 1 µl of a 
plasmid is added to the cells and incubated subsequently for 30 min on ice. The cells are 
exposed to heat shock at 42 °C for 1 min, transferred immediately back onto ice and 
furthermore incubated for 1.5 – 2 min. The cells are supplied with 900 µl LB-media and 
incubated at 37 °C and 600 rpm for 1 h. Following recovery from the heat shock, 100 µl of 
cells are transferred to an LB-agar plate supplemented with a selection antibiotic (Chapter 
5.1.1) and spread using a Drigalski-spatula. The LB-agar plate is incubated overnight at 
37 °C.  
                                                 
XXX
 Transformation of DH10-Bac for bacmid production will be discussed in the following chapter 
Transposition (Chapter 5.4.1) 
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5.3.7 Colony PCR 
Colony PCR
194,195
 is a variant of PCR methods to amplify a targeted gene sequence directly 
from bacterial colonies. This method is particularly useful during molecular cloning to verify 
successful ligation of the gene of interest in the vector. Colony PCR utilizes the same 
principle as the standard PCR (Chapter 5.3.1). The major difference is to use randomly 
selected colonies instead of an isolated DNA template. In addition, primers are frequently 
designed to bind upstream and downstream regions of the multiple cloning sites in the vector 
backbone to ensure the experimental success (Table 27). Consequently, colonies with the 
successful insertion of the gene of interest are differentiated from the counterparts by size of 
the amplified PCR products.      
Table 27 | Sequencing primers for pFH1 vector. 
Primer Oligonucleotide sequences 
pFH1 forward 5’ - GTA ACA GTT TTG TAA TAA AAA AAC C - 3’ 
pFH1 reverse 5’ - GTT TCA GGT TCA GGG GGA GGT GTG GG - 3’ 
During the procedure, each colony is carefully resuspended with 10 µl sterile ddH2O in a 
reaction tube using a sterile pipette tips. The resuspension is heated at 95 °C for 10 min. The 
cell lysate is subsequently centrifuged at > 10,000 g for 2 min. 1 µl of the supernatant is added 
to the colony PCR master mix that has been prepared in advance (Table 28). 
Table 28 | Component scheme for colony PCR master mix. Volume scaled to 1 colony. 
Component Volume [µl] Final Concentration 
Primer (forward) 1 1 µM 
Primer (reverse) 1 1 µM 
2 x Phusion
®
 Master Mix 5 1 x 
ddH2O 3 - 
Total 10 - 
Colony PCR is run with the following program (Table 29). The number of PCR cycles is set 
to 30 in order to ensure amplification of the DNA insert. Afterwards, the samples are 
subjected to agarose gel electrophoresis (Chapter 5.3.3) to confirm success of the previous 
ligation step (Chapter 5.3.5). 
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Table 29 | Thermocycling profiles for colony PCR. 
Steps Temperature [°C] Time [s] No. of cycles 
Initial denaturation 94 120 1 
Denaturation 94 30 
30 Annealing 53 30 
Elongation 72 60 per 1 kb 
Final extension 72 600 1 
Cooling down / Hold 4 ∞ - 
5.3.8 Isolation of the recombinant plasmid DNA 
After the successful insertion of the gene of interest, the recombinant plasmid DNA is isolated 
from the transformed cells. A colony of the transformed E. coli strain OmniMAX is 
inoculated into 5 ml LB-media with appropriate antibiotics and cultured overnight at 37 °C. 
The cell culture is centrifuged at > 10,000 g for 2 min. The isolation of the plasmid is carried 
out using QIAprep
®
 Spin Miniprep Kit (QIAGEN
®
) following the manufacturer's instruction. 
The principle is based on the alkaline cell lysis
196
.  
The cell pellet is resuspended with 250 µl resuspension buffer (P1) in which RNase has been 
added in advance. After addition of 250 µl lysis buffer (P2) and inversion of the sample for 
several times, the mixture is incubated for 5 min. After treatment with 350 µl neutralization 
buffer (N3) and subsequent inversion, plasmid in solution is separated by centrifugation 
(10 min, 16,100 rcf) from the genomic DNA, endogenous proteins, and other cellular 
components. The supernatant is given to the DNA-affinity column including a silica 
membrane, which is supplied in the kit. Plasmid DNA is bound to the membrane through 
centrifugation (16,100 rcf, 1 min), followed by addition of 500 µl binding buffer (PB). The 
silica column is washed twice by centrifugation with 750 µl washing buffer (PE). Prior to 
elution of the plasmid DNA, the spin column is centrifuged without any buffer to remove 
trace of ethanol, which might influence the following experiments. Finally, plasmid DNA is 
eluted with 30 – 50 µl elution buffer (EB) by centrifugation. The concentration of the 
obtained plasmid DNA is determined photometrically by NanoDrop
®
 (Chapter 5.2.1). 
5.3.9 Sequence identification 
Validation of the sequence identity is performed by a DNA sequencing process. During the 
molecular cloning experiments, the insert fragment is amplified using PCR-procedures. This 
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might be a potential error-prone step with sequence mutations, in spite of the intrinsic proof-
reading function of the DNA polymerases used. Therefore, plasmids produced recombinantly 
are monitored by this sequencing step before further use. The sequence identification is 
carried out by an external company StarSeq
®
 (Mainz, Germany). The samples are prepared 
with the total volume of 7 µl including plasmid DNA (600-800 ng) and primer (10 pmol; 
either forward or reverse). The sequencing results are aligned with the wild-type PTEN 
sequence (homo sapiens) from Uniprot
142
 (Uniprot-ID: P60484) using an online tool 
ClustalW2
197
. The results of the sequence identification are found in the Chapter 7.2. 
5.4 Protein expression using Bac-to-Bac® baculovirus expression system 
5.4.1 Transposition 
Recombinant protein expression using insect cells is performed based on Bac-to-Bac
®
 
baculovirus expressions system
198
 (Figure 44). The gene of interest is transformed into 
bacmid DNA by transposition in DH10Bac E. coli cells. The resulting recombinant bacmid 
DNA is used for transfection of insect cells to generate recombinant baculovirus particles, 
which in turn are used for subsequent infection of insect cell expression culture to produce the 
protein of interest. 
To generate the recombinant bacmid DNA harboring the gene of interest, 50 µl chemically 
competent DH10bac
TM
 E. coli cells are transformed with 1 – 10 ng sequence-verified PTEN 
construct in the pFH1 vector by heat shock transformation (Chapter 5.3.6.). Compared to the 
heat shock protocol described above, cells are treated differently after heat shock and 
re-cooling. 150 µl LB-Medium are added to the cells and incubated at 37 °C for 4 h. 
Following the incubation in which transposition of the gene of interest takes place, cells are 
spread out on a blue-white-screening plate containing IPTG and X-gal (5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside)199 (Chapter 5.1.1) and incubated at 37 °C for 2 days. Upon 
                p       ,             w w          ,                          b      p       β-
galactosidase, which conveys conversion of X-gal to indigo derivatives (5,5'-dibromo-4,4'-
dichloro-indigo). Four positive (white) and one negative (blue) colonies are transferred to a 
new blue-white-screening agar plate to ensure the assay result. 
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Figure 44 | General scheme of Bac-to-Bac
®
 baculovirus expressions system. Gene of interest from 
the donor plasmid is transferred to bacmid DNA by transposition, which is subsequently isolated and 
used for transfection. Insect cells that carry the bacmid DNA serve to amplify baculovirus and produce 
the protein of interest. This figure is reconstructed based on Bac-to-Bac® Baculovirus Expression 
System manual (Invitrogen
TM
, 2010)
176
. 
5.4.2 Isolation of the recombinant bacmid DNA 
Following the previous selection step (Chapter 5.4.1), the positive colonies (white) are used 
for the bacmid amplification. Each colony is inoculated in 5 ml LB media containing 
kanamycin (50 µg/ml), gentamycin (7 µg/ml), tetracycline (10 µg/ml) and incubated 
overnight at 37 °C and 160 rpm. The cell pellet is harvested by centrifugation (16,400 rcf, 2 
min). The supernatant is discarded. Cell lysis is carried out using solutions supplied in a 
commercially available kit, QIAprep
®
 Spin Miniprep Kit (QIAGEN
®
). Herein, the protocol is 
differentiated as follows. The cell pellet is resuspended with 300 µl Resuspension buffer (P1) 
in which RNase has been given in advance. The cell suspension is treated with 300 µl Lysis 
buffer (P2) and inverted several times. The reaction mixture is subsequently incubated for 
5 min. Finally, lysis is stopped by adding 300 µl Neutralization buffer (N3). The mixture is 
incubated for 10 min on ice, followed by centrifugation for 30 min (16,400 rcf, 4 °C). 1100 µl 
ice-cold isopropanol is added to the supernatant fraction. Bacmid DNA is precipitated by 
incubation at -20 °C for 2 h and separated by centrifugation for 30 min (16,400 rcf, 4 °C). The 
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obtained bacmid DNA pellet is washed with 900 µl ethanol (80 %). After the final 
centrifugation for 15 min (16,400 rcf, 4 °C), the supernatant is discarded and the bacmid DNA 
is dried on the sterile bench. Bacmid DNA is dissolved in the sterile elution buffer (40 µl, EB, 
QIAprep
®
 Spin Miniprep Kit). The harvested bacmid DNA is subsequently used for the 
transfection (Chapter 5.4.3). 
5.4.3 Transfection and baculovirus amplification 
Sf9 cells (insect cell line derived from spodoptera frugiperda) are appropriately diluted to 
0.5 x 10
6
 cells/ml with cell culture media (Spodopan, PAN
TM
 BIOTECH GmbH). Cells are 
counted using a Neubauer cell-counting chamber and trypan blue solution. 2 ml cell 
suspension is given to each well in 6-well cell culture plate. Thereby, one well is supplied 
with media only and serves as a contamination test. Cells in the culture plate are incubated for 
30 min at room temperature to make them adherent to the plate. Among the remaining five 
wells, one well serves as a negative control for the transfection. On the other side, cells are 
treated with the transfection mixture that has been prepared beforehand incubating 20 µl 
isolated bacmid DNA (Chapter 5.4.2), 10 µl X-tremeGENE
TM
 HP DNA Transfection Reagent 
(Roche
®
) and 200 µl Spodopan (PAN
TM
 BIOTECH GmbH) for 20 min at room temperature. 
The transfected cells are subsequently incubated for 3 days at 27 °C. Afterwards, cells in each 
well are transferred to 10 ml Sf9 cells (1 x 10
6
 cells/ml) which have been separately prepared 
in 10 cm cell culture plates. Following incubation for 4 days at 27 °C, cells are harvested and 
sedimented by centrifugation (500 rcf, 10 min). The baculovirus-containing supernatant is 
sterile filtered and supplied with 10 % (v/v) sterile fetal bovine serum (FBS). The harvested 
baculovirus (The first passage, V0-stock) is stored at 4 °C until further use.  
The high titer baculovirus (V1) is produced for protein expression. 50 ml Sf9 cells are 
prepared with the cell density of 1 x 10
6
 cells/ml and infected with 500 µl baculovirus (V0-
stock)
XXXI
. The cells are subsequently incubated for 5 days (27 °C, 110 rpm). Harvest of the 
V1-stock is carried out same as that of V0-stock. 
5.4.4 Recombinant protein expression in High FiveTM insect cells. 
High Five
TM
 cells, derived from trichoplusia ni, are used for overexpression of PTEN 
constructs. Prior to infection, cells are counted and diluted appropriately to 1 x 10
6
 cells/ml. 
                                                 
XXXI
 500 ml Erlenmeyer flask is used for 50 ml culture volume during virus amplification.  
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Subsequently, High Five
TM
 cells are infected with 1 % (v/v) of V1 baculovirus harboring the 
gene of interest and incubated for 3 days at 27 °C and 110 rpm
XXXII
. Cells are harvested by 
centrifugation at 4 °C (600 rcf, 20 min). The supernatant is discarded. The cell pellet is 
resuspended with lysis buffer (35 ml lysis buffer for 800 ml insect cell culture volume, 
Table 14), shock-frozen in liquid N2 and stored at -80 °C until further use.    
 
5.5 Recombinant protein expression in Escherichia coli 
PTEN constructs are overexpressed in the prokaryotic host organism E. coli. Rosetta
TM
 
(Novagen
TM
), a BL21 (DE3) derivative. This cell line carries an additional chloramphenicol-
resistant plasmid encoding the tRNAs that are rarely used in E. coli (rare codons).  
Competent cells of Rosetta
TM
 cell line are transformed with pET28a vector that contains the 
full-length PTEN construct (Chapter 5.3.6). The transformed cells are inoculated in 100 ml 
TB media (supplied with 50 µg/ml kanamycin and 34 µg/ml chloramphenicol) and grown 
overnight at 37 °C (160 rpm). On the following day, the cells are diluted 1:100 in fresh TB 
media (supplied with 50 µg/ml kanamycin and 34 µg/ml chloramphenicol) in a large scale 
and grown up to the optical density (OD600) of ~ 0.8 (37 °C, 120 rpm). The cells are cooled 
down to 20 °C and treated with 0.4 mM IPTG to induce protein expression. Full-length PTEN 
protein is produced for the next 16 h at 20 °C (120 rpm), followed by cell harvest through 
centrifugation at 4 °C (20 min, 4000 rcf). The cell pellet is resuspended with lysis buffer 
(30 ml per 1 l cell culture, Table 14), shock-frozen in liquid N2 and stored at -80 °C until 
further use.  
5.6 Isolation of the recombinantly expressed proteins and their purification 
5.6.1 Cell lysis 
The overexpressed proteins are isolated by cell lysis and subsequent protein purification. 
E. coli cells from large-scale expression are generally disrupted by Microfluidizer
®
, whereas 
insect cells are sonicated. In the first step, the frozen cell pellets from the previous steps 
(Chapters 0 and 5.5) are thawed at room temperature. A universal protease inhibitor PMSF 
and a red    g  g    β–mercaptoethanol are added up to 1 mM and 5 mM, respectively.    
                                                 
XXXII
 2000 ml Erlenmeyer flask is used for 400 ml culture volume during protein expression. 
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Microfluidizer
®
 - Prior to cell lysis by Microfluidizer
®
, 0.05 % (v/v) DNase (10 mg/ml) is 
additionally given to the cell suspension. The appliance, pre-equilibrated with lysis buffer and 
cooled down with ice in advance, disrupts the cells by passing them through a narrow reaction 
chamber. Thereby, the chamber is first exposed to high pressure, then the pressure is abruptly 
released. This induces a shearing force in the reaction chamber. Cells are lysed in 
consequence. To ensure complete disruption, the cells passed through Microfluidizer
®
 four 
times. 
Sonication - Thawed High Five
TM
 cells are disrupted by sonication. The insect cells are 
treated on ice with pulsed sonication (Sonifier Cell Disruptor, Branson Sonic Power Co.) as 
follows: 6 x 60 s at 45 % intensity, 1 s pulse on, 1 s pulse off.  
In both cases, a protein sample of the total fraction is spared for SDS-PAGE (Chapter 5.6.7) 
after the cell disruption. The soluble fraction containing the protein of interest is isolated by 
centrifugation at 4 °C (60 min, 64,000 rcf) and used to perform the following Ni-NTA affinity 
chromatography. A protein sample from this fraction is also taken for SDS-PAGE.  
5.6.2 Ni-NTA immobilized metal ion affinity chromatography  
Protein constructs discussed in this thesis harbor an N-terminal His6-tag involving six 
histidine residues. This protein tag can be utilized for protein purification, since it has an 
affinity for Ni
2+
 that is immobilized to the carrier material (Nitrilotriacetic acid, NTA). Taking 
advantage of the affinity property, the protein of interest is bound and washed on the column, 
followed by elution from the column using imidazole. In general, there are two different 
methods to perform affinity chromatography. The first one is to employ the pre-packed 
column and the other is to use the column material (Ni
2+
-beads). In this study, both methods 
are utilized as described below. 
HisTrap
TM
 column - Recombinant proteins produced from E. coli are purified at 4 °C using a 
peristaltic pump and 5 ml pre-packed HisTrap
TM
 HP-column (GE
®
 Healthcare Lifesciences). 
The column is first equilibrated with 5 CV of the lysis buffer at 1 ml/min. The supernatant 
fraction of the cell lysate (Chapter 5.6.1) is subsequently flown into the column at the same 
flow rate. Next, the column is washed with 10 CV of the washing buffer including low 
concentration of imidazole (30 mM). Thereby, unspecifically bound proteins are washed out. 
Finally, protein of interest is collected by flowing the elution buffer including high 
concentration of imidazole (300 mM).  
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Batch-purification - Recombinant proteins produced from High Five
TM
 cells are purified 
using Ni
2+
-NTA beads (QIAGEN
®
 Superflow) in a 50 ml conical centrifuge tube. This 
method takes advantage of accelerated sedimentation and isolation of bead materials by 
centrifugation (700 rcf, 10 min, 4 °C). In the first step, Ni
2+
-NTA beads (1 ml Ni
2+
-NTA 
beads slurry per 1 l insect cell culture) are equilibrated with 50 ml ddH2O and lysis buffer 
consecutively. After equilibration, buffer is discarded. The conical centrifuge tube including 
the beads is subsequently filled up with the supernatant fraction of the cell lysate, followed by 
incubation overnight at 4 °C and 3 rpm. Afterwards, beads are sedimented by centrifugation 
(700 rcf, 10 min, 4 °C). The supernatant is discarded. Beads are washed twice with 15 ml 
washing buffer containing 20 mM imidazole. Finally, the protein of interest is eluted with 
10 ml elution buffer containing 300 mM imidazole.  
In both cases, purified proteins from the elution step are furthermore subjected to the 
following purification step after determination of protein concentration (Chapter 5.2.2) and 
SDS-PAGE analysis (Chapter 5.6.7). 
5.6.3 Proteolytic cleavage of the protein affinity tag 
Following the affinity chromatography, His6-tag is removed from the protein construct by 
protease-mediated proteolytic cleavage. In this study, proteins produced by insect cells 
contained a recognition sequence of TEV-protease between N-terminal His6-tag and PTEN. 
TEV-protease cleaves its recognition site (ENLYFQ|G) specifically and leaves the protein 
construct without cloning artifacts except for an N-terminal glycine residue. His6-tagged 
TEV-protease is supplied by DPF (Dortmunder Protein Facility, MPI Dortmund). According 
to the manufacturer's data sheet, 1 mg of protein (75 kDa) harboring the TEV-recognition 
sequence is suggested to be digested with 0.06 mg TEV-protease. Concerning different 
protease concentrations in every purification batch, the concentration statement of the TEV-
protease is not provided in this thesis. The elution fraction from the affinity chromatography 
is treated with an appropriate amount of TEV-protease and incubated overnight at 4 °C. The 
success of the cleavage is determined by SDS-PAGE (Chapter 5.6.7).  
5.6.4 Ion exchange chromatography 
Proteins can be separated by their overall charges using ion exchange chromatography. The 
purification principle is based on the electrostatic interaction between mobile phase (proteins) 
and immobilized one (ligands linked with a column matrix). Proteins can be eluted separately 
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with increasing ionic strength of the running buffer (e.g. salt gradient or changing pH). 
Depending on the charge of the ligands, ion exchange chromatography columns are 
categorized into cation (anionic ligands on the bead material) and anion (cationic ligands) 
exchangers. Cation exchanger can be used for purification in the case of theoretical isoelectric 
points (pI values) higher than pH of the running buffer and vice versa. In this study, 
theoretical isoelectric points (pI values) of each protein construct have been calculated using 
ProtParam tool
181
 in advance (Table 30). PTEN constructs including the C-terminal tail show 
lower pI than pH of the running buffer, due to the acidic residues in the tail region. Therefore, 
anion exchanger is employed. In contrast, cation exchanger is the choice for PTEN core 
domains (tPTEN).  
Table 30 | Theoretical isoelectric points calculated by ProtParam tool
181
. The calculation is based 
on the amino acid property. Post-translational modification such as phosphorylation is not considered 
in the calculation. 
PTEN constructs 
Isoelectric points  
(pI-values) 
PTEN (1-403) 5.95 
PTEN (7-353) Δ286-309 8.69 
Full-length PTEN is purified using MonoQ
TM 
5/50 GL column (CV, 1 ml; GE
®
 Healthcare 
Lifesciences). The column is first equilibrated with 5 CV of IEX-buffer A containing 100 mM 
NaCl. Subsequently, full-length PTEN is loaded onto the column at a flow rate of 1 ml/min. 
The column is subsequently washed with 5 CV of IEX-buffer A. Protein of interest is eluted 
by increasing the NaCl concentration from 100 mM to 500 mM over 125 CV with linear 
gradient. For the protein elution, 0.5 ml/min is used as a flow rate. tPTEN is purified using 
HiTrap
TM
 SP HP (CV, 5 ml; GE
®
 Healthcare Lifesciences). General procedure is same as the 
description for anion exchange chromatography, except the gradient setting. NaCl 
concentration is increased from 100 mM to 400 mM over 12 CV. In both cases, protein 
elution is detected by absorbance at 280 nm and subsequently analyzed by SDS-PAGE 
(Chapter 5.6.7). Ion exchange chromatography columns are connected with Äkta FPLC (GE
®
 
Healthcare Lifesciences) during purification and controlled via Unicorn software (GE
®
 
Healthcare Lifesciences). 
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5.6.5 Protein Ultrafiltration 
PTEN is concentrated before the size exclusion chromatography and after the final 
purification. Utilizing the centrifugal force, proteins are concentrated on the filter membrane, 
which is supplied with different pore sizes involving the molecular weight cut-off. In 
preparation for protein concentration, Amicon
®
 Ultra Centrifugal Filter Unit (Merck 
Millipore) with 10 kDa cut-off is equilibrated by passing buffer through the filter membrane. 
It is facilitated by centrifuging the Amicon
®
 Ultra Centrifugal Filter Unit for 10 min at 3,000 
rcf and 4 °C. Thereby, trace of glycerol can be removed in the membrane. After discarding 
the buffer passed through, protein solution is transferred onto the filter membrane and 
centrifugation is run as mentioned above. Duration of the concentration depends on the total 
volume, molecular weight of the protein, purity, mono-dispersity, and the final protein 
concentration. Finally, protein concentration is determined by NanoDrop
®
 (Chapter 5.2.2). 
5.6.6 Size exclusion chromatography  
Final protein purification is performed using size exclusion chromatography. Its principle is 
based on the separation of molecules by size. Together with its purification property, this 
method allows to determine protein size in the native state and to change the buffer 
environment of the protein of interest.  
Prior to running size exclusion chromatography, protein constructs are concentrated 
(Chapter 5.6.5) and subsequently centrifuged in order to remove any precipitation (16,400 rcf, 
4 °C, 15 min), while the corresponding column is equilibrated with 1.5 CV of the filtered and 
degassed buffer (Table 14). Next, the prepared protein sample is injected onto the column and 
1 CV of the buffer is run with flow rate of 1 ml/min (preparative, HiLoad
TM
 16/60 
Superdex
TM
 200 preparative grade) or 0.5 ml/min (analytical, Superdex
TM
 200 10/30 GL 
analytical grade) at 4 °C. Protein elution is detected by absorbance at 280 nm and analyzed 
using SDS-PAGE (Chapter 5.6.7). Size exclusion chromatography columns are connected 
with Äkta FPLC (GE
®
 Healthcare Lifesciences) and controlled via Unicorn software (GE
®
 
Healthcare Lifesciences). 
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5.6.7 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE
XXXIII
 is employed to analyze the protein overexpression and its purity during 
protein purification. During the electrophoresis, protein samples run through polyacryamide 
gel and can be separated by size. The ratio of acrylamide used for polymerization varies 
depending on size of the protein of interest. Since PTEN constructs used in this study lie 
between 30 and 50 kDa, 12 % SDS gels are utilized for the separating gel (Table 31). Prior to 
the electrophoresis, protein samples are prepared by incubating with 5 x SDS sample buffer 
(Table 16) at 95 °C for 10 min.  
Table 31 | Component scheme for the SDS polyacrylamide gel preparation. 
Component 
Volume 
Separating gel (12 %) 
(Two gels) 
Volume 
Stacking gel 
(Two gels) 
ddH2O 4.9 ml 4.2 ml 
30 % Acrylamide (4K solution) 6.0 ml 1.0 ml 
Tris buffer for separating gel 3.8 ml  
Tris buffer for stacking gel  760 µl 
10 % SDS (w/v) 150 µl 60 µl 
10 % APS (w/v) 150 µl 60 µl 
TEMED 6 µl 6 µl 
10 µl of prepared samples and 4 µl of prestained protein standard marker (Page Ruler
TM
 Plus 
Prestained Protein Ladder, Fermentas
TM
) are given to each pocket in the gel that has been 
soaked in the SDS running buffer in advance. The electrophoresis is run under 160 V 
(constant voltage) for 70 min. SDS gels are transferred to the staining buffer (Table 16), 
boiled via microwave and incubated for 20 min at room temperature. Stained SDS gels are 
furthermore destained in boiling water, until the protein bands are clearly visible and the 
background blue staining is no longer present. The destained gels are documented with a 
scanner. 
                                                 
XXXIII
 In this study, Tris-Glycine SDS-PAGE is used based on Laemmli et al. (1970)
205
. 
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5.7 Protein crystallization and structure determination 
5.7.1 Protein crystallization 
Full-length PTEN (PTEN 1-403) is used for protein crystallization with commercially 
available pre-mixed crystallization buffers (Qiagen
®
 NeXtal JCSG Core Suites, 
Chapter 3.4.1). Each suite involves 96 conditions. Initial crystallization condition screening is 
carried out in 96-unit plate format (3553, Corning
®
), in which one large well for the reservoir 
solution and three small wells for protein drops make up one unit. Applying the sitting-drop 
vapor diffusion method
206
, protein solution containing PTEN is incubated with each reservoir 
solution of the suite. Reservoir solution (70 µl) of each crystallization condition is transferred 
to the large well of each unit on the 96-unit plate. The three small wells per unit are filled with 
protein solution (100 nl) involving three different concentrations (7, 14 and 21 mg/ml), 
followed by transfer of the corresponding reservoir solution (100 nl) onto the protein drops 
(ratio 1:1). This was carried out at 20 °C using the pipetting robot Mosquito (TTP Labtech). 
The 96-unit plate is sealed with a transparent film and incubated in a Rock Imager 1000 
(Formulatrix) at 20 or 4 °C, respectively. The crystallization process of each well is 
automatically recorded as an image in the regular terms and monitored using software Rock 
Maker 2.0 (Formulatrix). 
tPTEN (PTEN 7-353 ∆286-309) is crystallized based on the known crystallization condition 
(100 mM Tris, 1.3 M Na/K L(+)-tartrate and 5 – 10 % glycerol, 10 mM DTT (pH 8.0)). 
Applying the hanging-drop vapor diffusion method
206
, protein solution containing tPTEN is 
incubated with the reservoir solution in the 24-well plate format (Crystalgen 24 Well 
SuperClear
TM
 Plates, pregreased, Jena Bioscience). Thereby, pH (pH 6 – 10) XXXIV , 
temperature (20 or 4 °C), tartrate (1.2 – 1.35 M) and glycerol concentration (5 – 20 %) are 
varied to find the optimal condition. DTT is not added for the following soaking experiments. 
Reservoir solution of each crystallization condition (700 µl) is given to the well in a 
corresponding position. Protein solution of tPTEN (20 mg/ml, 1 µl) is mixed with 1 µl of the 
reservoir solution on 22 mm cover slides (ratio 1:1). The cover slide is turned upside down, 
sealed on each well and incubated. Crystal growth is monitored everyday.  
                                                 
XXXIV
 For the range of each pH, different buffer is utilized. pH 6 – 6.5: MES, pH 7 – 8.5: TRIS, pH 9 – 10: 
CAPS. 
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5.7.2 Freezing of protein crystals 
Prior to data collection, protein crystals are frozen for protection from radiation damage. 
However, freezing process of biological macromolecules leads to formation of crystalline ice, 
which results in crystal damage. Therefore, protein crystals should be frozen in a cryo 
solution, which is supplemented with frost protection agent (e.g. glycerol, ethylene glycol, 
xylitol) and facilitates vitreous freezing of water and crystallization solution. In the case of 
tPTEN, protein crystals are incubated in reservoir solution supplemented with 25 % glycerol 
(cryo solution, Table 17) for 2 min. tPTEN crystals are subsequently flash-frozen in liquid N2.  
 
5.7.3 Ligand-soaking experiment 
The crystal structures of H2O2- and bpV-phen-treated tPTEN (Ox) are obtained by soaking the 
protein crystals (reduced, Chapter 5.7.1) in the crystallization buffers supplemented with 
1 mM H2O2 (t = 1 h) and 1 mM bpV-phen (t = 4 h), respectively. After incubation, the protein 
crystals are back-soaked with cryo solution (Table 17, Chapter 5.7.2) for 10 min and flash-
frozen in liquid N2. 
 
5.7.4 Data collection 
X-ray dataset is collected at synchrotron (beamline PXII, Swiss Light Source, Villigen, 
Switzerland). During data collection, protein crystals are kept under the cryo stream at 100 K 
(-173 °C)
155
. Crystals are rotated by 360º with an oscillation range of 0.25º
156
 and exposed to 
20 % attenuation of radiation with 0.1 s exposure time for one frame. PILATUS detector is 
employed for detection and positioned with a distance of 345. For reduced and H2O2-treated 
PTEN crystals, monochromatic radiation is set at the wavelength of 1.000 Å, while the 
wavelength of 1.771 Å is applied for reduced and bpV-phen-treated PTEN crystals, in which 
anomalous scattering is utilized.  
5.7.5 Data processing 
Data collection results in a set of detection images (frames), which involves a pattern of 
reflections occurring from X-ray diffraction of the protein crystal. Each frame represents a 
small wedge of structural information generated by the rotation of the crystal in the X-ray 
beam. In addition, reflections on the detector images are distorted due to projection on the 
two-dimensional detector. For that reason, data processing serves to reconstruct the 
undistorted three-dimensional lattice. The underlying Bravais Lattice, space group symmetry 
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and unit cell geometries are determined from the reflection positions. A corresponding Miller 
index (h, k, l) is assigned to each reflection, followed by quantification of its intensity. 
Afterwards, symmetry-related reflections must be put on the same intensity. This is due to 
possible incidences such as change of the X-ray intensity during data collection, potential 
difference of sensitivity in different regions of the detector and the crystal larger in one 
direction than another. Finally, the structure factor amplitudes are calculated, which are the 
essential terms to generate electron density maps.   
The software XDS
157
 serves to calculate intensities of all reflections and index them. The 
scaling of intensities is performed with the software XSCALE
157
. XDSCONV
157
 is 
furthermore applied to calculate the structure factor amplitudes of the scaled intensities. For 
tPTEN structures, space group C2221 (SG No. 20) and unit cell constants (a = 206 Å, b = 
206 Å, c = 89 Å; α   90°, β   90° γ   90°) are given for data processing.  
5.7.6 Computer-aided structure determination 
The structure factor F(hkl) is a mathematical description of diffracted X-ray radiation that 
produces reflections at a detector. F(hkl) accounts for scattering property of hkl as a Fourier-
series and can be decomposed into the sum of simple oscillating functions. Every single term 
in the factor corresponds to contribution of an atom to reflections hkl. F(hkl) is composed of 
amplitude |F(hkl)| and phase term exp(iα(hkl)) as described in Eq. 2.   
 (   )    (   )      (  (   ))                                  (Eq. 2) 
F(hkl): structure factor; |F(hkl)|: structure factor amplitude; exp(iα(   )): phase term of the structure factor 
The structure factor F(hkl) allows to calculate electron density around the atoms in a unit cell. 
The electron density ρ at position x, y, z in the Cartesian coordinate system of the unit cell can 
be determined with following equations (Eq. 3 and 4).  
                      (   )  
 
 
∑  (   )      (    (        ))                                         (Eq. 3) 
               
 
 
∑   (   )     (  (   ))     (    (        ))            (Eq. 4) 
ρ(xyz): electron density in the Cartesian coordinate system at the position x, y, z; V: volume of the unit cell; 
F(hkl): structure factor; |F(hkl)|: structure factor amplitude; exp(iα(   )): phase term of the structure factor 
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Although the structure factor amplitude |F(hkl)| can be calculated using measured intensities 
of the diffraction pattern, the phase term exp(iα(hkl)) cannot be derived directly from the 
measurement, while this term is an indispensable factor to calculate the electron density. This 
           w     “p     p  b   ”. I   his study, the phase problem is resolved using 
molecular replacement (MR) method
207
. This method is based on utilizing phase term of the 
available crystal structure as a template. Therefore, it is prerequisite that the template structure 
involves high sequence homology to the crystallized protein. However, such template 
structures are frequently crystallized in a distinguished packing involving different 
crystallographic parameters (e.g. space group, unit cell constants etc.). Hence, MR method 
rotates and translates the template molecule within the unit cell. The structure factor 
amplitude of the template structure (|Fcal|) is determined at each position and compared with 
the observed one (|Fobs|). This method runs, until the maximal likelihood of its position and 
orientation is reached. In the case of tPTEN, a structural solution is yielded by the software 
PhaserMR (CCP4 suite
200,201
). The previously reported PTEN crystal structure (PDB
42
: 
1D5R
43
) is employed as a template.  
Applying the measured structure factor amplitude |Fobs(hkl)| and the phase term αhkl obtained 
from molecular replacement, the electron density map can be generated. This allows to build 
the structure model tPTEN in its electron density, which is facilitated by the software Coot
202
. 
The following refinement process using Refmac
203
 corrects geometric parameters of the 
structure model (e.g. bond lengths and angles between atoms) and approximates the 
calculated structural factor amplitude of the current model |Fcalc(hkl)| to the observed one 
|Fobs(hkl)|. In the case of tPTEN, structure refinement is performed with the detwin function, 
due to the twinned character of the crystals. The refinement process provides a new refined 
model and structure factor. The structure model can be subsequently improved by manual 
structure correction, followed by repeated refinement in the iterative way, until both structure 
factor amplitudes (|Fobs (hkl)| and |Fcalc (hkl)|) have reached the maximal agreement. As a 
measure of model quality, crystallographic R-factor Rcryst is applied to demonstrate the 
discrepancy between the observed data and the structure model. The smaller Rcryst is, the 
better the model is in accordance with the measured data. Since new structure factor is 
calculated based on the refined structure, erroneously refined region in the model can 
influence the calculation of the phase and results in biased model. Therefore, 5 % of the 
measured reflections are not included for the refinement process. Analogous to Rcryst (also 
called Rwork), Rfree is additionally calculated, which reflects the debiased R-factor. Difference 
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of both values should not be larger than 5 %
208,209
. Processing and refinement statistics are 
summarized in Table 4, Table 7 and Table 9.  
        
∑                 
∑       
                                               (Eq. 5) 
R: R-factor; Fobs: observed structural factor (experimental data); Fcal: calculated structural factor. 
Generation of 2 Fo – Fc omit maps is carried out using Sfcheck (CCP4 suite
200,201
). The 
anomalous scattering electron density maps are rendered by performing an additional data 
p        g w              g           ’s law, followed by calculation using Refmac, Cad, and 
FFT (CCP4 suite
200,201
). All figures involving crystal structures are generated using Pymol
204
. 
Table 32 | Summary of utilized softwares for X-ray crystallographic analysis. 
Package Software Usage 
XDS suite 
XDS Data processing 
XSCALE Scaling of dataset 
XDSCONV File format conversion 
CCP4 suite 
CAD Anomalous density map 
FFT Map generation 
Sfcheck Omit map calculation 
Matthews_coef Matthews coefficient calculation 
PhaserMR Molecular replacement 
Refmac Structure refinement 
- Pymol Graphical representation 
- Coot Model building 
5.8 Malachite green activity assay 
5.8.1 Determination of phosphatase activity 
Phosphatase activity of PTEN is investigated using PI(3,4,5)P3 diC8 as a substrate. This 
compound is a natural substrate PIP3 derivative truncated at fatty acid side chains. It is used to 
ensure the solubility and homogeneity of the assay. 60 nM PTEN is pre-treated with buffer 
either lacking or containing additives e.g. 50 µM PIP2, 50 µM nhPIP3, 400 µM H2O2, 1 µM 
bpV-phen, 1 µM bpV-pic, or 1 µM bpV-HOpic for 10 min (Figure 18). Phosphatase reaction 
is initiated by addition of PIP3 (final: 50 nM PTEN, 75 µM PIP3). The reaction mixture is 
incubated at 25 °C for 30 min. The reaction is quenched by transferring the reaction mixture 
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(V = 25 µl) to malachite green solution (V = 100 µl, Echelon Biosciences
®
) that has been 
prepared in 96-well plate (transparent, flat bottom) beforehand. Following color development 
for 30 min, absorbance of each well is measured at 620 nm employing a plate reader 
Safire2
TM
. The absorption values are converted to the released orthophosphate amount by 
extrapolating from the standard phosphate-malachite green curve. Relative PTEN activity is 
determined relative to untreated wild-type PTEN (devoid of activity modulators). 
Measurements are carried out in triplicates. GraphPad Prism
TM
 is used to calculate the relative 
PTEN activity including standard deviation.  
For clarity, substrate and additives are denoted in simplified forms. All phosphoinositide-
derived compounds e.g. PIP2, PIP3, nhPIP3 involve truncated fatty acid side chains diC8. 
5.8.2 IC50 determination of PTEN inhibitors 
Half maximal concentrations (IC50) of H2O2, bpV-phen, bpV-pic and bpV-HOpic are 
determined. Full-length PTEN is treated with the inhibitors at 25 °C for 10 min, which have 
been prepared with a 10-fold serial dilution beforehand. Concentrations of PTEN and the 
inhibitors during the treatment are as follows. PTEN: 60 nM; H2O2: 40 mM to 4 nM; bpV-
phen: 0.3 mM to 0.3 nM – 150 nM bpV-phen is included; bpV-pic / bpV-HOpic: 0.08 mM to 
0.08 nM – 1 µM and 40 nM bpV-pic / bpV-HOpic are included (Figure 20). The subsequent 
addition of PI(3,4,5)P3 diC8 triggers the phosphatase reaction. The reaction mixture is 
incubated at 25 °C for 30 min (final: 50 nM PTEN, 75 µM PI(3,4,5)P3 diC8). The reaction is 
quenched by transferring the reaction mixture (V = 25 µl) to malachite green solution (V = 
100 µl, Echelon Biosciences
®
). Following color development for 30 min, absorbance of each 
well is measured at 620 nm employing a plate reader Safire2
TM
. The absorption values are 
converted to the released orthophosphate amount to determine the relative phosphatase 
activity. Measurements are carried out in triplicates. GraphPad Prism
TM
 is used to calculate 
the relative PTEN activity including standard deviation. 
5.8.3 Characterization of reversible property of phosphatase inhibition 
For initial phosphatase inhibition, 100 µM full-length PTEN is incubated with either 3.5 mM 
H2O2 or 400 µM bpV-phen for 10 min. Each reaction sample is subsequently diluted with 
reaction buffer lacking reducing agents (mock) or containing DTT, GSH or Trx system to the 
following concentrations for 10 min: 5 µM PTEN, 4 mM DTT or GSH, Trx system (5 μM 
thioredoxin, 0.1 μM         xin reductase and 200 μM NA PH). The following addition of 
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PI(3,4,5)P3 diC8 triggers the phosphatase reaction (final: 1 µM PTEN, 75 µM PI(3,4,5)P3 
diC8). The reaction mixture is incubated at 25 °C for 30 min. The reaction is quenched by 
transferring the reaction mixture (V = 25 µl) to malachite green solution (V = 100 µl, Echelon 
Biosciences
®
). Following color development for 30 min, absorbance of each well is measured 
at 620 nm employing a plate reader Safire2
TM
. The absorption values are converted to the 
released orthophosphate amount to determine the relative phosphatase activity. Measurements 
are carried out in triplicates. GraphPad Prism
TM
 is used to calculate the relative PTEN activity 
including standard deviation. 
5.8.4 Characterization of inhibitory effect of orthovanadate on PTEN 
60 nM Full-length PTEN is pre-incubated with either reaction buffer, 0.01 mM bpV-phen or 
sodium orthovanadate (0.01, 0.1, 1 mM) for 10 min. PI(3,4,5)P3 diC8 is added to each 
reaction mixture, followed by incubation for 30 min at 25 °C (final: 50 nM PTEN, 75 µM 
PI(3,4,5)P3 diC8). The reaction is quenched by transferring the reaction mixture (V = 25 µl) to 
malachite green solution (V = 100 µl, Echelon Biosciences
®
). Following color development 
for 30 min, absorbance of each well is measured at 620 nm employing a plate reader 
Safire2
TM
. The absorption values are converted to the released orthophosphate amount to 
determine the relative phosphatase activity. Measurements are carried out in triplicates. 
GraphPad Prism
TM
 is used to calculate the relative PTEN activity including standard 
deviation.  
5.8.5 Impact of tartrate on redox-mediated inhibition and reactivation of PTEN 
To explore the impact of tartrate under ligand-soaking condition, redox-mediated inhibition 
and reactivation are tested in the presence of K/Na L(+)-tartrate and compared to tartrate-
lacking samples. 50 µM full-length PTEN is first incubated with reaction buffer lacking or 
containing 5 mM H2O2 in the presence or absence of 1.5 M K/Na L(+)-tartrate for 20 min. 
Each reaction sample is subsequently treated with buffer containing or lacking DTT (final: 
2.5 µM PTEN, 4 mM DTT) for 10 min. The concentration of K/Na L(+)-tartrate is maintained 
at 1.5 M for the tartrate-containing samples during dilution. The following addition of 
PI(3,4,5)P3 diC8 triggers the phosphatase reaction (final: 50 nM PTEN, 75 µM PI(3,4,5)P3 
diC8). The reaction mixture is incubated at 25 °C for 30 min. The reaction is quenched by 
transferring the reaction mixture (V = 25 µl) to malachite green solution (V = 100 µl, Echelon 
Biosciences
®
). Following color development for 30 min, absorbance of each well is measured 
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at 620 nm employing a plate reader Safire2
TM
. The absorption values are converted to the 
released orthophosphate amount to determine the relative phosphatase activity. Measurements 
are carried out in triplicates. GraphPad Prism
TM
 is used to calculate the relative PTEN activity 
including standard deviation. 
5.8.6 Kinetic measurement of phosphatase inhibition by H2O2 
For initial oxidative inhibition, 100 µM full-length PTEN is treated with H2O2 (2, 5 or 
20 mM) for the following time ranges: 5, 10, 20, 40 or 80 min (Figure 33). Each reaction 
sample is subsequently diluted with reaction buffer in the absence (mock) or presence of DTT 
(final: 5 µM PTEN, 10 mM DTT). The samples are incubated at 25 °C for 20 min. The 
following addition of PI(3,4,5)P3 diC8 triggers the phosphatase reaction (final: 1 µM PTEN, 
75 µM PI(3,4,5)P3 diC8). The reaction mixture is incubated at 25 °C for 30 min. The reaction 
is quenched by transferring the reaction mixture (V = 25 µl) to malachite green solution (V = 
100 µl, Echelon Biosciences
®
). Following color development for 30 min, absorbance of each 
well is measured at 620 nm employing a plate reader Safire2
TM
. The absorption values are 
converted to the released orthophosphate amount to determine the relative phosphatase 
activity. Measurements are carried out in triplicate of triplicates. GraphPad Prism
TM
 is used to 
calculate the relative PTEN activity including standard deviation. 
5.9 Sample preparation for mass-spectrometric methods 
100 µM PTEN constructs (full-length PTEN or PTEN 7-353 Δ286-309) are incubated with 
either reaction buffer, 1 mM H2O2 or 1 mM bpV-phen for 10 min at 25 °C. Subsequently, 
each sample is treated with iodoacetamide (2 mM, T = 25 °C, t = 10 min) for alkylation of 
free thiols and denatured in 8 M Urea. The following tryptic digest, HPLC-MS, MS/MS 
measurements and the corresponding data analysis are carried out by Dr. Tanja Bange and 
Franzisk Müller (MPI Dortmund). For more details about procedures, see reference No. 171. 
 
 
REFERENCES  111 
 
 
 
6 References 
1. Cohen, P. The origins of protein phosphorylation. Nature 4, E127–E130 (2002). 
2. Bialy, L. & Waldmann, H. Inhibitors of protein tyrosine phosphatases: next-
generation drugs? Angew. Chem. Int. Ed. Engl. 44, 3814–3839 (2005). 
3. Hunter, T. & Cooper, J. A. Protein-tyrosine kinases. Annu. Rev. Biochem. 54, 897–
930 (1985). 
4. Hunter, T. Signaling - 2000 and beyond. Cell 100, 113–127 (2000). 
5. Hunter, T. & Sefton, B. M. Transforming gene product of Rous sarcoma virus 
phosphorylates tyrosine. Proceedings of the National Academy of Sciences 77, 1311–
1315 (1980). 
6. Zhang, Z.-Y. Protein tyrosine phosphatases: structure and function, substrate 
specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol. 42, 209–234 
(2002). 
7. Picotti, P. Phosphoproteomics takes it easy. Nat Biotechnol 33, 929–930 (2015). 
8. Zhang, Z. Y. & Dixon, J. E. Active site labeling of the Yersinia protein tyrosine 
phosphatase: the determination of the pKa of the active site cysteine and the function 
of the conserved histidine 402. Biochemistry 32, 9340–9345 (1993). 
9. Peters, G. H., Frimurer, T. M. & Olsen, O. H. Electrostatic evaluation of the signature 
motif (H/V)CX5R(S/T) in protein-tyrosine phosphatases. Biochemistry 37, 5383–
5393 (1998). 
10. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. 
Rev. Mol. Cell Biol. 7, 833–846 (2006). 
11. Zhao, S., Sedwick, D. & Wang, Z. Genetic alterations of protein tyrosine 
phosphatases in human cancers. Oncogene 34, 3885–3894 (2014).  
12. Alonso, A. et al. Protein tyrosine phosphatases in the human genome. Cell 117, 699–
711 (2004). 
13. Zhao, S., Sedwick, D. & Wang, Z. Genetic alterations of protein tyrosine 
phosphatases in human cancers. Oncogene 34, 3885–3894 (2015). 
14. Li, X. et al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional 
effects in mammalian organogenesis. Nature 426, 247–254 (2003). 
15. Tootle, T. L. et al. The transcription factor Eyes absent is a protein tyrosine 
phosphatase. Nature 426, 299–302 (2003). 
16. Rayapureddi, J. P. et al. Eyes absent represents a class of protein tyrosine 
REFERENCES   112 
 
 
 
phosphatases. Nature 426, 295–298 (2003). 
17. Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at 
chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 
356–362 (1997). 
18. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human 
brain, breast, and prostate cancer. Science 275, 1943–1947 (1997). 
19. Myers, M. P. et al. The lipid phosphatase activity of PTEN is critical for its tumor 
supressor function. Proc. Natl. Acad. Sci. U.S.A. 95, 13513–13518 (1998). 
20. Singh, G. & M Chan, A. Post-Translational Modifications of PTEN and their 
Potential Therapeutic Implications. CCDT 11, 536–547 (2011). 
21. Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN 
tumour suppressor. Sci. Rep. 13, 283–296 (2012). 
22. Park, K. K. et al. Promoting axon regeneration in the adult CNS by modulation of the 
PTEN/mTOR pathway. Science 322, 963–966 (2008). 
23. Liu, K. et al. PTEN deletion enhances the regenerative ability of adult corticospinal 
neurons. Nat. Neurosci. 13, 1075–1081 (2010). 
24. Sun, F. et al. Sustained axon regeneration induced by co-deletion of PTEN and 
SOCS3. Nature 480, 372–375 (2011). 
25. Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the 
tumor suppressor PTEN. Cell 95, 29–39 (1998). 
26. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in 
human cancer. Nat. Rev. Cancer 2, 489–501 (2002). 
27. Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways: 
insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85–96 (2006). 
28. Alessi, D. R. et al. Characterization of a 3-phosphoinositide-dependent protein kinase 
which phosphorylates and activates protein kinase B alpha. Curr. Biol. 7, 261–269 
(1997). 
29. Franke, T. F. et al. The protein kinase encoded by the Akt proto-oncogene is a target 
of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81, 727–736 (1995). 
30. Burgering, B. M. & Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-
OH kinase signal transduction. Nature 376, 599–602 (1995). 
31. Laplante, M. & Sabatini, D. M. mTOR signaling at a glance. J. Cell. Sci. 122, 3589–
3594 (2009). 
32. Maehama, T. & Dixon, J. E. The tumor suppressor, PTEN/MMAC1, 
REFERENCES   113 
 
 
 
dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-
trisphosphate. Journal of Biological Chemistry 273, 13375–13378 (1998). 
33. Sun, H. et al. PTEN modulates cell cycle progression and cell survival by regulating 
phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. 
Proceedings of the National Academy of Sciences 96, 6199–6204 (1999). 
34. Myers, M. P. et al. P-TEN, the tumor suppressor from human chromosome 10q23, is 
a dual-specificity phosphatase. Proc. Natl. Acad. Sci. U.S.A. 94, 9052–9057 (1997). 
35. Tamura, M. et al. PTEN interactions with focal adhesion kinase and suppression of 
the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival 
pathway. Journal of Biological Chemistry 274, 20693–20703 (1999). 
36. Lietha, D. et al. Structural basis for the autoinhibition of focal adhesion kinase. Cell 
129, 1177–1187 (2007). 
37. Tamura, M. et al. Inhibition of cell migration, spreading, and focal adhesions by 
tumor suppressor PTEN. Science 280, 1614–1617 (1998). 
38. Tamura, M., Gu, J., Takino, T. & Yamada, K. M. Tumor suppressor PTEN inhibition 
of cell invasion, migration, and growth: differential involvement of focal adhesion 
kinase and p130Cas. Cancer Res. 59, 442–449 (1999). 
39. Shi, Y. et al. PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol 
21, 522–527 (2014). 
40. Tibarewal, P. et al. PTEN protein phosphatase activity correlates with control of gene 
expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. 
Sci Signal 5, ra18–ra18 (2012). 
41. Keniry, M. & Parsons, R. The role of PTEN signaling perturbations in cancer and in 
targeted therapy. Oncogene 27, 5477–5485 (2008). 
42. Bernstein, F. C. et al. The Protein Data Bank: a computer-based archival file for 
macromolecular structures. Ann. Rev. Biochem. 112, 535–542 (1977). 
43. Lee, J. O. et al. Crystal structure of the PTEN tumor suppressor: implications for its 
phosphoinositide phosphatase activity and membrane association. Cell 99, 323–334 
(1999). 
44. Yuvaniyama, J., Denu, J. M., Dixon, J. E. & Saper, M. A. Crystal structure of the 
dual specificity protein phosphatase VHR. Science 272, 1328–1331 (1996). 
45. Maehama, T., Taylor, G. S. & Dixon, J. E. PTEN and myotubularin: novel 
phosphoinositide phosphatases. Annu. Rev. Biochem. 70, 247–279 (2001). 
46. Torres, J. et al. Phosphorylation-regulated cleavage of the tumor suppressor PTEN by 
REFERENCES   114 
 
 
 
caspase-3: implications for the control of protein stability and PTEN-protein 
interactions. Journal of Biological Chemistry 278, 30652–30660 (2003). 
47. Trotman, L. C. et al. Ubiquitination regulates PTEN nuclear import and tumor 
suppression. Cell 128, 141–156 (2007). 
48. Campbell, R. B., Liu, F. & Ross, A. H. Allosteric activation of PTEN phosphatase by 
phosphatidylinositol 4,5-bisphosphate. Journal of Biological Chemistry 278, 33617–
33620 (2003). 
49. Funamoto, S., Meili, R., Lee, S., Parry, L. & Firtel, R. A. Spatial and temporal 
regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. 
Cell 109, 611–623 (2002). 
50. Iijima, M. & Devreotes, P. Tumor suppressor PTEN mediates sensing of 
chemoattractant gradients. Cell 109, 599–610 (2002). 
51. McConnachie, G., Pass, I., Walker, S. M. & Downes, C. P. Interfacial kinetic analysis 
of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic 
phospholipids. Biochem. J. 371, 947–955 (2003). 
52. Iijima, M., Huang, Y. E., Luo, H. R., Vazquez, F. & Devreotes, P. N. Novel 
mechanism of PTEN regulation by its phosphatidylinositol 4,5-bisphosphate binding 
motif is critical for chemotaxis. Journal of Biological Chemistry 279, 16606–16613 
(2004). 
53. Walker, S. M., Leslie, N. R., Perera, N. M., Batty, I. H. & Downes, C. P. The tumour-
suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem. J. 
379, 301–307 (2004). 
54. Vazquez, F. et al. Tumor suppressor PTEN acts through dynamic interaction with the 
plasma membrane. Proc. Natl. Acad. Sci. U.S.A. 103, 3633–3638 (2006). 
55. Odriozola, L., Singh, G., Hoang, T. & Chan, A. M. Regulation of PTEN activity by 
its carboxyl-terminal autoinhibitory domain. J. Biol. Chem. 282, 23306–23315 
(2007). 
56. Vazquez, F., Ramaswamy, S., Nakamura, N. & Sellers, W. R. Phosphorylation of the 
PTEN tail regulates protein stability and function. Mol. Cell. Biol. 20, 5010–5018 
(2000). 
57. Torres, J. & Pulido, R. The tumor suppressor PTEN is phosphorylated by the protein 
kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-
mediated degradation. Journal of Biological Chemistry 276, 993–998 (2001). 
58. Wu, X. et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-
REFERENCES   115 
 
 
 
localized multi-PDZ domain containing scaffold protein MAGI-2. Proceedings of the 
National Academy of Sciences 97, 4233–4238 (2000). 
59. Valiente, M. et al. Binding of PTEN to specific PDZ domains contributes to PTEN 
protein stability and phosphorylation by microtubule-associated serine/threonine 
kinases. Journal of Biological Chemistry 280, 28936–28943 (2005). 
60. Hopkins, B. D. et al. A secreted PTEN phosphatase that enters cells to alter signaling 
and survival. Science 341, 399–402 (2013). 
61. Liang, H. et al. PTENα,   PTEN I       T               g  A           I         , 
Regulates Mitochondrial Function and Energy Metabolism. Cell Metabolism 19, 
836–848 (2014). 
62. Pulido, R. et al. A unified nomenclature and amino acid numbering for human PTEN. 
Sci Signal 7, pe15–pe15 (2014). 
63. Malaney, P., Uversky, V. N. & Davé, V. Identification of intrinsically disordered 
regions in PTEN and delineation of its function via a network approach. Methods 77-
78, 69–74 (2015). 
64. Shi, Y., Paluch, B. E., Wang, X. & Jiang, X. PTEN at a glance. J. Cell. Sci. 125, 
4687–4692 (2012). 
65. Worby, C. A. & Dixon, J. E. PTEN. Annu. Rev. Biochem. 83, 641–669 (2014). 
66. Miller, S. J., Lou, D. Y., Seldin, D. C., Lane, W. S. & Neel, B. G. Direct 
identification of PTEN phosphorylation sites. FEBS Letters 528, 145–153 (2002). 
67. Al-Khouri, A. M., Ma, Y., Togo, S. H., Williams, S. & Mustelin, T. Cooperative 
phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) 
by casein kinases and glycogen synthase kinase 3beta. Journal of Biological 
Chemistry 280, 35195–35202 (2005). 
68. Maccario, H., Perera, N. M., Davidson, L., Downes, C. P. & Leslie, N. R. PTEN is 
destabilized by phosphorylation on Thr366. Biochem. J. 405, 439–444 (2007). 
69. Okahara, F., Ikawa, H., Kanaho, Y. & Maehama, T. Regulation of PTEN 
phosphorylation and stability by a tumor suppressor candidate protein. Journal of 
Biological Chemistry 279, 45300–45303 (2004). 
70. Rahdar, M. et al. A phosphorylation-dependent intramolecular interaction regulates 
the membrane association and activity of the tumor suppressor PTEN. Proc. Natl. 
Acad. Sci. U.S.A. 106, 480–485 (2009). 
71. Bolduc, D. et al. Phosphorylation-mediated PTEN conformational closure and 
deactivation revealed with protein semisynthesis. Elife 2, e00691 (2013). 
REFERENCES   116 
 
 
 
72. Vazquez, F. et al. Phosphorylation of the PTEN tail acts as an inhibitory switch by 
preventing its recruitment into a protein complex. Journal of Biological Chemistry 
276, 48627–48630 (2001). 
73. Das, S., Dixon, J. E. & Cho, W. Membrane-binding and activation mechanism of 
PTEN. Proc. Natl. Acad. Sci. U.S.A. 100, 7491–7496 (2003). 
74. Li, Z. et al. Regulation of PTEN by Rho small GTPases. Nature 7, 399–404 (2005). 
75. Yim, E.-K. et al. Rak functions as a tumor suppressor by regulating PTEN protein 
stability and function. Cancer Cell 15, 304–314 (2009). 
76. Maddika, S. et al. WWP2 is an E3 ubiquitin ligase for PTEN. Nature 13, 728–733 
(2011). 
77. Wang, X. et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128, 
129–139 (2007). 
78. Amodio, N. et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN 
negative regulator, in non-small-cell lung carcinomas. Am. J. Pathol. 177, 2622–2634 
(2010). 
79. Van Themsche, C., Leblanc, V., Parent, S. & Asselin, E. X-linked inhibitor of 
apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and 
compartmentalization. J. Biol. Chem. 284, 20462–20466 (2009). 
80. Okumura, K. et al. PCAF modulates PTEN activity. Journal of Biological Chemistry 
281, 26562–26568 (2006). 
81. Ikenoue, T., Inoki, K., Zhao, B. & Guan, K.-L. PTEN acetylation modulates its 
interaction with PDZ domain. Cancer Res. 68, 6908–6912 (2008). 
82. Lee, S. R. et al. Reversible Inactivation of the Tumor Suppressor PTEN by H2O2. 
Journal of Biological Chemistry 277, 20336–20342 (2002). 
83. Leslie, N. R. et al. Redox regulation of PI 3-kinase signalling via inactivation of 
PTEN. EMBO J. 22, 5501–5510 (2003). 
84. Chang, C.-J. et al. PTEN nuclear localization is regulated by oxidative stress and 
mediates p53-dependent tumor suppression. Mol. Cell. Biol. 28, 3281–3289 (2008). 
85. Shen, W. H. et al. Essential role for nuclear PTEN in maintaining chromosomal 
integrity. Cell 128, 157–170 (2007). 
86. Bassi, C. et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. 
Science 341, 395–399 (2013). 
87. Song, M. S. et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive 
complex in a phosphatase-independent manner. Cell 144, 187–199 (2011). 
REFERENCES   117 
 
 
 
88. Freeman, D. J. et al. PTEN tumor suppressor regulates p53 protein levels and activity 
through phosphatase-dependent and -independent mechanisms. Cancer Cell 3, 117–
130 (2003). 
89. Tang, Y. PTEN Autoregulates Its Expression by Stabilization of p53 in a 
Phosphatase-Independent Manner. Cancer Res. 66, 736–742 (2006). 
90. Li, A. G. et al. Mechanistic insights into maintenance of high p53 acetylation by 
PTEN. Mol. Cell 23, 575–587 (2006). 
91. Yiu, G. & He, Z. Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci. 7, 
617–627 (2006). 
92. Harel, N. Y. & Strittmatter, S. M. Can regenerating axons recapitulate developmental 
guidance during recovery from spinal cord injury? Nat. Rev. Neurosci. 7, 603–616 
(2006). 
93. Soltoff, S. P., Rabin, S. L., Cantley, L. C. & Kaplan, D. R. Nerve growth factor 
promotes the activation of phosphatidylinositol 3-kinase and its association with the 
trk tyrosine kinase. Journal of Biological Chemistry 267, 17472–17477 (1992). 
94. Korhonen, J. M., Saïd, F. A., Wong, A. J. & Kaplan, D. R. Gab1 mediates neurite 
outgrowth, DNA synthesis, and survival in PC12 cells. Journal of Biological 
Chemistry 274, 37307–37314 (1999). 
95. Christie, K. J., Webber, C. A., Martinez, J. A., Singh, B. & Zochodne, D. W. PTEN 
inhibition to facilitate intrinsic regenerative outgrowth of adult peripheral axons. J. 
Neurosci. 30, 9306–9315 (2010). 
96. Fujio, Y., Nguyen, T., Wencker, D., Kitsis, R. N. & Walsh, K. Akt promotes survival 
of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse 
heart. Circulation 101, 660–667 (2000). 
97. Mocanu, M. M. & Yellon, D. M. PTEN, the Achilles' heel of myocardial 
ischaemia/reperfusion injury? Br. J. Pharmacol. 150, 833–838 (2007). 
98. Keyes, K. T. et al. Pharmacological inhibition of PTEN limits myocardial infarct size 
and improves left ventricular function postinfarction. Am. J. Physiol. Heart Circ. 
Physiol. 298, H1198–208 (2010). 
99. Winterbourn, C. C. Reconciling the chemistry and biology of reactive oxygen 
species. Nat Chem Biol 4, 278–286 (2008). 
100. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. 
Rev. Cancer 11, 85–95 (2011). 
101. Shi, X., Zhang, Y., Zheng, J. & Pan, J. Reactive oxygen species in cancer stem cells. 
REFERENCES   118 
 
 
 
Antioxid. Redox Signal. 16, 1215–1228 (2012). 
102. Na, A. R. et al. A critical role for Romo1-derived ROS in cell proliferation. Biochem. 
Biophys. Res. Commun. 369, 672–678 (2008). 
103. Gupta, S. C. et al. Upsides and downsides of reactive oxygen species for cancer: the 
roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. 
Redox Signal. 16, 1295–1322 (2012). 
104. D'Autréaux, B. & Toledano, M. B. ROS as signalling molecules: mechanisms that 
generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 8, 813–824 (2007). 
105. Paulsen, C. E. & Carroll, K. S. Orchestrating redox signaling networks through 
regulatory cysteine switches. ACS Chem. Biol. 5, 47–62 (2010). 
106. Cumming, R. C. et al. Protein disulfide bond formation in the cytoplasm during 
oxidative stress. Journal of Biological Chemistry 279, 21749–21758 (2004). 
107. Bretón-Romero, R. & Lamas, S. Hydrogen peroxide signaling in vascular endothelial 
cells. Redox Biol 2, 529–534 (2014). 
108. Meng, T.-C., Fukada, T. & Tonks, N. K. Reversible oxidation and inactivation of 
protein tyrosine phosphatases in vivo. Mol. Cell 9, 387–399 (2002). 
109. Kwon, J. et al. Reversible oxidation and inactivation of the tumor suppressor PTEN 
in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. U.S.A. 101, 
16419–16424 (2004). 
110. Gupta, V. & Carroll, K. S. Sulfenic acid chemistry, detection and cellular lifetime. 
Biochim. Biophys. Acta 1840, 847–875 (2014). 
111. Kim, H.-J., Ha, S., Lee, H. Y. & Lee, K.-J. ROSics: chemistry and proteomics of 
cysteine modifications in redox biology. Mass Spectrom Rev 34, 184–208 (2015). 
112. Marino, S. M. & Gladyshev, V. N. Analysis and functional prediction of reactive 
cysteine residues. J. Biol. Chem. 287, 4419–4425 (2012). 
113. Besse, D., Siedler, F., Diercks, T., Kessler, H. & Moroder, L. The Redox Potential of 
Selenocystine in Unconstrained Cyclic Peptides. Angew. Chem. Int. Ed. Engl. 36, 
883–885 (1997). 
114. Lohse, D. L., Denu, J. M., Santoro, N. & Dixon, J. E. Roles of aspartic acid 181 and 
serine-222 in intermediate formation and hydrolysis of the mammalian protein-
tyrosine-phosphatase PTP1. Biochemistry 36, 4568–4575 (1997). 
115. Cho, S.-H. et al. Redox regulation of PTEN and protein tyrosine phosphatases in 
H(2)O(2) mediated cell signaling. FEBS Letters 560, 7–13 (2004). 
116. Tonks, N. K. Redox redux: revisiting PTPs and the control of cell signaling. Cell 121, 
REFERENCES   119 
 
 
 
667–670 (2005). 
117. Veal, E. A., Day, A. M. & Morgan, B. A. Hydrogen peroxide sensing and signaling. 
Mol. Cell 26, 1–14 (2007). 
118. Tsai, S. J. et al. Crystal structure of the human lymphoid tyrosine phosphatase 
catalytic domain: insights into redox regulation. Biochemistry 48, 4838–4845 (2009). 
119. Lee, S. R., Kwon, K. S., Kim, S. R. & Rhee, S. G. Reversible inactivation of protein-
tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. 
Journal of Biological Chemistry 273, 15366–15372 (1998). 
120. Barford, D., Flint, A. J. & Tonks, N. K. Crystal structure of human protein tyrosine 
phosphatase 1B. Science 263, 1397–1404 (1994). 
121. Barford, D., Das, A. K. & Egloff, M. P. The structure and mechanism of protein 
phosphatases: Insights into catalysis and regulation. Annu Rev Biophys Biomol Struct 
27, 133–164 (1998). 
122. Salmeen, A. et al. Redox regulation of protein tyrosine phosphatase 1B involves a 
sulphenyl-amide intermediate. Nature 423, 769–773 (2003). 
123. van Montfort, R. L. M., Congreve, M., Tisi, D., Carr, R. & Jhoti, H. Oxidation state 
of the active-site cysteine in protein tyrosine phosphatase 1B. Nature 423, 773–777 
(2003). 
124. Caselli, A. et al. The inactivation mechanism of low molecular weight 
phosphotyrosine-protein phosphatase by H2O2. Journal of Biological Chemistry 273, 
32554–32560 (1998). 
125. Chiarugi, P. et al. Two vicinal cysteines confer a peculiar redox regulation to low 
molecular weight protein tyrosine phosphatase in response to platelet-derived growth 
factor receptor stimulation. Journal of Biological Chemistry 276, 33478–33487 
(2001). 
126. Buhrman, G., Parker, B., Sohn, J., Rudolph, J. & Mattos, C. Structural mechanism of 
oxidative regulation of the phosphatase Cdc25B via an intramolecular disulfide bond. 
Biochemistry 44, 5307–5316 (2005). 
127. Fauman, E. B. et al. Crystal structure of the catalytic domain of the human cell cycle 
control phosphatase, Cdc25A. Cell 93, 617–625 (1998). 
128. Sohn, J. & Rudolph, J. Catalytic and chemical competence of regulation of cdc25 
phosphatase by oxidation/reduction. Biochemistry 42, 10060–10070 (2003). 
129. Mak, L. H., Vilar, R. & Woscholski, R. Characterisation of the PTEN inhibitor VO-
OHpic. J Chem Biol 3, 157–163 (2010). 
REFERENCES   120 
 
 
 
130. Mak, L. H. & Woscholski, R. Targeting PTEN using small molecule inhibitors. 
Methods 77-78C, 63–68 (2015). 
131. Schmid, A. C., Byrne, R. D., Vilar, R. & Woscholski, R. Bisperoxovanadium 
compounds are potent PTEN inhibitors. FEBS Letters 566, 35–38 (2004). 
132. Rosivatz, E. et al. A small molecule inhibitor for phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN). ACS Chem. Biol. 1, 780–790 (2006). 
133. Spinelli, L., Lindsay, Y. E. & Leslie, N. R. PTEN inhibitors: an evaluation of current 
compounds. Adv Biol Regul 57, 102–111 (2015). 
134. Shaver, A., Ng, J. B., Hynes, R. C. & Posner, B. I. Potassium (5-nitro-1,10-
phenanthroline-N1,N10)oxodiperoxovanadate(V) dihydrate: an insulin-mimetic 
peroxovanadate. Acta Crystallogr C Cryst Struct Commun 50, 1044–1046 (1994). 
135. Thompson, K. H. & Orvig, C. Coordination chemistry of vanadium in 
metallopharmaceutical candidate compounds. Coordination Chemistry Reviews 219, 
1033–1053 (2001). 
136. Zhang, Q.-G., Wu, D.-N., Han, D. & Zhang, G.-Y. Critical role of PTEN in the 
coupling between PI3K/Akt and JNK1/2 signaling in ischemic brain injury. FEBS 
Letters 581, 495–505 (2007). 
137. Guo, J.-Y. et al. Dose-Dependent Protective Effect of Bisperoxovanadium against 
Acute Cerebral Ischemia in a Rat Model of Ischemia/Reperfusion Injury. Int J Mol 
Sci 14, 12013–12022 (2013). 
138. Chen, Y. et al. Administration of a PTEN inhibitor BPV(pic) attenuates early brain 
injury via modulating AMPA receptor subunits after subarachnoid hemorrhage in 
rats. Neurosci. Lett. 588C, 131–136 (2015). 
139. Walker, C. L. et al. Systemic Bisperoxovanadium Activates Akt/mTOR, Reduces 
Autophagy, and Enhances Recovery following Cervical Spinal Cord Injury. PLoS 
ONE 7, e30012 (2012). 
140. Walker, C. L. & Xu, X.-M. PTEN inhibitor bisperoxovanadium protects 
oligodendrocytes and myelin and prevents neuronal atrophy in adult rats following 
cervical hemicontusive spinal cord injury. Neurosci. Lett. 573, 64–68 (2014). 
141. Tian, Y., Daoud, A. & Shang, J. Effects of bpV(pic) and bpV(phen) on H9c2 
cardiomyoblasts during both hypoxia/reoxygenation and H2O2-induced injuries. Mol 
Med Rep 5, 852–858 (2012). 
142. UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res. 43, 
D204–12 (2015). 
REFERENCES   121 
 
 
 
143. Clegg, R. A. & Holt, C. An E. coli over-expression system for multiply-
phosphorylated proteins and its use in a study of calcium phosphate sequestration by 
novel recombinant phosphopeptides. Protein Expr. Purif. 67, 23–34 (2009). 
144. Bäcker, S. Untersuchung des Phosphorylierungsgrades verschiedener PTEN-
Varianten (Master's Thesis). (TU Dortmund, 2013). 
145. Carter, S. G. & Karl, D. W. Inorganic phosphate assay with malachite green: an 
improvement and evaluation. J. Biochem. Biophys. Methods 7, 7–13 (1982). 
146. Kuepper, A. Investigation of the flexible terminal sequences of Phosphatase and 
TENsin homolog deleted on chromosome ten (Master's Thesis). (TU Dortmund, 
2013). 
147. Müller, C. Expression und Charakterisierung verschiedener PTEN-Konstrukte 
(Master's Thesis). (TU Dortmund, 2014). 
148. Stone, J. R. & Yang, S. Hydrogen peroxide: a signaling messenger. Antioxid. Redox 
Signal. 8, 243–270 (2006). 
149. Holmgren, A. & Luthman, M. Tissue distribution and subcellular localization of 
bovine thioredoxin determined by radioimmunoassay. Biochemistry 17, 4071–4077 
(1978). 
150. Schwertassek, U. et al. Reactivation of oxidized PTP1B and PTEN by thioredoxin 1. 
FEBS J. 281, 3545–3558 (2014). 
151. Meister, A. & Anderson, M. E. Glutathione. Annu. Rev. Biochem. 52, 711–760 
(1983). 
152. Hwang, J. H., Larson, R. K. & Abu-Omar, M. M. Kinetics and mechanistic studies of 
anticarcinogenic bisperoxovanadium(V) compounds: ligand substitution reactions at 
physiological pH and relevance to DNA interactions. Inorg Chem 42, 7967–7977 
(2003). 
153. Huyer, G. et al. Mechanism of inhibition of protein-tyrosine phosphatases by 
vanadate and pervanadate. Journal of Biological Chemistry 272, 843–851 (1997). 
154. Butler, A., Clague, M. J. & Meister, G. E. Vanadium Peroxide Complexes. Chemical 
reviews 94, 625–638 (1994). 
155. Rodgers, D. W. Cryocrystallography. Structure 2, 1135-40 (1994). 
156. Arndt, U. W. & Wonacott, A. J. The rotation method in crystallography. North 
Holland Publishing Co, Amsterdam. (1977). 
157. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010). 
158. Karplus, P. A. & Diederichs, K. Linking crystallographic model and data quality. 
REFERENCES   122 
 
 
 
Science 336, 1030–1033 (2012). 
159. Diederichs, K. & Karplus, P. A. Improved R-factors for diffraction data analysis in 
macromolecular crystallography. Nat Struct Mol Biol 4, 269–275 (1997). 
160. Barr, A. J. et al. Large-scale structural analysis of the classical human protein 
tyrosine phosphatome. Cell 136, 352–363 (2009). 
161. Cerovac, Z. et al. Activation of MAPK by potassium bisperoxo(1,10-
phenanthroline)oxovanadate (V). Neurochem. Int. 34, 337–344 (1999). 
162. Jaswal, J. S. & Tracey, A. S. Formation and decomposition of peroxovanadium(V) 
complexes in aqueous solution. Inorg Chem 30, 3718–3722 (1991). 
163. R     ,  ., Č   ý, M. & G     , R. A         -51 NMR study of the binding of 
vanadate and peroxovanadate to proteins. Magn Reson Chem 42, 745–749 (2004). 
164. Seargeant, L. E. & Stinson, R. A. Inhibition of human alkaline phosphatases by 
vanadate. Biochem. J. 181, 247–250 (1979). 
165. Brennan, S. & Cowan, P. L. A Suite of Programs for Calculating X-Ray Absorption, 
Reflection, and Diffraction Performance for a Variety of Materials at Arbitrary 
Wavelengths. Review of Scientific Instruments 63, 850–853 (1992). 
166. Strahs, G. & Kraut, J. Low-resolution electron-density and anomalous-scattering-
density maps of Chromatium high-potential iron protein. Ann. Rev. Biochem. 35, 
503–512 (1968). 
167. Shenoy, S. S., Nanda, H. & Lösche, M. Membrane association of the PTEN tumor 
suppressor: electrostatic interaction with phosphatidylserine-containing bilayers and 
regulatory role of the C-terminal tail. J. Struct. Biol. 180, 394–408 (2012). 
168. Nguyen, H.-N. et al. Opening the conformation is a master switch for the dual 
localization and phosphatase activity of PTEN. Scientific reports 5, 12600 (2015). 
169. Denu, J. M. & Tanner, K. G. Specific and reversible inactivation of protein tyrosine 
phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and 
implications for redox regulation. Biochemistry 37, 5633–5642 (1998). 
170. Cunnick, J. M., Dorsey, J. F., Mei, L. & Wu, J. Reversible regulation of SHP-1 
tyrosine phosphatase activity by oxidation. Biochem. Mol. Biol. Int. 45, 887–894 
(1998). 
171. Lee, C.-U. et al. Redox Modulation of PTEN Phosphatase Activity by Hydrogen 
Peroxide and Bisperoxidovanadium Complexes. Angew. Chem. Int. Ed. Engl. 54, 
13796–13800 (2015).  
172. Ballistreri, F. P., Barbuzzi, E. G., Tomaselli, G. A. & Toscano, R. M. Insulin mimesis 
REFERENCES   123 
 
 
 
of vanadium derivatives. Oxidation of cysteine by V(V) oxo diperoxo complexes. J. 
Inorg. Biochem. 80, 173–176 (2000). 
173. Paulsen, C. E. & Carroll, K. S. Cysteine-mediated redox signaling: chemistry, 
biology, and tools for discovery. Chemical reviews 113, 4633–4679 (2013). 
174. Leslie, N. R., Batty, I. H., Maccario, H., Davidson, L. & Downes, C. P. 
Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 27, 
5464–5476 (2008). 
175. Wei, Y., Stec, B., Redfield, A. G., Weerapana, E. & Roberts, M. F. Phospholipid-
binding Sites of Phosphatase and Tensin Homolog (PTEN): exploring the mechanism 
of phosphatidylinositol 4,5-bisphosphate activation. J. Biol. Chem. 290, 1592–1606 
(2015). 
176. Invitrogen
TM
, Bac-to-Bac® Baculovirus Expression System - An efficient site-
specific transposition system to generate baculovirus for high-level expression of 
recombinant proteins, User Manual Version F, (2010). 
177. Cantley, L. C. et al. Vanadate is a potent (Na,K)-ATPase inhibitor found in ATP 
derived from muscle. Journal of Biological Chemistry 252, 7421–7423 (1977). 
178. Hasegawa, Y. et al. Neuroprotective effect of postischemic administration of sodium 
orthovanadate in rats with transient middle cerebral artery occlusion. J Cereb Blood 
Flow Metab 23, 1040–1051 (2003). 
179. Kawano, T. et al. Neuroprotective effect of sodium orthovanadate on delayed 
neuronal death after transient forebrain ischemia in gerbil hippocampus. J Cereb 
Blood Flow Metab 21, 1268–1280 (2001). 
180. Takada, Y., Hashimoto, M., Kasahara, J., Aihara, K. & Fukunaga, K. Cytoprotective 
effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat 
heart involves Akt activation and inhibition of fodrin breakdown and apoptosis. 
Journal of Pharmacology and Experimental Therapeutics 311, 1249–1255 (2004). 
181. Wilkins, M. R. et al. Protein identification and analysis tools in the ExPASy server. 
Methods Mol. Biol. 112, 531–552 (1999). 
182. Saiki, R. K. et al. Enzymatic amplification of beta-globin genomic sequences and 
restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350–1354 
(1985). 
183. Saiki, R. K. et al. Primer-directed enzymatic amplification of DNA with a 
thermostable DNA polymerase. Scientific reports 239, 487–491 (1988). 
184. Shevchuk, N. A. et al. Construction of long DNA molecules using long PCR-based 
REFERENCES   124 
 
 
 
fusion of several fragments simultaneously. Nucleic Acids Res. 32, e19 (2004). 
185. Aaij, C. & Borst, P. The gel electrophoresis of DNA. Biochim. Biophys. Acta 269, 
192–200 (1972). 
186. Southern, E. M. Detection of specific sequences among DNA fragments separated by 
gel electrophoresis. Ann. Rev. Biochem. 98, 503–517 (1975). 
187. Kelly, T. J. & Smith, H. O. A restriction enzyme from Hemophilus influenzae. II. 
Ann. Rev. Biochem. 51, 393–409 (1970). 
188. Smith, H. O. & Wilcox, K. W. A restriction enzyme from Hemophilus influenzae. I. 
Purification and general properties. Ann. Rev. Biochem. 51, 379–391 (1970). 
189. Mertz, J. E. & Davis, R. W. Cleavage of DNA by R 1 restriction endonuclease 
generates cohesive ends. Proc. Natl. Acad. Sci. U.S.A. 69, 3370–3374 (1972). 
190. Jackson, D. A., Symons, R. H. & Berg, P. Biochemical method for inserting new 
genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules 
containing lambda phage genes and the galactose operon of Escherichia coli. Proc. 
Natl. Acad. Sci. U.S.A. 69, 2904–2909 (1972). 
191. Cohen, S. N., Chang, A. C., Boyer, H. W. & Helling, R. B. Construction of 
biologically functional bacterial plasmids in vitro. Proc. Natl. Acad. Sci. U.S.A. 70, 
3240–3244 (1973). 
192. Lehman, I. R. DNA ligase: structure, mechanism, and function. Science 186, 790–797 
(1974). 
193. Dagert, M. & Ehrlich, S. D. Prolonged incubation in calcium chloride improves the 
competence of Escherichia coli cells. Gene 6, 23–28 (1979). 
194. Holmes, D. S. & Quigley, M. A rapid boiling method for the preparation of bacterial 
plasmids. Anal. Biochem. 114, 193–197 (1981). 
195. Zon, L. I., Dorfman, D. M. & Orkin, S. H. The polymerase chain reaction colony 
miniprep. BioTechniques 7, 696–698 (1989). 
196. Birnboim, H. C. & Doly, J. A rapid alkaline extraction procedure for screening 
recombinant plasmid DNA. Nucleic Acids Res. 7, 1513–1523 (1979). 
197. Larkin, M. A. et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947–
2948 (2007). 
198. Life Technologies, Growth and Maintenance of Insect Cell Lines. 5.0, 1–41 (2013). 
199. Vilen, H., Aalto, J.-M., Kassinen, A., Paulin, L. & Savilahti, H. A direct transposon 
insertion tool for modification and functional analysis of viral genomes. J. Virol. 77, 
123–134 (2003). 
REFERENCES   125 
 
 
 
200. Potterton, E., Briggs, P., Turkenburg, M. & Dodson, E. A graphical user interface to 
the CCP4 program suite. Acta Crystallogr. D Biol. Crystallogr. 59, 1131–1137 
(2003). 
201. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta 
Crystallogr. D Biol. Crystallogr. 67, 235–242 (2011). 
202. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of 
Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010). 
203. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular 
structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 
53, 240–255 (1997). 
204.  The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC. 
205. Laemmli, U. K. Cleavage of Structural Proteins during the Assembly of the Head of   
Bacteriophage T4. Nature 227, 680–685 (1970). 
206. McPherson A. Current approaches to macromolecular crystallization. Eur J Biochem. 
189,1-23 (1990). 
207. Rossmann, M. G. The molecular replacement method. Acta Crystallogr. A 46, 73-82 
(1990). 
208. Brünger, A. T. Free R value: a novel statistical quantity for assessing the accuracy of 
crystal structures. Nature 355, 472-475 (1992). 
209. Brünger, A. T. Free R Value: Cross-Validation in Crystallography. Methods in 
Enzymology 277, 366-396 (1997). 
 
 
 
 
 
 
 
 
 
 
APPENDICES  126 
 
 
 
7 Appendices 
7.1 pFH1-Vector 
 
Figure 45 | Map of pFH1 vector used for the baculovirus-mediated protein expression. 
TTCTCTGTCACAGAATGAAAATTTTTCTGTCATCTCTTCGTTATTAATGTTTGTAATTGACTGAATATCAACGCT
TATTTGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCG
CAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTT
CGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGA
CCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGAC
GTTGGAGTCCACGTTCTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCT
TTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCG
AATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTT
TATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAA
AAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTT
TTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAAC
TGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAG
TTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTC
AGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCA
GTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAA
CCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATAC
CAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTAC
TTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGG
CCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCAC
TGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAA
ATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATAC
TTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCA
AAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATC
CTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATC
AAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGT
AGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAG
TGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGC
GGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTAC
AGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCG
GAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACC
TCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCT
TTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATA
ACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCG
AGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATAGACCAGC
CGCGTAACCTGGCAAAATCGGTTACGGTTGAGTAATAAATGGATGCCCTGCGTAAGCGGGTGTGGGCGGACAATA
AAGTCTTAAACTGAACAAAATAGATCTAAACTATGACAATAAAGTCTTAAACTAGACAGAATAGTTGTAAACTGA
AATCAGTCCAGTTATGCTGTGAAAAAGCATACTGGACTTTTGTTATGGCTAAAGCAAACTCTTCATTTTCTGAAG
TGCAAATTGCCCGTCGTATTAAAGAGGGGCGTGGCCAAGGGCATGGTAAAGACTATATTCGCGGCGTTGTGACAA
TTTACCGAACAACTCCGCGGCCGGGAAGCCGATCTCGGCTTGAACGAATTGTTAGGTGGCGGTACTTGGGTCGAT
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ATCAAAGTGCATCACTTCTTCCCGTATGCCCAACTTTGTATAGAGAGCCACTGCGGGATCGTCACCGTAATCTGC
TTGCACGTAGATCACATAAGCACCAAGCGCGTTGGCCTCATGCTTGAGGAGATTGATGAGCGCGGTGGCAATGCC
CTGCCTCCGGTGCTCGCCGGAGACTGCGAGATCATAGATATAGATCTCACTACGCGGCTGCTCAAACTTGGGCAG
AACGTAAGCCGCGAGAGCGCCAACAACCGCTTCTTGGTCGAAGGCAGCAAGCGCGATGAATGTCTTACTACGGAG
CAAGTTCCCGAGGTAATCGGAGTCCGGCTGATGTTGGGAGTAGGTGGCTACGTCTCCGAACTCACGACCGAAAAG
ATCAAGAGCAGCCCGCATGGATTTGACTTGGTCAGGGCCGAGCCTACATGTGCGAATGATGCCCATACTTGAGCC
ACCTAACTTTGTTTTAGGGCGACTGCCCTGCTGCGTAACATCGTTGCTGCTGCGTAACATCGTTGCTGCTCCATA
ACATCAAACATCGACCCACGGCGTAACGCGCTTGCTGCTTGGATGCCCGAGGCATAGACTGTACAAAAAAACAGT
CATAACAAGCCATGAAAACCGCCACTGCGCCGTTACCACCGCTGCGTTCGGTCAAGGTTCTGGACCAGTTGCGTG
AGCGCATACGCTACTTGCATTACAGTTTACGAACCGAACAGGCTTATGTCAACTGGGTTCGTGCCTTCATCCGTT
TCCACGGTGTGCGTCACCCGGCAACCTTGGGCAGCAGCGAAGTCGAGGCATTTCTGTCCTGGCTGGCGAACGAGC
GCAAGGTTTCGGTCTCCACGCATCGTCAGGCATTGGCGGCCTTGCTGTTCTTCTACGGCAAGGTGCTGTGCACGG
ATCTGCCCTTGCTTCAGGAGATCGGTAGACCTCGGCCGTCGCGGCGCTTGCCGGTGGTGCTGACCCCGGATGAAG
TGGTTCGCATCCTCGGTTTTCTGGAAGGCGAGCATCGTTTGTTCGCCCAGGACTCTAGCTATAGTTCTAGTGGTT
GGCTACAGCTTTGTTTGTACTATCAACAGGTTGAACTGCTGATCAACAGATCCTCTACGCGGCCGCGGTACCATA
ACTTCGTATAGCATACATTATACGAAGTTATCTGGTTTAAACGTACCCGTAGTGGCTATGGCAGGGCTTGCCGCC
CCGACGTTGGCTGCGAGCCCTGGGCCTTCACCCGAACTTGGGGGTTGGGGTGGGGAAAAGGAAGAAACGCGGGCG
TATTGGTCCCAATGGGGTCTCGGTGGGGTATCGACAGAGTGCCAGCCCTGGGACCGAACCCCGCGTTTATGAACA
AACGACCCAACACCCGTGCGTTTTATTCTGTCTTTTTATTGCCGTCATAGCGCGGGTTCCTTCCGGTATTGTCTC
CTTCCGTGTTTCAGTTAGCCTCCCCCATCTCCCGGTACCGCATGCTATGCATCAGCTGCTAGCACCATGGCTCGA
GATCCCGGGTGATCAAGTCTTCGTCGAGTGATTGTAAATAAAATGTAATTTACAGTATAGTATTTTAATTAATAT
ACAAATGATTTGATAATAATTCTTATTTAACTATAATATATTGTGTTGGGTTGAATTAAAGGTCCGTATACTAGT
ATCGATTCGCGACCTACTCCGGAATATTAATAGATCATGGAGATAATTAAAATGATAACCATCTCGCAAATAAAT
AAGTATTTTACTGTTTTCGTAACAGTTTTGTAATAAAAAAACCTATAAATATTCCGGATTATTCATACCGTCCCA
CCATCGGGCGCGGATCTACAACCCATATGTCGTACTACCATCACCATCACCATCACGATTACGATATCCCAACGA
CCGAAAACCTGTATTTTCAGGGCGCCATGGGATCCGGAATTCAAAGGCCTACGTCGACGAGCTCACTAGTCGCGG
CCGCTTTCGAATCTAGAGCCTGCAGTCTCGACAAGCTTGTCGAGAAGTACTAGAGGATCATAATCAGCCATACCA
CATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAA
TTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATA
AAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCTGAT
CACTGCTTGAGCCTAGAAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAG
CAATAACTATCATAACCCCTAGGAGATCCGAACCAGATAAGTGAAATCTAGTTCCAAACTATTTTGTCATTTTTA
ATTTTCGTATTAGCTTACGACGCTACACCCAGTTCCCATCTATTTTGTCACTCTTCCCTAAATAATCCTTAAAAA
CTCCATTTCCACCCCTCCCAGTTCCCAACTATTTTGTCCGCCCACAGCGGGGCATTTTTCTTCCTGTTATGTTTT
TAATCAAACATCCTGCCAACTCCATGTGACAAACCGTCATCTTCGGCTACTTT 
 
Table 33 | Sequence characteristics in the multiple cloning site. NdeI and SalI are used to insert the 
gene of interest.  
Nucleotide sequence Description 
CATATG NdeI 
ATG Translation start 
CATCACCATCACCATCAC His6-tag 
GAAAACCTGTATTTTCAGGGC TEV-site 
GGATCC BamHI 
GTCGAC SalI 
TAG Stop codon 
 
 
 
 
APPENDICES 128 
 
 
 
7.2 Sequencing results 
P         w   : 5’ GTA ACA GTT TTG TAA TAA AAA AAC C 3’ 
P             : 5’ GTT TCA GGT TCA GGG GGA GGT GTG GG 3’ 
Uniprot ID: P60484 (PTEN Homo Sapiens) 
M:   Translation start 
HHHHHH:  His6-tag 
ENLYFQG: TEV-recognition site 
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7.2.1 His-TEV-PTEN 1-403 
Plasmid description: pFH1/(NdeI)-His6-TEV-PTEN 1-403-(SalI)  
Clone description: Mi-2 
Forward 
Mi-2_forw          MSYYHHHHHHDYDIPTTENLYFQGMTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMG 60 
PTEN_human         ------------------------MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMG 36 
                                           ************************************ 
 
Mi-2_forw          FPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPP 120 
PTEN_human         FPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPP 96 
                   ************************************************************ 
 
Mi-2_forw          QLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYG 180 
PTEN_human         QLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYG 156 
                   ************************************************************ 
 
Mi-2_forw          EVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFV 240 
PTEN_human         EVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFV 216 
                   ************************************************************ 
 
Mi-2_forw          VCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVN 300 
PTEN_human         VCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVN 276 
                   ************************************************************ 
 
Mi-2_forw          TFFIPGPEETSE------------------------------------------------ 312 
PTEN_human         TFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRY 336 
                   ************                                                 
 
Mi-2_forw          ------------------------------------------------------------ 
PTEN_human         FSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQ 396 
                                                                                   
 
Mi-2_forw          ------- 
PTEN_human         HTQITKV 403 
 
Reverse 
PTEN_human         MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSK 60 
Mi-2_rev           ------------------------------------------------------------ 
                                                                                   
 
PTEN_human         HKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVA 120 
Mi-2_rev           ------------------------------------------------------------ 
                                                                                 
 
PTEN_human         AIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 180 
Mi-2_rev           ---------------------RGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 39 
                                        *************************************** 
 
PTEN_human         LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 240 
Mi-2_rev           LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 99 
                   ************************************************************ 
 
PTEN_human         FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 300 
Mi-2_rev           FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 159 
                   ************************************************************ 
 
PTEN_human         DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS 360 
Mi-2_rev           DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS 219 
                   ************************************************************ 
 
PTEN_human         SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 403 
Mi-2_rev           SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 262 
                   ******************************************* 
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7.2.2 His6-TEV-PTEN 6-403 
Plasmid description: pFH1/(NdeI)-His6-TEV-PTEN 6-403-(SalI)  
Clone description: Mi-26 
 
Forward 
PTEN_human         --------------------MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAE 40 
Mi-26_forw         HMSYYHHHHHHDYDIPTTENLYFQGKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAE 60 
                                       :    *********************************** 
 
PTEN_human         RLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLEL 100 
Mi-26_forw         RLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLEL 120 
                   ************************************************************ 
 
PTEN_human         IKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRT 160 
Mi-26_forw         IKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRT 180 
                   ************************************************************ 
 
PTEN_human         RDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQL 220 
Mi-26_forw         RDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQL 240 
                   ************************************************************ 
 
PTEN_human         KVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFI 280 
Mi-26_forw         KVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNK----------------- 283 
                   *******************************************                  
 
PTEN_human         PGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPN 340 
Mi-26_forw         ------------------------------------------------------------ 
                                                                              
 
PTEN_human         FKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQI 400 
Mi-26_forw         ------------------------------------------------------------ 
                                                                              
 
PTEN_human         TKV 403 
Mi-26_forw         --- 
                     
 
Reverse 
PTEN_human         MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSK 60 
Mi-26_rev          ------------------------------------------------------------ 
                                                                              
 
PTEN_human         HKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVA 120 
Mi-26_rev          ------------------------------------------------------------ 
                                                                              
 
PTEN_human         AIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 180 
Mi-26_rev          -----------------------KFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 37 
                                          ************************************* 
 
PTEN_human         LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 240 
Mi-26_rev          LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 97 
                   ************************************************************ 
 
PTEN_human         FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 300 
Mi-26_rev          FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 157 
                   ************************************************************ 
 
PTEN_human         DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS 360 
Mi-26_rev          DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS 217 
                   ************************************************************ 
 
PTEN_human         SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 403 
Mi-26_rev          SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 260 
                   ******************************************* 
 
APPENDICES 131 
 
 
 
7.2.3 His6-TEV-PTEN 16-403 
Plasmid description: pFH1/(NdeI)-His6-TEV-PTEN 16-403-(SalI)  
Clone description: Mi-33 
 
Forward 
PTEN_human         ----------MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNI 50 
Mi-33_forw         HMSYYHHHHHHDYDIPTTENLYFQGYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNI 60 
                                 *    .   : *********************************** 
 
PTEN_human         DDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQ 110 
Mi-33_forw         DDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQ 120 
                   ************************************************************ 
 
PTEN_human         WLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPS 170 
Mi-33_forw         WLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPS 180 
                   ************************************************************ 
 
PTEN_human         QRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSG 230 
Mi-33_forw         QRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSG 240 
                   ************************************************************ 
 
PTEN_human         PTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKV 290 
Mi-33_forw         PTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKV 300 
                   ************************************************************ 
 
PTEN_human         ENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKT 350 
Mi-33_forw         ENGSLCDQEIDSICSIERAD---------------------------------------- 320 
                   ********************                                         
 
PTEN_human         VEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 403 
Mi-33_forw         ----------------------------------------------------- 
 
Reverse 
PTEN_human         MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSK 60 
Mi-33_rev          ------------------------------------------------------------ 
                                                                              
 
PTEN_human         HKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVA 120 
Mi-33_rev          ------------------------------------------------------------ 
 
                                                                              
 
PTEN_human         AIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 180 
Mi-33_rev          ------------------------------------------------------------ 
                                                                              
 
PTEN_human         LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 240 
Mi-33_rev          ---------------------TIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 39 
                                        *************************************** 
 
 
 
PTEN_human         FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 300 
Mi-33_rev          FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 99 
                   ************************************************************ 
 
PTEN_human         DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS 360 
Mi-33_rev          DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS 159 
                   ************************************************************ 
 
PTEN_human         SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 403 
Mi-33_rev          SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 202 
                   ******************************************* 
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7.2.4 His6-TEV-PTEN 6-353 
Plasmid description: pFH1/(NdeI)-His6-TEV-PTEN 6-353-(SalI)  
Clone description: Mi-53 
 
Forward 
PTEN_human         --------------------MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAE 40 
Mi-53_forw         HMSYYHHHHHHDYDIPTTENLYFQGKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAE 60 
                                       :    *********************************** 
 
PTEN_human         RLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLEL 100 
Mi-53_forw         RLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLEL 120 
                   ************************************************************ 
 
PTEN_human         IKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRT 160 
Mi-53_forw         IKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRT 180 
                   ************************************************************ 
 
PTEN_human         RDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQL 220 
Mi-53_forw         RDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQL 240 
                   ************************************************************ 
 
PTEN_human         KVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFI 280 
Mi-53_forw         KVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFI 300 
                   ************************************************************ 
 
PTEN_human         PGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPN 340 
Mi-53_forw         PGPEET------------------------------------------------------ 306 
                   ******                                                       
 
PTEN_human         FKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQI 400 
Mi-53_forw         ------------------------------------------------------------ 
                                                                              
 
PTEN_human         TKV 403 
Mi-53_forw         --- 
 
Reverse 
PTEN_human         MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSK 60 
Mi-53_rev          ------------------------------------------------------------ 
                                                                              
 
PTEN_human         HKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVA 120 
Mi-53_rev          -----------------------------------------------------EDDNHVA 7 
                                                                      ******* 
 
PTEN_human         AIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 180 
Mi-53_rev          AIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 67 
                   ************************************************************ 
 
PTEN_human         LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 240 
Mi-53_rev          LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 127 
                   ************************************************************ 
 
PTEN_human         FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 300 
Mi-53_rev          FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 187 
                   ************************************************************ 
 
PTEN_human         DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS 360 
Mi-53_rev          DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEE------- 240 
                   *****************************************************        
 
PTEN_human         SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 403 
Mi-53_rev          ------------------------------------------- 
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7.2.5 His6-TEV-PTEN 16-353 
Plasmid description: pFH1/(NdeI)-His6-TEV-PTEN 16-353-(SalI)  
Clone description: Mi-63 
 
Forward 
PTEN_human         ----------MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNI 50 
Mi-63_forw         HMSYYHHHHHHDYDIPTTENLYFQGYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNI 60 
                                 *    .   : *********************************** 
 
PTEN_human         DDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQ 110 
Mi-63_forw         DDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQ 120 
                   ************************************************************ 
 
PTEN_human         WLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPS 170 
Mi-63_forw         WLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPS 180 
                   ************************************************************ 
 
PTEN_human         QRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSG 230 
Mi-63_forw         QRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSG 240 
                   ************************************************************ 
 
PTEN_human         PTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKV 290 
Mi-63_forw         PTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKV 300 
                   ************************************************************ 
 
PTEN_human         ENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKT 350 
Mi-63_forw         ENGSLCDQEIDSICSIER------------------------------------------ 318 
                   ******************                                           
 
PTEN_human         VEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 403 
Mi-63_forw         ----------------------------------------------------- 
 
Reverse 
PTEN_human         MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSK 60 
Mi-63_rev          ------------------------------------------------------------ 
                                                                              
 
 
PTEN_human         HKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVA 120 
Mi-63_rev          ------------------------------------------------------------ 
                                                                              
 
PTEN_human         AIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 180 
Mi-63_rev          -----------------------------------------DKKGVTIPSQRRYVYYYSY 19 
                                                            ******************* 
 
PTEN_human         LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 240 
Mi-63_rev          LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 79 
                   ************************************************************ 
 
PTEN_human         FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 300 
Mi-63_rev          FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 139 
                   ************************************************************ 
 
PTEN_human         DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS 360 
Mi-63_rev          DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEE------- 192 
                   *****************************************************        
 
PTEN_human         SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 403 
Mi-63_rev          ------------------------------------------- 
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7.2.6 His-TEV-PTEN 7-353 Δ286-309 
Protein construct: His6-TEV-PTEN 7-353 Δ286-309 
Plasmid description: pFH1/(NdeI)-His-TEV-PTEN 7-353ID-(SalI)  
Clone description: Mi-41 
Forward 
PTEN_human       -------------------MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAER 41 
Mi-41_forw       HMSYYHHHHHHDYDIPTTENLYFQGEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAER 60 
                                       :  *********************************** 
 
PTEN_human       LEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELI 101 
Mi-41_forw       LEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELI 120 
                 ************************************************************ 
 
PTEN_human       KPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTR 161 
Mi-41_forw       KPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTR 180 
                 ************************************************************ 
 
PTEN_human       DKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLK 221 
Mi-41_forw       DKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLK 240 
                 ************************************************************ 
 
PTEN_human       VKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIP 281 
Mi-41_forw       VKIYSSN----------------------------------------------------- 247 
                 *******                                                      
 
PTEN_human       GPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNF 341 
Mi-41_forw       ------------------------------------------------------------ 
                                                                              
 
PTEN_human       KVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQIT 401 
Mi-41_forw       ------------------------------------------------------------ 
                                                                              
 
PTEN_human       KV 403 
Mi-41_forw       -- 
 
Reverse 
PTEN_human       MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSK 60 
Mi-41_rev        ------------------------------------------------------------ 
                                                                              
 
PTEN_human       HKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVA 120 
Mi-41_rev        --------------------------------------------------------NHVA 4 
                                                                         **** 
 
PTEN_human       AIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 180 
Mi-41_rev        AIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY 64 
                 ************************************************************ 
 
PTEN_human       LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 240 
Mi-41_rev        LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY 124 
                 ************************************************************ 
 
PTEN_human       FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI 300 
Mi-41_rev        FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEE--------------- 169 
                 *********************************************                
 
PTEN_human       DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS 360 
Mi-41_rev        ---------DNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEE------- 213 
                          ********************************************        
  
PTEN_human       SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV 403 
Mi-41_rev        ------------------------------------------- 
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7.3 SDS-PAGE and SEC analyses of the protein purification 
 
Figure 46 | SDS-analysis of protein purification (PTEN 6-403) 
 
Figure 47 | SDS-analysis of protein purification (PTEN 16-403) 
 
Figure 48 | SDS-analysis of protein purification (PTEN 6-353) 
 
Figure 49 | SDS-analysis of protein purification (PTEN 16-353) 
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Figure 50 | Size exclusion chromatography chromatograms of PTEN constructs. (a) Preparative 
size exclusion chromatogram of full-length PTEN 1-403 using HiLoad
TM
 Superdex
TM
 S200 16/60. (b – 
f) Analytical size exclusion chromatograms of various PTEN constructs using HiLoad
TM
 Superdex
TM
 
S200 10/30. Void volumes are marked with a red bar. 
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7.4 Detection of disulfide formation using HPLC-MS and MS/MS 
Full-length PTEN 
 
Figure 51 | Determination of disulfide formation between C71 and C124 in full-length PTEN 
using HPLC-coupled high resolution mass spectrometry. Compared to (a) buffer treatment, the 
disulfide-bridged tryptic fragment is detected after incubation with (b) 1 mM H2O2 or (c) 1 mM bpV-
phen (T = 25 °C, 100 µM PTEN, t = 10 min). The corresponding peak in HPLC chromatogram and its 
high resolution MS-spectra (mass error < 1 ppm) are represented in the left and right panel, 
respectively. Treatment with 10 mM DTT dimishes the disulfide-bridged tryptic fragment (b and c, 
lower panel). Sample preparation is performed by the author of this thesis. The measurements and data 
analysis are carried out by Dr. Tanja Bange and Franziska Müller. This figure is from the reference 
No. 171, © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
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Figure 52 | MS/MS spectra confirms disulfide formation between C71 and C124 in full-length 
PTEN. Following treatment with (a) 1 mM H2O2 and (b) 1 mM bpV-phen (T = 25 °C, 100 µM PTEN, 
t = 10 min), MS/MS spectra of corresponding samples are searched giving the mass of C71-containing 
peptide (IYNLCAER) cross-linked to any peptide fragments including C124. The spectra show the 
annotated disulfide-bridged peptides. The tryptic fragment has been sequenced over 300 times. Sample 
preparation is performed by the author of this thesis. The measurements and data analysis are carried 
out by Dr. Tanja Bange and Franziska Müller. This figure is from the reference No. 171, © 2015 The 
Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.  
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Truncated PTEN 
 
Figure 53 | Determination of disulfide formation between C71 and C124 in tPTEN using HPLC-
coupled high resolution mass spectrometry. Compared to (a) buffer treatment, the disulfide-bridged 
tryptic fragment is detected after incubation with (b) 1 mM H2O2 or (c) 1 mM bpV-phen (T = 25 °C, 
100 µM PTEN, t = 10 min). The corresponding peak in HPLC chromatogram and its high resolution 
MS-spectra (mass error < 1 ppm) are represented in the left and right panel, respectively. Treatment 
with 10 mM DTT dimishes the disulfide-bridged tryptic fragment (b and c, lower panel). Sample 
preparation is performed by the author of this thesis. The measurements and data analysis are carried 
out by Dr. Tanja Bange and Franziska Müller. This figure is from the reference No. 171, © 2015 The 
Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
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Figure 54 | MS/MS spectra confirms disulfide formation between C71 and C124 in tPTEN. 
Following treatment with (a) 1 mM H2O2 and (b) 1 mM bpV-phen (T = 25 °C, 100 µM PTEN, 
t = 10 min), MS/MS spectra of corresponding samples are searched giving the mass of C71-containing 
peptide (IYNLCAER) cross-linked to any peptide fragments including C124. The spectra show the 
annotated disulfide-bridged peptides. The tryptic fragment has been sequenced over 300 times. Sample 
preparation is performed by the author of this thesis. The measurements and data analysis are carried 
out by Dr. Tanja Bange and Franziska Müller. This figure is from the reference No. 171, © 2015 The 
Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
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7.5 Influence of tartrate on oxidative inhibition and reactivation 
 
Figure 55 | Tartrate does not have a significant impact on oxidation and reactivation of PTEN. 
In order to confirm the oxidative inhibition and reactivation of PTEN under the crystal soaking 
condition, phosphatase activity of PTEN is determined under high concentration tartrate. Full-length 
PTEN (50 µM) is treated with H2O2 (5 mM, 20 min) in buffer (gray) or buffer containing tartrate 
(1.5 M, white). Following oxidation, 20-fold dilution (10 min) is performed with buffer lacking or 
containing 4 mM DTT. Phosphatase activities are given relative to the untreated protein sample 
(absence of H2O2, tartrate and DTT). Errors account for ± SD (triplicates; ns: P > 0.05). This figure is 
from the reference No. 171, © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. 
KGaA. 
 
Figure 56 | Tartrate has low impact on the phosphatase activity of PTEN. Half-maximal 
concentration (IC50) of tartrate is determined by enzymatic activity measurements using malachite 
green assay. (50 nM full-length PTEN, 75 µM PI(3,4,5)P3-diC8 as substrate, T = 25 °C, t = 30 min; 
triplicates, errors represent ± SD.) 
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7.6 SDS-PAGE and SEC analyses of the protein purification 
 
 
Figure 57 | Size exclusion chromatography chromatograms of H2O2-treated PTEN 1-403 and its 
phosphatase activity.  (a) H2O2-treatment (2 mM) of the purified PTEN 1-403 (upper) results in two 
species, which are separated using the subsequent size exclusion chromatography (lower). HiLoad
TM
 
Superdex
TM
 S200 16/60 prep grade is used. (b) Phosphatase activity of each species is determined 
using malachite green assay. H2O2-treated species show effective inhibition after the following 
purification, of which the phosphatase activity is restored completely in the presence of DTT (4 mM). 
(T = 25 °C,    p       ,                    1σ; *** P < 0.001) 
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8 Abbreviations 
A (Base)  = Adenine 
Akt (PKB)  = Protein kinase B 
APC/C  = Anaphase promoting complex / cyclosome 
APS   = Ammonium persulfate 
ASU   = Asymmetric unit 
BamHI  = Restriction enzyme (recognition sequence G^GATCC) 
bp   = Base pair 
bpV   = Bisperoxidovanadium 
bpV-HOpic  = Bisperoxido (5-hydroxypyridine-2-carboxy) oxovanadate (V) 
bpV-phen  =  Bisperoxido(1,10-phenanthroline) oxovanadate (V) 
bpV-pic  = Bisperoxido (picolinato) oxovanadate (V) 
BSA   = Bovine serum albumin 
C (Base)  = Cytosine 
C’   = C-terminus 
Cα   = Carbon atom at the alpha position in an amino acid 
ca.   = Circa 
CBP   = CREB-binding protein 
CBR3-loop  =  Calcium-binding region 3 loop 
CC1/2   = Correlation coefficient of two half datasets 
CDC25B  = M-phase inducer phosphatase 2 
CDH1   = Adaptor protein of APC 
CHAPS  = 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CK2   = Casein kinase 2 
CV   = Column volume 
ddH2O   = Bidistilled water 
DMSO  = Dimethyl sulfoxide 
DNA   = Deoxyribonucleic acid 
DNase   = Desoxyribonuclease 
dNTP   = Deoxynucleotide triphosphate 
DPF   = Dortmund protein facility 
DTT   = Dithiothreitol 
DUSP   = Dual specificity phosphatase 
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E. coli   = Escherichia coli 
EDTA   = Ethylenediaminetetraacetic acid 
e.g.   = exempli gratia, for example 
EGF   = Epidermal growth factor 
et al.   = And others 
FAK   =  Focal adhesion kinase 
FBS   = Fetal Bovine Serum 
Fcal   = Structure factor (calculated) 
Fobs   = Structure factor (observed) 
FP   = Fluorescence polarization 
FPLC   = Fast protein liquid chromatography 
fw   = Forward 
G (Base)  = Guanine 
GSH   = Glutathione reduced 
GST   = Glutathione S-transferase 
GSK3β  = Glycogen synthase kinase 3β 
HIF-1α  = Hypoxia-induced factor-1α 
High Five  = Trichoplusia ni 
His6-Tag  = Affinity chromatography involving six histidine in a row 
HPLC   = High performance liquid chromatography 
HPLC-MS  =  HPLC-coupled mass spectrometry 
IC50   = half maximal inhibitory concentration 
IEX   = Ion exchange chromatography 
IMAC   = Immobilized metal ion affinity chromatography 
IP3   = Inositol trisphosphate 
IPTG   = Isopropyl-β-D-thiogalactopyranoside 
IRS   = Insulin receptor substrate 
JCSG   = Joint Center for Structural Genomics 
kb   = Kilobase 
kDa   = Kilodalton 
KD   = Dissociation constant 
Ki   = Inhibition constant 
LB   = Lysogeny broth 
LMW-PTP  = Low molecular weight protein tyrosine phosphatase 
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LYP   =  Lymphoid tyrosine phosphatase 
MBP   = Maltose binding protein 
MCS   = Multiple cloning site 
MES (buffer)  = 2-(N-morpholino)ethanesulfonic acid 
MPI   =  Max Planck Institute 
Mr   = Molecular mass 
MS   = Mass spectrometry 
MS/MS  = Tandem mass spectrometry 
mTORC1/2  = Mammalian target of rapamycin complex 1/2 
m/z   = Mass-to-charge ratio 
N’   = N-terminus 
NADPH  = Nicotinamide adenine dinucleotide phosphate 
NdeI   = Restriction enzyme (recognition sequence CA^TATG) 
NEDD4-1  = Ubiquitin Ligase 
NF-κB   = Nuclear factor kappa-light-chain-enhancer of activated B cells 
nhPIP3   = Non-hydrolyzable variant of PIP3, 3S-PI-(3,4,5)-P3 
Ni-NTA  = Nickel-nitrilotriacetic acid 
NMR   =  Nuclear magnetic resonance 
NOX   = NADPH oxidase 
N/A   = Not available 
ns   = Not significant 
OD   = Optical density 
Ox.   = Oxidized (species) 
P (statistics)  = P value  
PBM   = PIP2-binding motif 
PCAF   = Lysine acetyltransferase 2B 
PCR   = Polymerase chain reaction 
PDB   = Protein Data Bank 
PDGF   = Platelet-derived growth factor 
PDPK1  = Phosphoinositide dependent protein kinase 1 
PDZ   = PSD95/SAP90, Discs large und Zonula occludentes-1 
pH   = Potentia hydrogenii 
pI   = Isoelectric point 
PIP2   = Phosphatidylinositol-4,5-bisphosphate 
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PIP3   = Phosphatidylinositol-3,4,5-trisphosphate 
PI3-K   = Phosphoinositide-3-Kinase 
P-loop   = Phosphate-binding loop 
PMSF   = Phenylmethylsulfonyl fluoride 
ppm   = Parts per million 
PTP   = Protein tyrosine phosphatase 
PTEN   = Phosphatase and TENsin homolog deleted on chromosome 10 
RA   = Relative abundance 
RACK   = fyn-related kinase (also known as FRK) 
rcf   = Relative centrifugal force 
rev   = Reversed 
RMSD   = Root-mean-square deviation 
RNAse A  = Ribonuclease A 
ROCK   = rho-associated, coiled-coil-containing protein kinase 
ROS    = Reactive oxygen species 
rpm   = Rotation per minute  
RTK   = Receptor-tyrosine kinase 
SalI   = Restriction enzyme (recognition sequence G^TCGAC) 
SD   = Standard deviation 
SDS   = Sodium dodecylsulfate 
SDS-PAGE  = Sodium dodecylsulfate polyacrylamide gelelektrophorese 
SEC   = Size exclusion chromatography 
Sf9   = Spodoptera frugiperda 
SG   = Space group 
SHP-1/2  = Src homology region 2 domain-containing phosphatase-1/2 
STAT3  = Signal transducer and activator of transcription 3 
T (Base)  = Thymine 
TAE (buffer)  = Tris acetate EDTA buffer 
TCEP   = Tris-(2-carboxyethyl)-phosphine 
TEMED  = Tetramethylethylendiamine 
TEV   = Tobacco Etch Virus protease recognition site 
Th   = Thomson (Th = unified atomic mass unit / electric charge unit) 
THB   = Thrombin protease recognition site 
TM
   = Trademark 
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tPTEN   = PTEN 7-353 ∆286-309 
Tris (buffer)  = 2-Amino-2-(hydroxymethyl)-propane-1,3-diol 
Trx   = Thioredoxin 
Ub   = Ubiquitin    
UV   = Ultraviolet  
VHR   = Vaccinia H1-related phosphatase 
v/v   = Volume per volume 
w/v   = Weight per volume 
WWP2  = NEDD4-like E3 ubiquitin ligase 
XDS   = X-ray Detector Software  
X-gal   = 5-Brom-4-chlor-3-indoxyl-β-D-galactopyranosid 
XIAP   = X-linked inhibitor of apoptosis protein  
3S-PI-(3,4,5)-P3  =  PIP3 substituted with thiophosphate at D3 position 
∆   =  Delta; “            ” 
©   = Copyright 
®
   = Registered trademark 
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Table 34 | Three- and one-letter codes of 20 canonical amino acids. 
Amino acid Three-letter code One-letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutaminic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
 
